Conditions: Small for Gestational Age
Keywords: Small for Gestational Age, Omnitrope®/Somatropin, rhGH,SGA
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 278
Healthy volunteers: no

Brief summary:
This study is performed to investigate the long-term safety, in particular the diabetogenic potential and immunogenicity of rhGH therapy in short children born small for gestational age (SGA).

Detailed description:
Prospective, open label, non-comparative, multicenter study. Short children born SGA were to be treated until they reached final height, but treatment could be discontinued earlier if medically indicated or if there was inadequate response to treatment.

Arms:
arm 1: All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.

Interventions: intervention 1: Omnitrope
Intervention descriptions: intervention 1: All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.

Protocol document:
Prot_000.pdf: 
Long-term Phase IV Multicentre Study on the Safety and Efficacy of Omnitrope® 
Official Title: 
NCT Number: 
NCT00537914 
Document Date: 
Clinical Study Protocol Version 6.0: 07 February 2020
(rhGH) in Short Children Born Small for Gestational Age (SGA) 


Omnitrope®
Study protocol EP00-401
Long-term phase IV multicentre study on the safety and 
efficacy of Omnitrope® (rhGH) in short children born Small 
for Gestational Age (SGA) 
Author(s):
Sandoz GmbH
Sponsor:
Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria
Date:
07-Feb-2020
Version:
6.0 incorporating amendment 5
Phase:
IV
EudraCT number
2006-002506-58
Number of pages:
55
Property of Sandoz 
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of Sandoz


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 2 of 55
Study No. EP00-401 
Protocol History
Document version (v) No
Released by
Comment
Protocol v 1.0
07 March 2007
Amendment 01
24 August 2007
incorporated into Protocol v 1.0, leading to
Protocol v 2.0
24 August 2007
Amendment 02
27 November 
2008
incorporated into Protocol v 2.0, leading to
Protocol v 3.0
27 November 
2008
Amendment 03
22 March 2012
incorporated into Protocol v3.0, leading to
Protocol v 4.0
22 March 2012
Amendment 04
24 August 2017 
incorporated into Protocol v4.0, leading to
Protocol v 5.0
24 August 2017
Amendment 05
07 February 2020
incorporated into Protocol v6.0, leading to
Protocol v 6.0
07 February 2020


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 3 of 55
Study No. EP00-401 
Table of contents
Protocol History...................................................................................................................2
Table of contents .................................................................................................................3
List of tables ........................................................................................................................6
List of abbreviations............................................................................................................7
Amendment 5 ......................................................................................................................8
Study status..........................................................................................................................8
Protocol synopsis...............................................................................................................10
Flow Chart Treatment Period ............................................................................................13
1
Background........................................................................................................................15
1.1
Investigational product ..........................................................................................15
1.2
The indication SGA...............................................................................................15
1.2.1
Type 2 Diabetes and SGA.....................................................................17
1.2.2
Syndrome X and SGA...........................................................................17
1.2.3
Growth Hormone therapy in SGA patients...........................................18
1.2.4
Metabolic effects of growth hormone treatment in patients born 
SGA.......................................................................................................20
2
Study Purpose....................................................................................................................20
3
Objectives..........................................................................................................................21
3.1
Primary objective(s)...............................................................................................21
3.2
Secondary objectives .............................................................................................21
4
Study design ......................................................................................................................21
5
Population..........................................................................................................................22
5.1.
Inclusion/exclusion criteria....................................................................................23
5.1.1
Inclusion criteria....................................................................................23
5.1.2
Exclusion criteria ..................................................................................23
6
Treatment...........................................................................................................................24
6.1
Investigational drug ...............................................................................................24
6.1.1
Omnitrope® 5 mg/ml powder and solvent for solution for injection ....24
6.1.2
Omnitrope® 5 mg/ 1.5 ml and Omnitrope® 10 mg/ 1.5 ml solution 
for injection...........................................................................................25
6.2
Treatment groups...................................................................................................25
6.3
Treatment assignment............................................................................................25
6.4
Treatment blinding.................................................................................................25
6.5
Treating the patient................................................................................................25
6.5.1
Dose.......................................................................................................25


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 4 of 55
Study No. EP00-401 
6.5.2
Study drug administration.....................................................................25
6.5.3
Treatment duration................................................................................26
6.5.4
Permitted study drug dose adjustments.................................................26
6.5.5
Dose increase ........................................................................................26
6.5.6
Rescue medication ................................................................................26
6.5.7
Prohibited medication ...........................................................................27
6.5.8
Concomitant treatment..........................................................................27
6.5.9
Study drug discontinuation ...................................................................27
6.5.10
Premature patient withdrawal ...............................................................28
6.5.11
Emergency unblinding of treatment assignments .................................28
6.6
Contraception measures.........................................................................................29
7
Visit Schedule and assessments.........................................................................................30
7.1
Procedures by visits ...............................................................................................30
7.1.1
Screening Period (Visit 00)...................................................................30
7.1.2
Start of Treatment (Visit 01).................................................................31
7.1.3
3-Month Treatment Visit (Visit 02)......................................................31
7.1.4
6-Month Treatment Visit (Visit 03)......................................................32
7.1.5
9-Month Treatment Visit (Visit 04)......................................................32
7.1.6
12-Month Treatment Visit (Visit 05)....................................................32
7.1.7
15-Month Treatment Visit (Visit 06)....................................................33
7.1.8
18-Month Treatment Visit (Visit 07)....................................................33
7.1.9
21-Month Treatment Visit (Visit 08)....................................................33
7.1.10
24-Month Treatment Visit (Visit 09) and subsequent visits 
performed annually (Visit 11, Visit 13 etc) ..........................................34
7.1.11
30-Month Treatment Visit (Visit 10) and subsequent visits 
performed annually (Visit 12, Visit 14 etc) ..........................................34
7.1.12
Final Visit of treatment period..............................................................34
7.2
Treatment exposure and compliance .....................................................................35
7.3
Efficacy..................................................................................................................35
7.3.1
Methods and timing for assessing, recording and analysis of 
efficacy parameters ...............................................................................35
7.3.2
Anthropometric Measurements.............................................................35
7.3.3
Presentation and Calculation of Auxological Data...............................35
7.3.4
Weight measurements...........................................................................36
36
7.4
Safety.....................................................................................................................36
7.4.1
Carbohydrate metabolism .....................................................................36


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 5 of 55
Study No. EP00-401 
7.4.2
Immunogenicity ....................................................................................37
7.4.3
Fundoscopy ...........................................................................................37
7.4.4
Physical examination ............................................................................37
7.4.5
Vital signs..............................................................................................37
7.4.6
Laboratory evaluations..........................................................................37
7.4.7
Adverse events ......................................................................................38
7.4.8
Serious adverse events ..........................................................................40
7.5
Tolerability/acceptability.......................................................................................41
7.6
Resource utilization ...............................................................................................41
8
Safety monitoring..............................................................................................................41
8.1
Serious adverse event reporting.............................................................................41
8.2
Reporting procedures for technical complaints .....................................................42
8.3
Reporting of study treatment errors including misuse/abuse ................................42
8.4
Pregnancy reporting...............................................................................................43
8.5
Data Monitoring Board..........................................................................................43
9
Data review and database management.............................................................................43
9.1
Site monitoring ......................................................................................................43
9.2
Data collection.......................................................................................................44
9.3
Medical Monitoring...............................................................................................44
10 Data analysis......................................................................................................................44
10.1
Analysis sets ..........................................................................................................44
10.1.1
Safety analysis set .................................................................................44
10.1.2
Full analysis set.....................................................................................44
10.2
Patient demographics/other baseline characteristics .............................................45
10.3
Treatments (study drug, rescue medication, other concomitant therapies, 
compliance)............................................................................................................45
10.3.1
Study drug administration.....................................................................45
10.3.2
Concomitant medication .......................................................................45
10.3.3
Treatment compliance...........................................................................45
10.4
Analysis of safety endpoints..................................................................................45
10.4.1
Carbohydrate metabolism .....................................................................45
10.4.2
Immunogenicity ....................................................................................46
10.4.3
Safety lab / urine analysis .....................................................................46
10.4.4
(Serious) Adverse Events / Incidents ....................................................46
10.4.5
Vital signs / weight................................................................................46
10.4.6
Physical examination ............................................................................46
10.5
Analysis of efficacy endpoints...............................................................................46


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 6 of 55
Study No. EP00-401 
10.5.1
Auxological endpoints ..........................................................................46
10.5.2
Pharmacodynamic endpoints ................................................................47
47
10.6
Interim analysis......................................................................................................47
10.7
Sample size calculation..........................................................................................47
10.8
Power for analysis of critical secondary variables ................................................47
10.9
Subgroup analyses .................................................................................................48
11 Discussion and rationale for study design features ...........................................................48
12 Procedures and instructions: Administrative procedures ..................................................49
12.1
Changes to the protocol .........................................................................................49
12.2
Ethics and Good Clinical Practice .........................................................................49
12.2.1
Institutional Review Board/ Independent Ethics Committee................49
12.2.2
Informed consent...................................................................................49
12.2.3
Declaration of Helsinki .........................................................................50
13 References .........................................................................................................................50
Appendices ........................................................................................................................54
Tanner Breast Stages .........................................................................................................54
Handling of elevated blood glucose levels and OGTT .....................................................54
Recommended Dosage of Omnitrope® ............................................................................55
List of tables
Table 4-1
Study Outline ........................................................................................22


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 7 of 55
Study No. EP00-401 
List of abbreviations
AB
Antibody
AE
Adverse event
AIDS
Acquired immunodeficiency syndrome
ANC
Absolute neutrophil count
BMI
Body Mass Index
BW
Body weight
CA
Calendar Age
CBC
complete blood count
CRF
Case report form
CRO
Contract research organization
EMEA
European Agency for the Evaluation of Medicinal Products
fT4
Free thyroxine 
GCP
Good clinical practice
GH
Growth hormone
HDL
High-density lipoproteins
hGH
Human growth hormone
HIV
Human immunodeficiency virus
HSDS
Height standard deviation score
HV
Height velocity
HVSDS
Height velocity standard deviation score
IEC
Independent ethics committee
IGFBP-3
Insulin-like growth factor binding protein 3
IGF-I
Insulin-like growth factor
IGT
Impaired glucose tolerance
IRB
Institutional review board
IUGR
Intrauterine growth retardation 
LDL
Low-density lipoproteins
LHRH
Luteinising hormone-releasing-hormone
OGTT
Oral glucose tolerance test
RBC
Red blood cell count
rhGH
Recombinant human growth hormone
SAE
Serious adverse event
SD
Standard deviation
SDS
Standard deviation score
SGA
Small for gestational age
SGOT
Serum-Glutamat-Oxalacetat-Transaminase
SGPT
Serum-Glutamat-Pyruvat-Transaminase
SmPC
Summary of medicinal Product Characteristics
SOP
Standard operating procedure
TSH
Thyroid stimulating hormone
WBC
White blood cell count
WHO
World Health Organization


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 8 of 55
Study No. EP00-401 
Amendment 5
Amendment rationale
Patients treated with rhGH in study EP00-401 were allowed to enter the post-treatment 
observation EP00-402 to monitor the occurrence of type 2 diabetes mellitus over a 10-years’ 
time span after treatment completion. According to the termination in 2018 of the 
complementary EP00-402 study: “A phase IV multicenter, long-term safety follow-up 
planned for 10 years after stopping growth hormone treatment in patients who have completed 
study EP00-401”, references to patients’ enrolment into the terminated EP00-402 study were 
removed from the EP00-401 protocol by this amendment.
This protocol amendment provides also further clarification of the lost to follow up definition. 
This clarification is implemented to limit protocol deviations resulting from prolonged
interruption(s) of Omnitrop dosing and to facilitate compliance to visit schedule.
Study status
A total of 278 patients had been enrolled in the study. The last subject was enrolled on 29-
Apr-2010. As of 31-Dec-2019, 32 patients, hereof 7 female patients, are still on Omnitrope 
therapy and will continue treatment until they reach their final height. So far, no case of 
pregnancy has been reported in the study. One hundred twenty seven female patients have 
already completed the study. Clinical Study Report with the final results for the long-term 
observation study EP00-402 was submitted to EMA on the 18-April-2019.
Changes to the protocol will allow to limit protocol deviations due to prolonged interruptions 
of Omnitrop treatment. 
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
List of changes made in this amendment are:
Section Protocol synopsis 

Reference to inclusion into EP00-402 study removed
Section 2 Study Purpose

Reference to inclusion into EP00-402 study removed
Section 6.5.9 Study drug discontinuation Reference to inclusion into EP00-402 study 
removed
Section 6.5.10 Premature withdrawal Reference to inclusion into EP00-402 study removed

Definition of lost to follow up clarified
Section 11 Discussion and rationale for study design features

Reference to inclusion into EP00-402 study removed
The changes described in this amended protocol are considered non-substantial.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 9 of 55
Study No. EP00-401 
This amended protocol will be sent to the Institutional Review Board (IRBs)/Independent 
Ethics Committees (IECs) and Health Authorities (HA) for approval or notification as 
required according to local regulations.
The changes herein do not affect the Informed Consent Form.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 10 of 55
Study No. EP00-401 
Protocol synopsis
Title of study: 
Long-term phase IV multicentre study on the safety and efficacy of Omnitrope® (rhGH) in short 
children born Small for Gestational Age (SGA) 
Study Purpose:
This study is performed as part of the Marketing Authorisation Holder’s post-marketing 
pharmacovigilance plan to investigate the long-term safety, in particular the diabetogenic potential and 
immunogenicity of rhGH therapy in short children born small for gestational age (SGA). In addition, 
within a supplemental follow-up study (Protocol number EP00-402) Sandoz was documenting the 
long-term safety during a follow-up period of 10 years after stopping growth hormone treatment and till 
closure of the study.
Objectives:
The primary objective of this study is to evaluate the long-term effect of growth hormone treatment on 
the development of diabetes during the treatment period in short children born SGA. The secondary 
objectives of this study are: 

to report the incidence of anti-rhGH antibodies (ABs) during treatment

to evaluate the efficacy (with respect to changes in height parameters) of Omnitrope®
treatment in short children born SGA

to evaluate IGF-I and IGFBP-3 levels during treatment 

to evaluate incidence and severity of adverse events
Inclusion/Exclusion criteria
Inclusion criteria:
1.
Pre-pubertal (Tanner stage I) children born SGA 
Boys: > 4 years of age (bilateral testicular volume <4 ml) (Marshall 1979)
Girls: > 4 years of age (bilateral Tanner breast stage 1) (Marshall 1969)
2.
Growth disturbance defined as current height SDS < -2.5 (and parental adjusted SDS < -1) 
for chronological age and sex according to country specific references. If country specific 
references are not available, pre-defined published references will be used.
3.
Birth weight and/or length below -2 SD for gestational age (according to country specific 
references). For the evaluation of gestational age, the date of the last menstrual period or 
ultrasonographic data obtained during the pregnancy should be used. If country specific 
references are not available, pre-defined procedures / published references will be used.
4.
Height records  between 18 months and 6 months prior to the start of GH treatment must be 
available
5.
Calculated height velocity SDS < 0 during the last year according to Prader (1989).
6.
Written informed consent of patient (for children who can read and write) and parent or legal 
guardian
Exclusion criteria:
1.
Onset of puberty
2.
Closed epiphyses
3.
Diabetes mellitus type I or type II 
4.
Fasting blood glucose > 100 mg/dl or > 5.6 mmol/l measured in venous blood sample
5.
Abnormal findings in OGTT defined by > 140 mg/dl or > 7.8 mmol/l after 120 minutes 
6.
Known IGF-I level above +2SD for sex and age


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 11 of 55
Study No. EP00-401 
7.
Acute critical illness e.g. suffering complications following open heart surgery, abdominal 
surgery, multiple accidental trauma, acute respiratory failure 
8.
Known to be hepatitis B or hepatitis C positive or HIV-positive, known to have advanced 
diseases such as AIDS or tuberculosis 
9.
Any other disease, genetic disorder or malformation or treatment known to be associated with 
growth retardation, e.g. Turner or Noonan syndrome, Laron syndrome, Russell-Silver 
syndrome, Prader-Willi syndrome, skeletal dysplasias, chronic renal failure, cystic fibrosis, 
heart and liver diseases, malabsorption (coeliac disease), malnutrition, patients receiving 
radiation therapy of head or spinal cord
10. History of malignancy of any organ system, treated or untreated, within the past 5 years 
whether or not there is evidence of local recurrence or metastases, with the exception of 
localized basal cell carcinoma of the skin
11. Known or suspected hypersensitivity to rhGH or any of the excipients (e.g. benzyl alcohol)
12. Previous treatment with any hGH preparation
13. Oral, inhalative or parenteral treatment with glucosteroids, except for physiological 
replacement, or hypothyroidism which has been left untreated, or was inadequately treated, 
or treated for less than 3 months 
14. Treatment with LHRH / gonadotropin releasing hormone (GnRH) analoga (e.g. triptorelin)
15. Treatment with antidiabetic medication (e.g. metformin, insulin)
16. Drug abuse, substance abuse, or alcohol abuse
17. Known to be immunocompromised
18. Intake of growth promoting medication, e.g. anabolic steroids
19. Use of other investigational drugs within 30 days of enrolment 
20. Patients unwilling and/or parents/guardians who are not capable of ensuring compliance with 
the provisions of the study protocol
Investigational therapy:
Omnitrope® (rhGH) supplied as Omnitrope® 5 mg/ 1.5 ml and 10mg / 1.5 ml solution for injection. 
These formulations will be referred to as Omnitrope® throughout this document. 
A dose of 0.035 mg/kg body weight (BW) per day will be administered by daily subcutaneous injection 
in the evening. Dose adjustments will be allowed during therapy consistent with label 
recommendations.
Study design:
Phase IV, prospective, open label, non-comparative, multicentre trial. Omnitrope® treatment will 
continue until final height is reached. Treatment should be discontinued after the first year of treatment 
if the height velocity SDS is below +1. Treatment should be discontinued if height velocity is below 2 
cm/year
 
 
Measurements of carbohydrate metabolism (in terms of fasting plasma glucose, insulin and HbA1c
levels) will be performed throughout treatment. Anti-rhGH antibodies (ABs) will be measured during 
Omnitrope® treatment. Patients will be monitored for safety and efficacy throughout treatment. 
Efficacy assessments:
Height, standardised height (HSDS), height velocity (HV) and standardised HV (HVSDS) will be 
assessed at baseline, every 3 months during the first two years of GH treatment and semi-annually 
thereafter until final height is reached (end of treatment). 
 
 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 12 of 55
Study No. EP00-401 
IGF-I and IGFBP-3 serum levels will be assessed by a central laboratory at baseline, at 3, 6, 9 and 12 
months, then biannually during treatment, and at the end of treatment. 
Safety assessments:
Carbohydrate metabolism: Fasting plasma glucose and insulin levels will be measured at baseline, 
at 6 and 12 months, then annually during GH treatment, and at the end of treatment. Glycosylated 
haemoglobin (HbA1C) will be measured at baseline, at 6 and 12 months, then annually during GH 
treatment and at the end of treatment. An oral glucose tolerance test (OGTT) will be performed at 
baseline, at 6 and 12 months and then annually during GH treatment, and at the end of treatment. 
Immunogenicity: Subjects will be screened for anti-rhGH antibodies (ABs) at baseline, at 3, 6, 9, 12, 
18 and 24 months, then annually during GH treatment and the end of treatment. Antibody-induced lack 
or loss of efficacy will be examined by comparing height outcome data between antibody-positive and 
antibody-negative subjects.
Additional safety criteria: Additional criteria for assessing safety will consist of monitoring and 
recording all adverse events, vital signs and body weight, physical condition, haematology, blood 
chemistry, thyroid function tests, lipids and urinalysis. Fundoscopy will be performed if intracranial 
hypertension is suspected (severe or recurrent headache, visual problems, nausea and/or vomiting). 
Adverse events, body weight and physical condition will be assessed at every study visit during 
Omnitrope® treatment. Laboratory tests for safety will be performed at baseline, at 6 and 12 months, 
then annually thereafter for the remainder of GH treatment, unless more frequent assessment is 
clinically indicated. 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 13 of 55
Study No. EP00-401 
Flow Chart Treatment Period
Treatment Period
TIME POINT
Screening
Start
3 mo
± 
3wks
6 mo
± 
3wks
9 mo
± 
3wks
12 
mo
± 
3wks
15 
mo
± 
3wks
18 mo
± 3wks
21 
mo
± 
3wks
24 
mo
± 
3wks
30 
mo
± 
3wks
36 
mo
± 
3wks
42 mo, 54 
mo etc…
± 3wks
48 mo, 60 
mo, etc…
± 3wks
End
± 3wks
VISIT
00
01
02
03
04
05
06
07
08
09
10
11
12, 14 etc…
annual visits
13, 15 etc…
annual visits
Final visit
Written Informed 
consent
X
Demographic data
X
Medical History 
X
SGA Diagnosis
X
Physical examination, 
weight (kg) and height 
(cm), pubertal status
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Vital signs
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Haematology
X
X
X
X
X
X
X
Blood chemistry incl. 
fT4, TSH, HbA1C, 
fasting plasma glucose 
and insulin levels
X
X
X
X
X
X
X
Urinalysis
X
X
X
X
X
X
X
Pregnancy test
X1
X1
X1
X1
X1
X1
Anti-hGH AB
X
X
X
X
X
X
X
X
X
X
IGF-I, IGFBP-3
X
X
X
X
X
X
X
X
X
X
X
X
OGTT 
X
X
X
X
X
X
X


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 14 of 55
Study No. EP00-401 
Treatment Period
TIME POINT
Screening
Start
3 mo
± 
3wks
6 mo
± 
3wks
9 mo
± 
3wks
12 
mo
± 
3wks
15 
mo
± 
3wks
18 mo
± 3wks
21 
mo
± 
3wks
24 
mo
± 
3wks
30 
mo
± 
3wks
36 
mo
± 
3wks
42 mo, 54 
mo etc…
± 3wks
48 mo, 60 
mo, etc…
± 3wks
End
± 3wks
VISIT
00
01
02
03
04
05
06
07
08
09
10
11
12, 14 etc…
annual visits
13, 15 etc…
annual visits
Final visit
Concomitant 
medication
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Fundoscopy
X3
X3
X3
X3
X3
X3
X3
X3
X3
X3
X3
X3
X3
X3
Drug dispensing and 
recording
X
X
X
X
X
X
X
X
X
X
X
X
X
Drug return 
(accountability) and 
recording
X
X
X
X
X
X
X
X
X
X
X
X
X
1: urine pregnancy test only in female patients after onset of menarche 
3: Fundoscopy will be performed only if intracranial hypertension is suspected


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 15 of 55
Study No. EP00-401 
1
Background
1.1
Investigational product
The active substance of Omnitrope® is somatropin, a growth hormone produced by a 
genetically modified strain of Escherichia coli. Omnitrope® is a biological medicinal product 
authorized in the EU. Omnitrope® , 1.3 mg/ml and 5 mg/ml, powder and solvent for solution 
for injection, Omnitrope® 5 mg/ 1.5 ml solution for injection and Omnitrope® 10mg/ 1.5 ml 
solution for injection, obtained marketing authorization in the following indications:
Children

Growth disturbance due to insufficient secretion of growth hormone (GH) and growth 
disturbance associated with Turner syndrome and chronic renal insufficiency.

Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental 
adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth 
weight and/or length below -2 standard deviation (SD), who failed to show catch-up 
growth (height velocity (HV) SDS <0 during the last year) by 4 years of age or later.

Prader-Willi syndrome (PWS) for improvement of growth and body composition. The 
diagnosis PWS should be confirmed by appropriate genetic testing.
Adults

Replacement therapy in adults with pronounced growth hormone deficiency. 
Detailed conditions for the use of Omnitrope® are described in the Summary of Product 
Characteristics (SmPC).
1.2
The indication SGA 
The most common definition of the term “small for gestational age” (SGA) is a birth weight 
and/or length of ≥ 2 standard deviations (SD) below the mean for the infant’s gestational age 
and sex (based on data derived from a reference population) (Lee et al 2003). The standards 
for neonatal growth were established by Usher and McLean (Usher and McLean 1969). These 
decades-old growth curves are based upon measurement of intrauterine growth between 25 
and 44 weeks of gestation of white infants born at sea level. Given that the race and ethnicity 
are known to be important modifiers of foetal growth patterns and that improvements in 
prenatal care and nutrition as well as the identification of factors that adversely affect the 
foetus may have resulted in a trend toward larger neonates, efforts should be made to improve 
the existing reference data.
The term SGA does not refer to foetal growth but to the size of the infant at birth. Intrauterine 
growth retardation (IUGR), while not a synonym, is commonly used interchangeably with 
SGA. Technically, IUGR implies a pathophysiological cause for the inhibition of normal 
growth in utero. Not all SGA infants have suffered from IUGR, while certain infants born 
after a period of IUGR are not necessarily SGA.
Impaired foetal growth may be due to placental, foetal and maternal causes. Placental factors 
include any mismatch between placental perfusion and foetal oxygenation. Placental 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 16 of 55
Study No. EP00-401 
insufficiency, placental abruption, infarction, and vascular abnormalities are the most 
common contributors to foetal growth impairment. 
15% - 20% of SGA cases may be a result of foetal factors, including genetic and 
chromosomal abnormalities, congenital malformations, innate metabolic problems, infections, 
and multiple gestations (Lin and Santolaya-Forgtas 1998). Maternal factors include medical 
conditions (such as hypertension, diabetes mellitus, systemic lupus erythematosus, renal 
disorders, collagen vascular diseases, infections), demographic factors (age, height, weight, 
maternal and paternal ethic origin, parity), nutritional status, cigarette smoking, illicit drug use, 
alcohol abuse, and the use of certain therapeutic drugs (Lee et al 2001). 
Ultrasound criteria are used as a diagnostic standard in the identification of SGA. 
Ultrasonographic foetal indices such as crown-rump length during the first trimester correlate 
well with gestational age, but they must be recorded accurately and birth length must 
subsequently be measured precisely for a correct diagnosis of SGA (Degani 2001).
Between 3% and 10% of all live births each year are described as SGA (Rosenfeld and Cariati 
2002). More than 90% of these children catch up to normal height by 2 to 3 years of age. 
According to data from the National Centre for Health Statistics (in the US), approximately 
91,000 infants were born SGA in 1999 in the United States (the most recent year for which 
adult birth data are available from the National Centre for Health Statistics (Ventura et al 
1999)). In 2000, 4,058,814 infants were born in the United States according to the data from 
the National Centre for Health Statistics (Rosenfeld and Cariati 2002). Using this figure and 
defining SGA as the ≤2.3 percentile, approximately 93,400 SGA infants are born annually in 
the United States. Extrapolating from that figure, the number of SGA children in the United 
States between the ages of 2 and 16 years with persistent short stature is estimated to be 
146,000.
Catch-up growth of an infant born SGA is defined as accelerated growth that results in the 
attainment of length and weight within 2 SD of the mean for corresponding sex and age. This 
surge in growth generally begins immediately after birth, with the largest increases occurring 
by 6 months of age. SGA babies who fail to display catch-up growth by 2 years of age, are at 
increased risk of adult short stature (Albertsson-Wikland and Karlberg 1997).
Endocrine and metabolic outcomes may be related to failure to achieve catch-up. While GH 
levels have a relatively small effect on in utero growth, insulin and insulin-like growth factors 
(IGFs) are key modifiers of foetal growth and development. Endocrine studies in utero show 
that growth retarded foetuses have reduced insulin (Economides et al 1989) and IGF-I 
(Lassarre et al 1991) levels and in the neonatal period, babies born SGA have low IGF-I 
levels and IGFBP-3 levels despite elevated GH secretion (Cance-Rouzaud et al 1998). Failure 
of catch-up growth is associated with persistent low IGF-I and IGFBP-3 levels (Boguszewski 
et al 1997), suggesting ongoing dysfunction of the GH/IGF-I axis. In contrast to their high 
neonatal GH levels, older SGA children may have reduced GH secretion.
In addition to short stature, SGA infants may be predisposed to a number of developmental 
problems. Infants born with SGA usually have less body fat than those who are born adequate 
for gestational age. Serum concentrations of leptin, a protein produced by adipose tissue and 
involved in the regulation of the appetite and body weight are reduced in short children born 
SGA, possibly leading to lack of appetite and inadequate consumption of calories 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 17 of 55
Study No. EP00-401 
(Boguszewski et al 2000). SGA can have adverse effects on the health of children during 
infancy and childhood, including slower physical growth, possibly slower mental 
development and higher morbidity. Some evidence suggests that SGA may affect brain 
development, leading to an increased risk of slight yet significant cognitive and 
neurodevelopmental impairment. For example, one study showed that absence of catch-up 
growth among male infants who were born SGA was the most important predictor of 
subnormal performance in standard psychological tests (Lundgren 2001).
SGA children are also more likely to have congenital abnormalities. Severely growth-retarded 
infants are at markedly increased risk for foetal and neonatal death, hypoglycaemia, 
hypocalcaemia, polycythemia.
There is also convincing evidence that SGA is a predisposing factor for the development of 
hypertension (Barker et al 1990), diabetes (Hales et al 1991) and cardiovascular disease 
(Barker et al 1993) in adult life.
1.2.1
Type 2 Diabetes and SGA
Studies in Europe, North America, and the developing world (Reynolds and Phillips 1998, 
Phillips 1996, Boyko 2000, Curhan et al 1996, Lithell et al 1996, McCance et al 1994, Rich-
Edwards et al 1999) have shown that low birth weight in babies born at term is associated 
with a higher prevalence of glucose intolerance and type 2 diabetes in adult life. For example, 
Rich-Edwards and colleagues (Rich-Edwards et al 1999) investigated the relationship between 
birth weight and type 2 diabetes in more than 69,000 adult women as part of the Nurses 
Health Study. There was an inverse association between the risk of type 2 diabetes in 
adulthood and the entire range of birth weight. The trend was strong and statistically 
significant with adults who weighed < 5 pounds at birth, who had 1.8 times the risk of 
developing type 2 diabetes compared with their normal birth weight counterparts. Similar 
results have been found among men and women across a variety of populations.
As with the association between SGA and adult cardiovascular disease, the “foetal origins” 
hypothesis focuses on the intrauterine environment as the etiologic agent. Alternatively, 
insulin resistance may be controlled by the same genetic factors that regulate foetal growth 
(Stern et al 2000, Rich-Edwards et al 1997). Hattersley and colleagues (Hattersley and Tooke 
1999) theorize that genetically determined insulin resistance results in impaired insulin-
mediated growth in the foetus as well as insulin resistance in adult life. These researchers 
propose that there is an insulin-resistant genotype that may predispose to low birth weight, 
insulin resistance, diabetes, and hypertension.
1.2.2
Syndrome X and SGA
Certain chronic and metabolic disorders including hypertension, glucose intolerance, central 
obesity, and dyslipidemia tend to cluster in the same individuals, leading to an increased risk 
of mortality from cardiovascular disease. This syndrome is referred to by several names, 
including syndrome X, the metabolic syndrome, and insulin resistance syndrome. Several 
studies have demonstrated an increased prevalence of syndrome X among adults born SGA 
(Valdez et al 1994, Li et al 2001, Ong and Dunger 2002, Yarbrough et al 1998). Moreover, 
adult overweight and obesity increase the risk of syndrome X, and studies show adults born 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 18 of 55
Study No. EP00-401 
SGA may have an increased risk of obesity. Thus, close clinical follow-up of weight, height, 
and body mass index (BMI) in patients born SGA is particularly important.
Yarbrough and colleagues (Yarbrough et al 1998) studied 303 postmenopausal white women 
aged 50-84 years to examine the relationship between birth weight and the metabolic 
syndrome. The metabolic syndrome was defined as the grouping of hypertension, 
dyslipidemia, and abnormal glucose tolerance in an individual. The metabolic syndrome was 
present in 7.9% of this study population. Compared with women in the highest birth weight 
group, those in the lowest birth weight group (mean =5.51) had a significantly increased 
prevalence (12.0% vs 4.3%, P < 0.05) and 2.41 times the risk (95% CI = 1.06 - 5.51) of 
developing the metabolic syndrome. In addition, women in the lowest birth weight group who 
became adults in the highest BMI group had the highest prevalence of the metabolic 
syndrome (approximately 30%).
Leger and associates (Leger et al 1997) conducted a similar study in young adults. The 
regional cohort comprised 236 subjects born SGA and 281 subjects born adequate for 
gestational age with a mean age of 20.6 years. After adjusting for sex and BMI, mean plasma 
glucose concentration 30 minutes after a glucose load was significantly higher in subjects 
born SGA compared with subjects born adequate for gestational age, as were insulin and pro-
insulin concentrations 30 and 120 minutes after a glucose load.
1.2.3
Growth Hormone therapy in SGA patients
Growth Hormone (GH) therapy is indicated for children who were born SGA and have 
persistent short stature (below - 2 SD); are at least 2 years of age; and are growing at an 
average or subnormal rate of age, provided that other causes for short stature such as growth
inhibiting medication, chronic disease, endocrine disorders, emotional deprivation or 
syndromes (except Silver Russell syndrome) have been ruled out (Lee et al 2001).
The aims for GH therapy in children born SGA who fail to catch up are to:

Increase height during childhood,

Sustain the height gain in adolescence, and

Normalise final adult height.
Results of several trials indicate that high-dose GH therapy accelerates short-term height 
velocity in short children born SGA.
In the first studies examining the effects of GH therapy in children with insufficient catch-up 
growth, GH was given with low frequency or in substitution doses. Since the growth 
responses were inconsistent, researchers began to evaluate high-dose GH schedules.
De Zegher et al (2002) evaluated the effects of daily high-dose GH therapy over 2 years in 50 
short, prepubertal, non-GH-deficient children born SGA in an open-label, controlled, 
multicentre trial. Catch-up growth was observed in none of the untreated and in all of the 
treated children. Both treatment groups experienced significantly greater height velocity 
(P < 0.001), height velocity SDS (P < 0.001), and height gain SDS (P < 0.001) compared with 
the control group. There were, however, no significant differences between the two GH doses. 
Height velocity was greater in the first year of treatment compared with the second. The mean 
gain in height for the treatment groups was 2.3 SDS. GH-induced catch-up growth was 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 19 of 55
Study No. EP00-401 
associated with an acceleration of bone maturation. There were associated elevations in serum 
concentrations of insulin, IGF-I and IGFBP-3.
In a follow-up study, De Zegher et al (1999) reported on the further prepubertal growth of the 
children treated in the previous study after withdrawal of the high-dose GH treatment. Of the 
38 treated children, none developed precocious puberty and 22 remained prepubertal. Height 
increased by an average of 2.5 SD over the 2-year treatment period and decreased by 0.4 SD 
during the first and 0.3 SD in the second year after GH withdrawal. No further GH treatment 
was given to those children (n=13) whose mean adjusted height stabilised at an SDS of 
around -1.0 after completion of the first treatment phase. When stature was very short at the 
completion of the first phase (mean adjusted height = -3.3 SD score; n=9), a second course of 
GH treatment of 0.2 IU/kg/day was initiated either 2 years (n=5) or 3 years (n=4) after initial 
GH withdrawal. 
This second treatment phase was associated with further growth and also resulted in a mean 
adjusted height of -1.0 SD score.
De Zegher et al (2000) also reported the data of four randomized, multicentre studies 
examining the effects of continuous and discontinuous GH therapy in a total of 49 untreated 
and 139 treated children born SGA. At the start of the study, the average age of the children 
was 5.2 years. Two studies examined the effects of continuous GH treatment at a dose of 
0.033 or 0.067 mg/kg/day over a 6-year period. The other 2 studies examined the impact of 
discontinuous GH treatment at a range of 0.033-0.10 mg/kg/day. In the discontinuous regimen, 
the initial treatment period of 2 to 3 years was followed by a withdrawal phase of 1 to 2 years 
and then either none, one, or more additional treatment phases at the same dose. Continuous 
GH treatment for 6 years was associated with mean increases in height of 2.0 SD for the low-
dose and 2.7 SD for the high-dose regimens. Discontinuous GH treatment, with an average 
dose of 0.032 mg/kg/day over the course of 6 years, resulted in a mean height increase of 1.6 
SD. Patients in the untreated group, on the other hand, increased their height by a mean of 
only 0.2 SD. Bone maturation progressed similarly in all treatment groups. The average GH 
doses over the 6 year period, parental-adjusted height SD scores, and age at start of treatment 
were the prime predictors of the growth response.
Sas et al (1999) began a randomized, double-blind, dose-response, multicentre trial on the 
long-term effects of continuous GH therapy (five years) in 79 prepubertal children with short 
stature born SGA. Twenty-two patients with GH deficiency were included in the study and 
there was no untreated control group. Patients were randomized to receive 3 IU/m2 body 
surface per day or 6 IU/m2 body surface per day. Five of the 79 children dropped out of the 
study for such reasons as poor compliance, concomitant treatment, and possible GH 
insensitivity. Their data were not included in the analysis. After 5 years of treatment, the mean 
height SD for chronological age was increased significantly over baseline (P < 0.001). In 
addition, almost every subject had reached a height within the normal range after the 
treatment period. Except for the children who remained prepubertal over the course of the 5 
years, there was no significant growth difference in response to the 2 doses. GH treatment was 
associated with an acceleration of bone maturation, increase in bone age, and increase in 
predicted adult height regardless of the GH dose.
On the basis of efficacy data but taking into account the concerns of long-term safety, the 
Committee for Proprietary Medicinal Products (CPMP) of EMEA recommended that the 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 20 of 55
Study No. EP00-401 
treatment with GH of the children with growth disturbance (current height SDS <-2.5 and 
parental adjusted height SDS <-1) born SGA, who failed to show catch-up growth by 4 years 
of age or later, should be initiated at a dose of 0.035 mg/kg/day and continued until final 
height is reached (CPMP/3477/03).
1.2.4
Metabolic effects of growth hormone treatment in patients born SGA
In view of the fact that several studies have found an association between low birth weight 
and impaired insulin sensitivity, type 2 diabetes, hypertension and cardiovascular disease in 
later life, and because growth hormone is known to increase fasting and postprandial insulin 
levels, concern has been expressed regarding the possible detrimental effects of GH therapy in 
children born SGA.
Sas et al (2000) evaluated the changes in body metabolism, blood pressure and lipid 
metabolism in 79 GH-treated children (2 dose groups, 1 mg/m2/day and 2 mg/m2/day). The 
authors measured skin fold thickness, systemic blood pressure, and blood lipids in the 79 
subjects. 
Compared with normal children, the short children born SGA had significantly lower BMI, 
higher systolic blood pressure, and normal lipids. During GH treatment, BMI increased 
significantly over baseline values with no overall changes in body fat percentage compared 
with age-matched healthy controls. These findings demonstrated that GH therapy decreases 
adipose tissue mass and increases muscle mass in this group of patients. Both systolic and 
diastolic blood pressure SDS also decreased significantly (P < 0.05) during therapy. After 6 
years of therapy, there were no differences in blood pressure measurements between the 
treatment group and age-matched controls. While pre-treatment mean lipid values were 
normal, GH treatment was associated with significant changes in the lipid profiles during the 
first year of therapy; total cholesterol (P < 0.001) and LDL cholesterol (P < 0.001) decreased 
significantly and stabilised thereafter.
In the same study (Hokkon-Koelega et al 2004, Sas et al 2001), all 79 children underwent 
standard oral glucose tolerance tests at baseline, after 1 and 6 years of GH treatment and 6 
months after discontinuation of GH therapy. Before GH therapy 8% of the children had 
impaired glucose tolerance (IGT) according to WHO criteria. IGT was found in 4% of 
children after 6 years of therapy and in 10% of children after stopping GH treatment. GH 
therapy induced considerably higher fasting and glucose-stimulated insulin levels, indicating 
insulin resistance. After discontinuation of GH therapy the mean serum glucose levels 
remained normal and the mean serum insulin levels decreased significantly, to normal age-
matched reference values. HbA1C levels were always in the normal range and none of the 
children developed diabetes mellitus. 
2
Study Purpose
Epidemiological evidence suggests that children born SGA may be at an increased risk of 
insulin resistance and type 2 diabetes in later life. Given that GH therapy has been shown to 
induce transient resistance to the actions of insulin in children, concerns over the diabetogenic 
potential of GH therapy in individuals predisposed to metabolic abnormalities, such as 
children born SGA, have been raised. However in most recent investigations which followed-


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 21 of 55
Study No. EP00-401 
up SGA patients after treatment completion no increased risk of insulin resistance or type 2 
diabetes could be observed in the long-term perspective (van der Steen et al 2017, Poidvin et 
al 2017, Poidvin et al 2017).
This study is performed as part of the Marketing Authorisation Holder’s post-marketing 
pharmacovigilance plan to investigate the long-term safety, in particular the diabetogenic 
potential and immunogenicity of rhGH therapy in short children born small for gestational age 
(SGA). Within an additional study EP00-402, Sandoz was documenting the long-term safety 
during a follow-up period of 10 years after stopping growth hormone treatment till study 
closure.
The purpose of this study is 
(a) to monitor short children born SGA for the development of diabetes during Omnitrope®
treatment and 
(b) to report the incidence of anti-rhGH antibodies (ABs) during treatment GH treatment.
3
Objectives
3.1
Primary objective(s)
The primary objective of this study is to evaluate the long-term effect of growth hormone 
treatment on the development of diabetes in short children born SGA during treatment. 
3.2
Secondary objectives
The secondary objectives of this study are: 

to report the incidence of anti-rhGH antibodies (ABs) during Omnitrope® treatment

to evaluate the efficacy (with respect to changes in height parameters) of Omnitrope® 
treatment in short children born SGA

to evaluate IGF-I and IGFBP-3 levels during treatment 

to evaluate incidence and severity of adverse events
4
Study design
This study is designed as a phase IV, prospective, open label, non-comparative, multicentre 
trial. Safety and efficacy will be assessed periodically during treatment. 
Treatment should be discontinued after the first year of treatment if the height velocity SDS is 
below +1. Treatment will continue until final height (height velocity < 2 cm/year, 
 
 
 is reached but will be discontinued earlier if medically indicated or if 
there is inadequate response to treatment.
A summary of the study plan is given below.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 22 of 55
Study No. EP00-401 
Table 4-1
Study Outline
PHASE
Treatment
TIME
POINT
Start
3
mo
6
mo
9
mo
12
mo
Study visits until final height
End
VISIT
01
02
03
04
05
  06, 07, 08, 09, etc.
End of treatment
THERAPY
0.035 mg/kg BW/day
5
Population
The study population will consist of a representative group of children of both sexes, aged ≥4, 
with short stature born small for gestational age (SGA).
SGA is defined as per the label indication authorised by the EMEA:
“Growth disturbance (current height standard deviation score (SDS) < -2.5 and parental 
adjusted SDS < -1) in short children born small for gestational age (SGA), with a birth weight 
and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height 
velocity (HV) SDS < 0 during the last year) by 4 years of age or later.”
Standardized and controlled Enrolment Authorization:
To assist Investigators to avoid errors in the local calculation of the auxological parameters by 
applying different ways of calculation and to ensure that only patients in strict adherence to 
the SGA definition in the study protocol are enrolled, a standardized and controlled procedure 
for patient enrolment authorization (“Enrolment Authorization Fax”) was implemented after 
the first 60 patients were enrolled in the study (by November 2008).
For the patients enrolled before implementation of the “Enrolment Authorization Fax” a 
standardized approach for the recalculation of growth indication for inclusion according to 
inclusion criteria 2, 3 and 5 was implemented in March 2009. 
Historical data will be used to screen the subjects for eligibility, i.e. records of birth length 
and weight, as well as height and weight measurements taken 1 year (between 18 months and 
6 months) before the start of GH treatment for calculation of HVSDS. For the evaluation of 
gestational age, the date of the last menstrual period will be used, however, if this is not 
known, ultrasonographic data obtained during the pregnancy may be used. 
The study will be performed in approximately 40 centres in Europe. The treating physicians 
shall be appropriately qualified and experienced in the diagnosis and management of SGA. 
The patients will be treated as out-patients.
 Subjects dropping out before 
completing 1 year of treatment will be replaced.
 
 
 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 23 of 55
Study No. EP00-401 
 
 
Patients who have started their treatment with Omnitrope® 5 mg/ml powder and solvent for 
injection will continue with Omnitrope® 5 mg/1.5 ml solution for injection from Visit 5 on (i.e. 
after 12 months of treatment with Omnitrope® 5 mg/ml powder and solvent for injection). 
Depending on the weight and corresponding injection volume patients may also switch to 
Omnitrope® 10 mg/ 1.5 ml solution for injection. 
5.1.
Inclusion/exclusion criteria
The investigator must ensure that all patients who meet the following inclusion and none of 
the exclusion criteria are offered enrolment in the study. No additional exclusions can be 
applied by the investigator, in order for the study population to be representative of all eligible 
patients.
5.1.1
Inclusion criteria
1. Pre-pubertal (Tanner stage I) children born SGA 
Boys: > 4 years of age (bilateral testicular volume < 4 ml) 
Girls: > 4 years of age (bilateral Tanner breast stage 1)
2. Growth disturbance defined as current height SDS < -2.5 (and parental adjusted SDS < -1) 
for chronological age and sex according to country specific references. If country specific 
references are not available, pre-defined published references will be used.
3. Birth weight and/or length below -2 SD for gestational age (according to country specific 
references). For the evaluation of gestational age, the date of the last menstrual period or 
ultrasonographic data obtained during the pregnancy should be used. If country specific 
references are not available, pre-defined procedures / published references will be used.
4. Height records between 18 months and 6 months prior to the start of GH treatment must 
be available
5. Calculated height velocity SDS < 0 during the last year according to Prader (1989). 
6. Written informed consent of patient (for children who can read and write) and parent or 
legal guardian
5.1.2
Exclusion criteria 
1. Onset of puberty
2. Closed epiphyses
3. Diabetes type I or type II
4. Fasting blood glucose > 100 mg/dl or > 5.6 mmol/l measured in venous blood sample
5. Abnormal findings in OGTT defined by > 140 mg/dl or > 7.8 mmol/l after 120 minutes 
6. Known IGF-I level above +2SD for sex and age
7. Acute critical illness e.g. suffering complications following open heart surgery, abdominal 
surgery, multiple accidental trauma, acute respiratory failure. 
8. Known to be hepatitis B or hepatitis C positive or HIV-positive, known to have advanced 
diseases such as AIDS or tuberculosis 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 24 of 55
Study No. EP00-401 
9. Any other disease, genetic disorder or malformation or treatment known to be associated 
with growth retardation, e.g. Turner or Noonan syndrome, Laron syndrome, Russell-Silver 
syndrome, Prader-Willi syndrome, skeletal dysplasias, chronic renal failure, cystic fibrosis, 
heart and liver diseases, malabsorption (coeliac disease), malnutrition, patients receiving 
radiation therapy of head or spinal cord
10. History of malignancy of any organ system, treated or untreated, within the past 5 years 
whether or not there is evidence of local recurrence or metastases, with the exception of 
localized basal cell carcinoma of the skin
11. Known or suspected hypersensitivity to hGH or any of the excipients (benzyl alcohol)
12. Previous treatment with any hGH preparation
13. Oral, inhalative or parenteral treatment with glucosteroids, except for physiological 
replacement, or hypothyroidism which has been left untreated, or was inadequately treated, 
or treated for less than 3 months 
14. Treatment with LHRH / gonadotropin releasing hormone (GnRH) analoga (e.g. 
triptorelin)
15. Treatment with antidiabetic medication (e.g. metformin, insulin)
16. Drug, substance, or alcohol abuse
17. Known to be immunocompromised
18. Intake of growth promoting medication, e.g. anabolic steroids 
19. Use of other investigational drugs within 30 days of enrolment 
20. Patients unwilling and/or parents/guardians who are not capable of ensuring compliance 
with the provisions of the study protocol
6
Treatment
6.1
Investigational drug
6.1.1
Omnitrope® 5 mg/ml powder and solvent for solution for injection
Omnitrope® 5 mg/ml is supplied with 1 vial containing somatropin as a powder and a 
cartridge containing diluent (bacteriostatic water for injection containing 1.5% benzyl alcohol 
as preservative). Omnitrope® is to be stored refrigerated at 2ºC to 8ºC and protected from light. 
Freezing must be avoided. 
After reconstitution by means of a specifically designed reconstitution set (“Transfer Set“) 
provided by Sandoz, one cartridge contains 5.0 mg (15 IU) somatropin per ml. 
The reconstituted Omnitrope® solution for injection can be stored up to 21 days at 2ºC to 8ºC 
in the refrigerator. The cartridges are designed to be used in a pen injection device, the 
Omnitrope® Pen, which will be provided by Sandoz. 
Parents and patients, if appropriate, will be sufficiently trained on the use of the Transfer set 
and the dose and injection technique by means of the Omnitrope® Pen.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 25 of 55
Study No. EP00-401 
6.1.2
Omnitrope® 5 mg/ 1.5 ml and Omnitrope® 10 mg/ 1.5 ml solution for 
injection
Omnitrope®  5 mg/ 1.5 ml (injection containing 0.9 % benzyl alcohol as preservative) and
Omnitrope® 10mg/ 1.5 ml are supplied in cartridges containing solution for injection. 
Omnitrope® is to be stored refrigerated at 2ºC to 8ºC and protected from light. Freezing must 
be avoided.
The cartridges are designed to be used in a pen injection device, the Omnitrope® Pen will be 
provided by Sandoz. After opening and first injection the cartridge should remain in the pen 
and has can be stored up to 28 days at 2ºC to 8ºC in the refrigerator. 
Parents and patients, if appropriate, will be sufficiently trained on the dose and injection 
technique by means of the Omnitrope® Pen.
6.2
Treatment groups
There will only be one treatment group.
6.3
Treatment assignment 
This study is not randomized.
Each patient is uniquely identified in the study by a combination of his/her centre number and 
patient number. The centre number is assigned by Sandoz to the investigative site. Upon 
signing the informed consent form, the first patient is assigned patient number 001 per site, 
and subsequent patients are assigned consecutive numbers (e.g., the second patient is assigned 
patient number 002, the third patient is assigned patient number 003). Once assigned to a 
patient, a patient number will not be reused. If the patient fails to start treatment for any 
reason, the reason for not being started on treatment will be entered on the Screening Log, and 
the Demography CRF should also be completed.
Only this unique identifier number will be used to identify the enrolled patients.
6.4
Treatment blinding
Treatment during this study is open-label.
6.5
Treating the patient
6.5.1
Dose
A daily dose of 0.035 mg/kg per day will be administered by subcutaneous injection in the 
evening. A table is provided in the appendix for calculation of the individual dose according 
to the individual body weight.
6.5.2
Study drug administration
Each study site will be supplied, by Sandoz, with study drug in country specific packaging 
identifying the medication as study drug. Investigator staff will identify the study drug for 
dispensing to the patient using the centre and patient code number. Prior to dispensing study 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 26 of 55
Study No. EP00-401 
drug to the patient, investigator staff shall transfer the tear-off label with the serial number of 
the vials to the respective CRF page. 
A daily dose of 0.035 mg/kg per day will be administered by subcutaneous injection in the 
evening. The injection site should be varied to prevent lipoatrophy. 
The investigator should instruct the patient to administer the study drug exactly as prescribed 
(promote compliance). All doses dispensed to the patient and all dose changes during the 
study must be recorded on the Dose Administration Record CRF. 
For handling of study medication please refer to section 6.1.
6.5.3
Treatment duration
Omnitrope® treatment will continue until final height is reached. Treatment should be 
discontinued after the first year of treatment if the height velocity SDS is below +1 (see also 
6.5.9 Study drug discontinuation). 
 
 
A standardized controlled procedure for the calculation of the treatment response (“Treatment 
Response Control Fax”) was implemented.
6.5.4
Permitted study drug dose adjustments
Dose adjustments will be allowed during therapy consistent with label recommendations to 
take individual responsiveness into consideration. This dose may be adjusted at subsequent 
study visits; investigators are requested to adapt the dose at every study visit according to the 
changing body weight after initiation of therapy. 
For patients who are unable to tolerate the protocol-specified dose scheme, dose adjustments 
and interruptions up to 3 weeks are permitted in order to keep the patient on study drug. This 
may for instance be required if transient labelled side effects occur. Please also refer to section 
6.5.10. 
All changes must be recorded on the Dose Administration Record CRF.
6.5.4.1
Dose reduction
If IGF-I exceeds +2SD compared to references for age and pubertal status, the IGF-I/IGFBP-3 
ratio will be determined. If IGF-I/IGFBP-3 ratio also exceeds +2SD, a dose reduction is 
recommended. The extent of the dose reduction will be at the discretion of the investigator. 
6.5.5
Dose increase
An increase of recommended dose of 0.035 mg/kg per day is not allowed, especially if based 
on concomitant treatment e.g. treatment with LHRH/GnRH analoga. In case an increase of the 
dose is required for obtaining increased growth velocity, the patient has to discontinue the 
study.
6.5.6
Rescue medication
Not applicable


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 27 of 55
Study No. EP00-401 
6.5.7
Prohibited medication
Treatment with antidiabetic medication (e.g metformin, insulin) is not allowed during the 
study. If treatment with antidiabetics becomes necessary, the patient has to discontinue the 
study.
6.5.8
Concomitant treatment
Other medication which is considered necessary for the patient’s welfare may be given at the 
discretion of the investigator. Administration of all such drugs must be reported in the 
appropriate section of the Case Report Forms (CRFs), along with dose information, dates of 
administration and reason for use. 
Any diagnostic, therapeutic or surgical procedure should be recorded, including the date, 
indication, descriptions of the procedure and clinical findings.
6.5.9
Study drug discontinuation
Treatment can be terminated at any time, at the discretion of the investigator or the Sponsor, 
or at the patient’s request, in the event of an AE or due to treatment failure. 
Study drug treatment has to be discontinued in the following cases during treatment period:

Occurrence of overt diabetes mellitus; defined as fasting blood glucose >126 mg/dl or 
> 7.0 mmol/l and abnormal findings in OGTT defined by > 200 mg/dl or > 11.1 mmol/l 
after 120 minutes. For further instruction see appendix 

Requirement of an increase of the recommended dose to obtain increased growth velocity

Renal transplantation

Diagnosis of benign intracranial hypertension 

Malignancy

Pregnancy

Withdrawal of informed consent

Treatment failure
Treatment failure is defined as: Inadequate response to treatment, e.g. height velocity standard 
deviation score (HVSDS) below +1 in the first year. 
Furthermore a standardized controlled procedure for the calculation of the treatment response 
(via “Treatment Response Control Fax”) was implemented (see also 6.5.3 treatment duration) 
to ensure a unified flawless computation and to authorize treatment continuation, if applicable 
(managed by Data Management at Metronomia). In case the Investigator does not agree with 
the assessment by Data Management, Sandoz is informed and initiates the re-assessment of 
the treatment response data via an independent specialist reader.
Patients who are withdrawn from the study before completing at least one year of treatment 
with Omnitrope® will be replaced.
Study drug must be discontinued if the investigator concludes that continuation would result 
in significant safety risk for that patient and in the event of pregnancy.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 28 of 55
Study No. EP00-401 
Patients who discontinue study drug before completing the study should not be considered 
withdrawn from the study and should be scheduled for a final visit as soon as possible, at 
which time all of the assessments for the final visit will be performed. 
A Study Drug Discontinuation form should be completed, giving the date and reason for 
stopping the study drug. All patients who discontinue study drug, including those who refuse 
to return for a final visit, will be contacted for safety evaluations during the 4 weeks following 
the last dose of the study drug.
Patients who discontinued this study for any reason will not be able to re-enter the study.
6.5.10
Premature patient withdrawal
Patients may voluntarily withdraw from the study or be dropped from it at the discretion of the 
investigator at any time. Patients should also be withdrawn at any time if the investigator 
concludes that it would be in the patient’s best interest. Patients must be withdrawn from the 
study if any of the following occur:

Withdrawal of informed consent
Protocol violations should not lead to patient withdrawal unless they indicate a significant risk 
to the patient’s safety. Patients may be considered withdrawn if they state an intention to 
withdraw, or fail to return for visits, or become lost to follow-up for any reason.
A patient is considered to be lost to follow up in case patient status is unclear because they fail 
to appear for study visit within visit window without stating an intention to withdraw and the 
patient does not react to at least three attempts of the investigator to schedule the visit within 
visit window (the investigator should show “due diligence” by documenting in the source 
documents steps taken to contact the patient, e.g. dates of telephone calls, registered letters, 
etc.)
A patient who does not attend the visit during visit window is considered as lost to follow up, 
unless
-
(s)he experiences medical condition, which prevents her/him from appearing to the 
visit within visit window and
-
patient notifies the investigator about this condition during visit window or earlier and
-
before or during visit window sponsor grants upfront written approval for the visit 
outside of visit window.
If premature withdrawal occurs for any reason, the investigator must determine the primary 
reason for the patient’s premature withdrawal from the study and record this information on 
the CRF. For lost to follow up patients the termination fax specifying the reason of 
withdrawal should be provided to DM within 4 weeks of calculated visit date.
6.5.11
Emergency unblinding of treatment assignments
Not applicable.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 29 of 55
Study No. EP00-401 
6.6
Contraception measures
Females of child-bearing potential are defined as all females physiologically capable of 
becoming pregnant. This includes female pediatric patients who are menarchal or who 
become menarchal during the study. 
All menarchal girls and their parents/caregivers should be informed about the potential risks 
of pregnancy and the need to prevent pregnancy during the study. It is important to be 
sensitive in introducing this issue, as understanding and comprehension of puberty, sexual 
activity, pregnancy and contraception is influenced by age, as well as factors such as precocity, 
socio(educational) economic and familial background. These discussions with the patient and 
her parents/caregivers are therefore best performed by investigators familiar with the pediatric 
subject and her family and should be guided by requirements of the local regulatory 
authorities. These discussions should take into account the socio-economic, cultural factors 
and religious beliefs of the adolescent participant and her family. The investigator should also 
discuss the management of the pregnancy test results with the patient and her 
parents/caregivers. The privacy of the patient should be considered in accordance with the 
local law and ethics.
Urine pregnancy tests will be performed for all females of child-bearing potential according to 
the schedule in the Flow Chart. Additional pregnancy tests may be performed at the 
investigator’s discretion during the study. Patients becoming pregnant must be discontinued 
from study drug.
All female patients of child-bearing potential, defined as all women physiologically capable 
of becoming pregnant must use effective methods of contraception during dosing of study 
treatment. Effective contraception methods include:

Total abstinence (when this is in line with the preferred and usual lifestyle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation 
methods) and withdrawal are not acceptable methods of contraception 

Female sterilization (have had surgical bilateral oophorectomy with or without 
hysterectomy), total hysterectomy or tubal ligation. In case of oophorectomy alone, 
only when the reproductive status of the woman has been confirmed by follow up 
hormone level assessment 

Male sterilization. For female subjects participating in the study, the vasectomized 
male partner must be the sole partner for that subject 

Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository 

Use of oral, injected or implanted hormonal methods of contraception or other forms 
of hormonal contraception that have comparable efficacy (failure rate <1%), for 
example hormone vaginal ring or transdermal hormone contraception

Placement of an intrauterine device (IUD) or intrauterine system (IUS)
In case of use of oral contraception it is recommended that the female patients of childbearing 
potential is exerting abstinence for a period of 3 months until safe onset of action of the oral 
contraception.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 30 of 55
Study No. EP00-401 
7
Visit Schedule and assessments
The Flow Chart (synopsis) lists assessments and indicates with an “X” the visits during which 
they are performed. Patients should be seen for all visits at the designated time-point or as 
close to it as possible. A time window for the visits of up to +/- three weeks will be allowed.
All data obtained from the assessments listed in the Flow-Chart and described in detail in the 
subsections below must be supported in the patient’s source documentation. 
The study visit schedule consists of screening period for up to 8 weeks prior to the initiation 
of therapy followed by an open treatment period until final height is reached. The study plan 
timetable (please refer to the Flow Chart Treatment Period) indicates the number and timing 
of the planned visits. During these visits, the mentioned efficacy and safety parameters will be 
assessed. It is important to maintain the visit schedule during the treatment period as 
accurately as possible. If any individual visit date does not conform to the planned schedule, 
the subsequent visit should be realigned to maintain the schedule relative to the start of the 
treatment period.
The clinical and laboratory investigational plan per visit is summarized in the Flow Chart 
Treatment Period.
7.1
Procedures by visits
7.1.1
Screening Period (Visit 00)
At the screening visit (to be performed within 8 weeks prior to visit 1), all data to confirm the 
diagnosis SGA will be collected in addition to demographic and baseline data to determine the 
patient’s eligibility for study participation.

Demographics (date of birth, sex, ethnic origin) 

Medical and surgical history

Prenatal history 

Placental dysfunction (eclampsia, infarcts), genetic causes

Maternal disease

Gestational age

Birth history

Vaginal/caesarean, Apgar-score, blood pH, body weight, body length, neonatal 
complications (need for glucose, respiratory support)

Infant growth data

Retrospective weight, length, feeding mode

Pre-treatment growth data

Height measurement between 18 months and 6 months prior to the start of 
Omnitrope® treatment to enable calculation of pre-treatment height velocity

Current standing height

Physical examination, puberty stage and vital signs


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 31 of 55
Study No. EP00-401 

Body mass index

Parental height and weight

Growth hormone secretion

Collection of historical data with regard to growth hormone secretion

Written informed consent will be obtained before any measurements are made. 

Recording of patient’s and parents’ data in the respective CRF

Patients history and details of concomitant medications

Recording of historical X-ray radiograph of the patient’s left hand and wrist
7.1.2
Start of Treatment (Visit 01)
The following investigations and assessments will be performed during clinical examination: 

Physical examination including height, body weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for laboratory testing: Haematology and clinical chemistry including 
thyroid function, fasting plasma glucose and fasting plasma insulin 

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

OGTT 

Urinary analysis (dip stick)
 

Concomitant medication recording

Adverse Events recording

Drug dispensing and recording
At this visit, patients/parents will be carefully instructed by the investigator/clinical staff on 
the use of the pen injector, the pen needle, and the appropriate injection technique including 
cleaning of the injection site and discharging of the used needle. The first injection of 
Omnitrope® will be administered. Patients will receive a three months supply of study drug 
packed in a cool box and will be instructed to place the study medication in the refrigerator at 
home as soon as possible. The dispensed study drug will also be recorded in the Drug 
Accountability Form.
7.1.3
3-Month Treatment Visit (Visit 02)
At visit 02, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

Concomitant medication recording

Adverse Events recording 

Fundoscopy, if needed


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 32 of 55
Study No. EP00-401 

Drug dispensing, drug accountability and recording
7.1.4
6-Month Treatment Visit (Visit 03)
At visit 03, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for laboratory testing: Haematology and clinical chemistry including 
thyroid function, fasting plasma glucose and fasting plasma insulin 

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

OGTT 

Urinary analysis (dip stick)

Pregnancy test (only in female patients after onset of menarche)

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.5
9-Month Treatment Visit (Visit 04)
At visit 04, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.6
12-Month Treatment Visit (Visit 05)
At visit 05, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for laboratory testing: Haematology and clinical chemistry including 
thyroid function, fasting plasma glucose and fasting plasma insulin 

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

OGTT 

Urinary analysis (dip stick)

Pregnancy test (only in female patients after onset of menarche)
 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 33 of 55
Study No. EP00-401 

Concomitant medication recording

Adverse Events recording 

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.7
15-Month Treatment Visit (Visit 06)
At visit 06, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.8
18-Month Treatment Visit (Visit 07)
At visit 07, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.9
21-Month Treatment Visit (Visit 08)
At visit 08, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 34 of 55
Study No. EP00-401 
7.1.10
24-Month Treatment Visit (Visit 09) and subsequent visits performed 
annually (Visit 11, Visit 13 etc) 
The following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for laboratory testing: Haematology and clinical chemistry including 
thyroid function, fasting plasma glucose and fasting plasma insulin 

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

OGTT

Urinary analysis (dip stick)

Pregnancy test (only in female patients after onset of menarche)
 

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.11
30-Month Treatment Visit (Visit 10) and subsequent visits performed 
annually (Visit 12, Visit 14 etc)
The following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for IGF-I and IGFBP-3 determination

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug dispensing, drug accountability and recording
7.1.12
Final Visit of treatment period
At final visit of treatment period, the following investigations will be performed: 

Physical examination including height, weight and pubertal status

Vital signs (blood pressure and heart rate)

Blood sampling for laboratory testing: Haematology and clinical chemistry including 
thyroid function, fasting plasma glucose and fasting plasma insulin 

Blood sampling for anti-hGH antibodies, IGF-I and IGFBP-3 determination

OGTT 

Urinary analysis (dip stick)

Pregnancy test (only in female patients after onset of menarche)


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 35 of 55
Study No. EP00-401 
 

Concomitant medication recording

Adverse Events recording

Fundoscopy, if needed

Drug accountability and recording
7.2
Treatment exposure and compliance
Patient compliance will be assessed by the collection of used, partly used and unused vials as 
well as cartridges at each visit. The number of returned vials and the quantity of unused 
treatment remaining in the vials will provide information on treatment compliance, which will 
be recorded in the source document at each visit. Patients must comply with the dose schedule. 
The daily dose should be maintained in the range between 80% and 120% of the 
recommended daily dose of 0.035 mg/kg BW depending on the patient’s responsiveness. 
7.3
Efficacy
7.3.1
Methods and timing for assessing, recording and analysis of efficacy 
parameters
At each visit, which should take place preferably in the morning, patient’s height and weight 
will be assessed and noted. 
7.3.2
Anthropometric Measurements
Height measurements will be performed using a wall-mounted stadiometer. Whenever 
possible, a patient will be measured at each visit at a similar daytime by the same trained 
person to minimise observer bias. The technique as described by Tanner et al (1966) should 
be used.
7.3.3
Presentation and Calculation of Auxological Data
Height velocity (HV) will be calculated in cm/year as the difference between two height 
measurements divided by the time interval in days between these two measurements 
multiplied by 365.25.
Height and height velocity will not only be expressed in cm and cm/year, respectively, but 
also in Standard Deviation Scores (SDS), the relative deviation from the mean value of 
normally growing children of same sex and chronological age or bone age. The SDS values 
for height and HV will be calculated according to the following formula SDS= (X1-X2)/SD, 
where X1 means the measured value, X2 the mean value for the relevant chronological age 
(or bone age, where appropriate), and SD stands for the standard deviation for the mean of 
relevant age. For the calculation of HVSDS, the mean between the CA at the two height 
measurements should be considered as the relevant CA.
Since the formula for the calculation of SDS is not common practice in all countries 
(especially for the calculation of height SDS) the inclusion of a patient is evaluated according 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 36 of 55
Study No. EP00-401 
to national common practice. The following formula is widely used and allowed for inclusion 
instead of the formula used for the statistical analysis of the study cited above:
)
percentile
3rd
-
(median
*
0.5
S
median
lue
measuredva
DS


All standardized controlled procedures and methods applied for the calculation of auxological 
data (with reference to Inclusion Criteria No. 2, 3 and 5) to ensure a common basis and 
comparability of data derived from the different countries will be filed in the Trial Master File 
and described in the Clinical Study Report.
7.3.4
Weight measurements
Weight will be measured according to the usual clinical practice.
 
 
 
7.4
Safety
7.4.1
Carbohydrate metabolism 
Fasting plasma glucose and insulin levels will be measured at baseline, at 6 and 12 months, 
then annually during GH treatment, and at the end of treatment. 
After an overnight fast, venous blood samples will be taken to assess fasting glucose and 
insulin levels. Insulin resistance will be estimated using both the homeostasis model 
assessment (HOMA) (Matthews et al 1985) and quantitative insulin sensitivity check index 
(QUICKI) (Katz et al 2000, WHO 2002).
*
405
(mg/dl)
glucose
fasting
U/ml)
(
insulin
fasting
HOMA



*use constant 22.5 instead of 405 if glucose concentration is reported in mmol/L
(mg/dl)
glucose
fasting
log
U/ml)
(
insulin
fasting
log
1
QUICKI



Glycosylated haemoglobin (HbA1C) will be measured at baseline, at 6 and 12 months and then 
annually during GH treatment, and at the end of treatment. 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 37 of 55
Study No. EP00-401 
An oral glucose tolerance test (OGTT) will be performed at baseline, at 6 and 12 months and 
then annually during GH treatment, and at the end of treatment. 
The OGTT is a provocation test to examine the efficiency of the body to metabolise glucose. 
The OGTT provides information on latent diabetes states. The OGTT will be carried out 
according to WHO criteria (2002). After 3 days of an unrestricted, carbohydrate–rich diet, and 
after overnight fasting, 1.75 grams of glucose per kg body weight (up to a maximum of 75 g) 
will be administered orally after being dissolved in 250-300 ml of water. Blood samples will 
be taken 10 minutes before, and 120 minutes after the glucose load. Diabetes mellitus is 
defined by > 200 mg/dl or > 11.1 mmol/L blood glucose after 120 minutes.
7.4.2
Immunogenicity
Subjects will be screened for anti-rhGH antibodies (ABs) at baseline, at 3, 6, 9, 12, 18 and 24 
months, then annually during GH treatment and at the end of treatment. Antibody-induced 
lack or loss of efficacy will be examined by comparing height outcome data between 
antibody-positive and antibody-negative subjects.
7.4.3
Fundoscopy
Fundoscopy will be performed only if intracranial hypertension is suspected (severe or 
recurrent headache, visual problems, nausea and/or vomiting).
7.4.4
Physical examination
Patients will undergo a general physical examination and will also be questioned about and 
examined for any local or systemic adverse events. At each scheduled visit during treatment a 
thorough physical examination including of the following will be made: head (external), eyes, 
ears, nose and throat, lungs, cardiovascular system, abdomen, musculoskeletal system, skin, 
lymph nodes, central nervous system and, where appropriate, others. Prepubertal or pubertal 
status should be assessed by the investigator and expressed in stages as described by Tanner 
and Whitehouse (1976).
7.4.5
Vital signs
Vital signs (blood pressure and pulse rate) will be recorded at each visit during treatment in a 
standardised manner, i.e., after the patient has rested for five minutes in the sitting position.
7.4.6
Laboratory evaluations
7.4.6.1
Local Laboratories
Local laboratories will be responsible for performing blood serum and urine determinations; 
clinical chemistry and complete blood count (CBC) (automated 5-part differential 
recommended), absolute neutrophil count (ANC) and platelet counts.
All supernatants of samples are destroyed after analysis.
The following laboratory safety tests will be performed at baseline, at 6 and 12 months and 
annually thereafter for the remainder of GH treatment, and at the end of treatment, unless 
more frequent assessment is clinically indicated.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 38 of 55
Study No. EP00-401 
Haematology:
Haemoglobin, haematocrit, white blood cell count (total and 
differential) (WBC), red blood cell count (RBC), platelet count, mean 
cell volume (MCV), mean cell haemoglobin (MCH), mean cell 
haemoglobin 
concentration 
(MCHC), 
HbA1C, 
erythrocyte 
sedimentation rate (ESR). 
Biochemistry:
Creatinine, urea, aspartate aminotransferase (SGOT/AST), alanine 
aminotransferase (SGPT/ALT), gamma-glutamyltransferase (gamma-
GT), alkaline phosphatase, total bilirubin, albumin, total protein, HDL, 
LDL, sodium, potassium, chloride, glucose*, insulin*, uric acid, total 
cholesterol*, triglycerides*, calcium, phosphorus.
Thyroid function:
Free thyroxine (fT4) and thyroid stimulating hormone (TSH).
Urinalysis:
pH, glucose, ketones, bilirubin, protein. Pregnancy test only in girls 
after onset of menarche.
*fasting serum levels; fasting is defined as no caloric intake for at least 8h
7.4.6.2
Central Laboratory
Central laboratory will process samples for antibody analysis, IGF-I and IGFBP-3. 
Instructions on preparation and shipment of samples will be provided in the corresponding 
Manual. Serum samples stored deep frozen at –70°C for central determination of IGF-I, 
IGFBP-3 and anti-hGH antibodies. For central laboratory details please refer to lab manual. 
7.4.6.2.1 Anti-hGH antibodies 
Anti-hGH antibodies serum levels will be assessed at baseline, at 3, 6, 9, 12, 18 and 24 
months, then annually during treatment, and at the end of treatment. 
Samples will be stored by the sponsor according currently applicable guidelines in order to 
potentially re-analyze anti-hGH antibodies at a later stage, if needed.
7.4.6.2.2 IGF-I and IGFBP-3 serum levels
IGF-I and IGFBP-3 serum levels will be assessed at baseline, at 3, 6, 9 and 12 months, then 
every 6 months during treatment, and at the end of treatment. All supernatants of samples are 
destroyed after analysis.
7.4.7
Adverse events
The investigator has the responsibility for managing the safety of individual subject and 
identifying adverse events.
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign, including abnormal laboratory findings, symptom or disease) in a subject 
after providing written informed consent for participation in the study until the end of study 
visit. Therefore, an AE may or may not be temporally or causally associated with the use of a 
investigational medicinal product.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 39 of 55
Study No. EP00-401 
In addition, all reports of intentional misuse and abuse of the product are also considered an 
adverse event irrespective if a clinical event has occurred.
The occurrence of adverse events should be sought by non-directive questioning of the subject 
at each visit during the study. Adverse events also may be identified when they are 
volunteered by the subject during or between visits or through physical examination, 
laboratory test, or other assessments. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:

they induce clinical signs or symptoms,

the investigator considers them to be clinically relevant,

they require therapy.
Clinically relevant abnormal laboratory values or test results should be identified through a 
review of values outside of normal ranges/clinically notable ranges, relevant changes from 
baseline or the previous visit, or values which are considered to be non-typical in subject with 
underlying disease. 
Adverse events must be recorded on the adverse events CRF with the following information 
within 10 days of learning of its occurrence (if the event is serious (refer to Section 7.4.8) it 
must be recorded in the CRF within 24 hours of learning of its occurrence):

the severity grade (indicating most severe grade during the course of the adverse event) 

mild: usually transient in nature and generally not interfering with normal activities

moderate: sufficiently discomforting to interfere with normal activities

severe: prevents normal activities

its relationship to the study drug(s) (suspected/not suspected)
Not suspected: The temporal relationship of the clinical event to trial drug 
administration makes a causal relationship unlikely, or other drugs, therapeutic 
interventions or underlying conditions provide a sufficient explanation for the 
observed event.
Suspected: The temporal relationship of the clinical event to trial drug administration 
makes a causal relationship possible, and other drugs, therapeutic interventions or 
underlying conditions do not provide a sufficient explanation for the observed event.
If the event is due to lack of efficacy or progression of underlying illness (i.e. 
progression of the study indication) the assessment of causality will usually be ‘Not 
suspected’. The rationale for this guidance is as follows:

the symptoms of a lack of efficacy or progression of underlying illness are not 
caused by the trial drug, they happen in spite of its administration

both lack of efficacy and progression of underlying disease can only be evaluated 
meaningfully by an analysis of cohorts, not on a single subject

its duration (start and end dates) or ‘ongoing’ at the 30 day safety follow-up /end of study 
visit

whether it constitutes a serious adverse event (SAE) (see Section 7.4.8 for the definition of 
SAE)


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 40 of 55
Study No. EP00-401 
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements; see Section 8.1

action taken: All adverse events must be treated appropriately. Treatment may include one 
or more of the following: no action taken (i.e. further observation only); study drug dosage 
adjusted/temporarily interrupted; study drug permanently discontinued due to this adverse 
event; concomitant medication given; non-drug therapy given, subject 
hospitalized/subject’s hospitalization prolonged. 

Its outcome (not recovered/not resolved; recovered/resolved; recovering/resolving, 
recovered/resolved with sequelae; fatal; or unknown)
Once an adverse event is identified, it must be followed until its resolution or until it is judged 
to be permanent, and assessment must be made at each visit (or more frequently, if necessary) 
of any changes in severity, the suspected relationship to the study drug, the interventions 
required to treat it, and the outcome.
Information about common side effects already known about the investigational drug can be 
found in the Investigator Brochure (IB). This information will be included in the subject 
informed consent form and must be discussed with the subject during the study as needed. 
Any new information regarding the safety profile of the medicinal product that is identified 
between IB updates will be communicated as appropriate, for example, via an Investigator 
Notification or an Aggregate Safety Finding report. New information might require an update 
to the informed consent form and has then to be discussed with the subject.
The investigator must also instruct each subject to report any new adverse event (beyond the 
protocol observation period) that the subject, or the subject’s personal physician, believes 
might reasonably be related to study treatment. This information must be recorded in the 
investigator’s source documents, however, if the AE meets the criteria of an SAE, it must be 
reported to the sponsor.
7.4.8
Serious adverse events
A SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the 
following criteria:

is fatal or life-threatening 

results in persistent or significant disability/incapacity

constitutes a congenital anomaly/birth defect

requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for:

routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition (specify what this includes)

elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since the start of study drug

treatment on an emergency outpatient basis for an event not fulfilling any of the 
definitions of a SAE given above and not resulting in hospital admission 

social reasons and respite care in the absence of any deterioration in the subject’s 
general condition


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 41 of 55
Study No. EP00-401 

is medically significant, i.e. defined as an event that jeopardizes the subject or may require 
medical or surgical intervention to prevent one of the outcomes listed above
Death without known medical event must always be reported as SAE.
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if more severe.
All malignant neoplasms will be assessed as serious under “medically significant” if other 
seriousness criteria are not met.
Medical and scientific judgment must be exercised in deciding whether other situations should 
be considered serious AEs, such as important medical events that might not be immediately 
life threatening or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Examples of such 
events are intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospitalization or development of drug 
dependency or abuse.
Any suspected transmission of an infectious agent via a medicinal product is also considered a 
serious adverse event.
7.5
Tolerability/acceptability
Not applicable
7.6
Resource utilization
Not applicable
8
Safety monitoring
8.1
Serious adverse event reporting
To ensure subject safety, the investigator has to report every SAE, regardless of suspected 
causality, occurring after the subject has provided informed consent and until 30 days after 
following the last administration of study treatment must be reported to the sponsor (or 
designated CRO) within 24 hours of learning of its occurrence using the SAE reporting form, 
and recorded in the CRF.
Any SAEs experienced after this 30 day period should only be reported to the sponsor (or 
designated CRO) if the investigator suspects a causal relationship to the study drug.
All follow-up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow-up to the original episode 
within 24 hours of the investigator receiving the follow-up information. Likewise, queries 
issued by the sponsor regarding the SAE must be responded to within 24 hours.
An SAE that is considered completely unrelated to a previously reported one must be reported 
separately as a new event.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 42 of 55
Study No. EP00-401 
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form. The investigator must assess the relationship to study drug, complete the SAE Report 
Form in English, and send the completed, signed form within 24 hours to the sponsor. The 
contact details for SAE reporting are listed in the investigator folder provided to each site.
The original copy of the SAE Report Form and the fax confirmation sheet must be kept at the 
study site.
Follow-up information must be provided using a new SAE Report Form stating that this is a 
follow-up to the previously reported SAE. The follow-up information must describe whether 
the event has resolved or continues, if and how it was treated, whether the blind was broken or 
not, and whether the subject continued or withdrew from study participation. Each re-
occurrence, complication, or progression of the original event must be reported as a follow-up 
to that event regardless of when it occurs.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert 
(new occurrence) and is thought to be related to the study drug, the sponsor may urgently 
require further information from the investigator for Health Authority reporting. The sponsor 
may need to inform all investigators involved in any study with the same drug that this SAE 
has been reported. Suspected Unexpected Serious Adverse Reactions (SUSARs) will be 
collected and reported to the competent authorities and relevant ethics committees in 
accordance with EU Guidance 2011/C 172/01 or as per national regulatory requirements in 
participating countries.
8.2
Reporting procedures for technical complaints
Any technical complaint about the study drug needs to be reported to the sponsor within 24 
hours of identification of the defect (for details refer to the study drug handling manual). 
Technical complaints are complaints about an optical, organoleptic, qualitative, quantitative, 
mechanical or functional defect of a pharmaceutical product or medical device. This may 
include:

Any fault of quality and/or effectiveness e.g. particles

Any fault of the containers and outer packages e.g. surface imperfection, container leakage, 
broken syringe/plunger, missing contents, device malfunction

Any fault of the labeling e.g. missing or illegible label

Any falsification of the medicinal product or device e.g. suspected product mix-up, or 
tampering.
For reporting of adverse events caused by the defect (if applicable) refer to Section 7.4.7.
8.3
Reporting of study treatment errors including misuse/abuse 
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally and inappropriately 
used not in accordance with the protocol.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 43 of 55
Study No. EP00-401 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by harmful physical or psychological effects.
Study treatment errors, misuse or abuse will be collected and reported in the CRF AE page 
irrespective of it being associated with an AE/SAE.
8.4
Pregnancy reporting
To ensure patient safety, each pregnancy in a patient on study drug must be reported to 
Sandoz within 24 hours of learning of its occurrence. The pregnancy must be followed up to 
determine outcome, including spontaneous or voluntary termination, details of the birth, and 
the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications. 
Pregnancy must be recorded on a Pregnancy Form and reported by the investigator to the 
sponsor. Pregnancy follow-up must be recorded on the same form and must include an 
assessment of the possible relationship to the Sandoz study drug of any pregnancy outcome. 
Any SAE experienced during pregnancy must be reported on the SAE Report Form. 
8.5
Data Monitoring Board
Not Applicable
9
Data review and database management
9.1
Site monitoring
Before study initiation, at a site initiation visit or at an investigator’s meeting, a Sandoz 
representative or designee will review the protocol and CRFs with the investigators and their 
staff. During the study, the monitor will visit the site regularly to check the completeness of 
patient records, the accuracy of entries on the CRFs, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study drug is being 
stored, dispensed, and accounted according to specifications. Key trial personnel must be 
available to assist the monitor during these visits. 
The investigator must maintain source documents for each patient in the study, consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory data and the results of any other tests or assessments. All information 
on CRFs must be traceable to these source documents in the patient's file. Data not requiring a 
written or electronic record will be defined before study start and will be recorded directly on 
the CRFs, which will be documented as being the source data. The investigator must also 
keep a copy of the signed informed consent form. 
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency with the CRF entries. Sandoz monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and the recording of data that will be used for all primary and safety 
variables. 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 44 of 55
Study No. EP00-401 
Additional checks of the consistency of the source data with the CRFs are performed 
according to the study-specific monitoring plan. No information in source documents about 
the identity of the subjects will be disclosed. 
9.2
Data collection
Designated investigator staff must enter the information required by the protocol onto the 
Sandoz CRFs that are printed on 2-part, non-carbon-required paper. Monitors will review the 
CRFs for completeness and accuracy and instruct site personnel to make any required 
corrections or additions. The original CRFs are forwarded to the CRO by monitors or by the 
investigational site, the copy is being retained at the investigational site. Once the CRFs are 
received by the CRO, their receipt is recorded, the original copy is scanned and forwarded to 
the responsible data management staff for processing. After scanning the original copy is 
placed in Central Files.
9.3
Medical Monitoring
Medical Monitoring is the summary of all Medical Review activities performed throughout 
the entire conduct of the study on different levels by different parties. This is to ensure 
patients’ safety and welfare and consistency of data. Medical Review is performed by CRAs 
during the Monitoring Visit (PRA), at Data Management/Data Validation (Metronomia), and 
at the sponsor (Study and Program Management at Sandoz). All tasks comprised to warrant a 
common understanding of duties and schedules of the respective parties in charge have been 
laid down in writing and filed in the Trial Master File. 
10
Data analysis
The analyses will be described in more detail in Statistical Analysis Plans which will be 
written for each of the interim analyses as well as for the final analysis.
10.1
Analysis sets
10.1.1
Safety analysis set
The safety analysis set (SAF) will comprise all subjects who receive at least one dose of study 
medication and had at least one post-baseline safety assessment. 
10.1.2
Full analysis set
The full analysis set (FAS) will follow the intent-to-treat-principle and therefore consists of 
all patients who received at least one dose of study medication. 
The assignment of the patients to the respective analysis set will be done prior to each interim 
and to the final analysis during a specific data review meeting. 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 45 of 55
Study No. EP00-401 
10.2
Patient demographics/other baseline characteristics
Descriptive statistics will be used to describe background and demographic variables such as 
age, weight, and height, and frequency tables will be used to describe the gender and race of 
the patients.
Relevant medical history and current medical conditions, previous medication, results of 
laboratory screens, drug tests, and any other relevant information will be listed and 
summarized using descriptive statistics or frequency tables depending on the type of variable 
(continuous or discrete).
10.3
Treatments (study drug, rescue medication, other concomitant 
therapies, compliance)
10.3.1
Study drug administration
The extent of exposure will be analyzed using descriptive statistics. Tables showing 
descriptive statistics for the dose per kg body weight will be presented by visit to assess the 
appropriateness of the applied doses.
10.3.2
Concomitant medication
Concomitant medication will be coded according to WHO-DRL and the medications will be 
tabulated by ATC term. 
10.3.3
Treatment compliance
The percentage of medication used compared to the amount prescribed will be analyzed for 
each visit and the frequency of non-compliant patients (daily dose range <80% or >120%) 
will be tabulated. 
10.4
Analysis of safety endpoints
10.4.1
Carbohydrate metabolism
Fasting plasma glucose and insulin levels will be measured at baseline, at 6 and 12 months, 
then annually during GH treatment, and at the end of treatment. For each of these visits 
descriptive statistics will be calculated and presented together with the absolute and relative 
changes as compared to baseline.
Insulin resistance will be estimated using both the homeostasis model assessment (HOMA)  
(Matthews et al 1985) and quantitative insulin sensitivity check index (QUICKI) (Katz et al 
2000, WHO 2002). The effect of Omnitrope® treatment on HOMA and QUICKI scores, 
calculated subsequent to each plasma glucose and insulin measurement, will be evaluated at 
each visit using descriptive statistics for the observed values along with the changes from 
baseline.
Glycosylated haemoglobin (HbA1C) will be measured at baseline, at 6 and 12 months and then 
annually during GH treatment, and at the end of treatment. The effect of treatment on the 
HbA1C levels will also be displayed using descriptive statistics.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 46 of 55
Study No. EP00-401 
An oral glucose tolerance test (OGTT) will be performed at baseline, at 6 and 12 months and 
then annually during GH treatment, and at the end of treatment. 
10.4.2
Immunogenicity
Subjects will be screened for anti-rhGH antibodies (ABs) at baseline, at 3, 6, 9, 12, 18 and 24 
months, then annually during treatment, and at the end of treatment. For each time point the 
number and percentage of patients with anti-rhGH antibodies (ABs) will be tabulated.
Antibody-induced lack or loss of efficacy will be examined by comparing height outcome 
data between antibody-positive and antibody-negative subjects.
10.4.3
Safety lab / urine analysis
Haematology, blood chemistry and urine analysis results will be displayed by visit using 
descriptive statistics and / or frequency tables depending on the type of variable (continuous 
or discrete). Shift tables for the number and percentage of clinically significant results will 
also be provided.
10.4.4
(Serious) Adverse Events / Incidents
Adverse events will be coded using MedDRA (Version to be determined depending on the 
time of the analysis). The number and percentage of patients having at least one (serious) 
adverse event will be tabulated. The (serious) adverse events will be displayed by system 
organ class and preferred term and the relationship to the study drug, intensities and outcome 
will be shown in corresponding frequency tables. 
Since incidents are qualified as clinical SAEs they are handled in the same way as all other 
clinical SAEs. A near incident is handled as a clinical SAE in case of seriousness, otherwise 
as an adverse event.
10.4.5
Vital signs / weight
The development of the vital signs (blood pressure, pulse) as well as weight and BMI will be 
analyzed using descriptive statistics for each visit. 
10.4.6
Physical examination
Shift tables for normal / abnormal findings will be presented by body system for each visit 
versus baseline. 
10.5
Analysis of efficacy endpoints
10.5.1
Auxological endpoints
These are height, height SDS, height velocity and height velocity SDS. These parameters will 
be monitored at baseline, at every 3 months during GH treatment and at the end of treatment. 
The effectiveness of treatment in inducing growth will be determined by descriptive statistics 
of the height at each scheduled visit including a comparison to the height at baseline. Similar 
analyses will be conducted for the height SDS.


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 47 of 55
Study No. EP00-401 
The effectiveness of treatment in accelerating linear growth rate will be determined by 
analyzing the annual height velocity in cm/year (the difference between two height 
measurements divided by the time interval between these two measurements multiplied by 
365.25) at each scheduled visit and by comparing it to the height velocity determined at 
baseline using historical data. Similar analyses will be conducted for the height velocity SDS.
Treatment will be considered to be ineffective (leading to drug discontinuation) if HVSDS 
remains below +1 in the first year of treatment.
10.5.2
Pharmacodynamic endpoints
These are IGF-I and IGFBP-3 serum levels, which will be assessed at baseline, at 3, 6, 9 and 
12 months, then bi-annually during treatment, and at the end of treatment. 
The effect of treatment on serum IGF-I and IGFBP-3 levels will be evaluated using 
descriptive statistics for the observed values at each visit together with the absolute and 
relative changes as compared to baseline.
 
 
10.6
Interim analysis 
Interim analyses are planned at the following time points:

Q4/2011 with data of patients who completed 1 year of treatment

Q4/2012 with data of patients who completed 2 years of treatment

Q4/2020 with data of patients who finished treatment
Additional ad-hoc interim analyses will be performed in case needed for interactions with 
health authorities.
10.7
Sample size calculation
There was no formal sample size calculation for this study which is intended to exploratorily 
investigate the long-term effect of the treatment with respect to the development of diabetes. 
No such incidences are currently available to allow for a rigorous sample size estimation. 
Results obtained in this study will be compared to data published in the literature.
200 subjects were agreed upon during the discussion with the EMEA. Taking into account a 
drop-out rate of 20%, 240 patients will be included in the study. Subjects dropping out before 
completing 1 year of treatment will be replaced.
10.8
Power for analysis of critical secondary variables
Not applicable 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 48 of 55
Study No. EP00-401 
10.9
Subgroup analyses
Since the study population will consist of subjects treated with Omnitrope® 5 mg/ml powder 
for the first twelve months and with Omnitrope® 5 mg/1.5 ml solution for injection thereafter 
as well as of subjects treated continuously with Omnitrope® 5 mg/1.5 ml solution for injection, 
a corresponding subgroup analysis will be performed. The main focus of such subgroup 
analysis will be on the comparison of the safety profiles during the first twelve months of 
treatment as well as on the effects on the growth related parameters for the first twelve months 
of treatment and also for the whole treatment period.
Further subgroup analysis will be done for an overweight population with international cut-
off points for BMI for overweight by sex and age as defined by the percentile that passes 
through BMI of 25 at age 18. 
All comparisons will be performed descriptively using adequate frequency tables and 
descriptive statistics. Details of the analyses will be laid down in the statistical analysis plans 
for the respective (interim) analyses.
11
Discussion and rationale for study design features
This study has been designed in accordance with the post-approval pharmacovigilance plan to 
extend the safety database of Omnitrope® and to address the EMEA’s request:

to investigate the diabetogenic potential of Omnitrope® in short children born SGA, and

to further investigate the immunogenicity of Omnitrope® in short children born SGA.
More specifically, the primary objective of this study is:

to monitor the development of diabetes during Omnitrope® treatment.
The secondary objectives of this study are:

to monitor the development of anti-hGH antibodies during Omnitrope® treatment,

to evaluate the safety (incidence and occurrence of adverse events) of Omnitrope® 
treatment in short children born SGA, and

to evaluate the efficacy (with respect to changes in height parameters, serum IGF-I and 
IGFBP-3 levels) of Omnitrope® treatment in short children born SGA.
All included subjects will receive Omnitrope® 0.035 mg/kg/day as per recommended dose for 
short stature secondary to SGA. Dose adjustments will be allowed during therapy consistent 
with label recommendations. Omnitrope® treatment will continue until final height is reached 
but will be discontinued earlier if there is inadequate response to treatment (e.g., height 
velocity standard deviation score (HVSDS) remains below +1 in the first year).
To address concerns regarding the risk of developing diabetes mellitus in GH-treated short 
children born SGA, specific parameters such as fasting plasma glucose and insulin levels will 
be measured at pre-defined time points throughout treatment with Omnitrope®. 
Subjects will be monitored for safety throughout treatment. Height, height SDS, HV and 
HVSDS will be determined until final height is reached. 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 49 of 55
Study No. EP00-401 
12
Procedures and instructions: Administrative procedures
12.1
Changes to the protocol
Any change or addition to this protocol requires a written protocol amendment that must be 
approved by Sandoz, the Coordinating Investigator as well as the Principal Investigator(s) 
before implementation. Amendments significantly affecting the safety of subjects, the scope 
of the investigation or the scientific quality of the study, require additional approval by the 
IRB/IEC of all centers, and, in some countries, by the regulatory authority. A copy of the 
written approval of the IRB/IEC and the regulatory authority, where applicable, must be given 
to the study monitor.
12.2
Ethics and Good Clinical Practice
This study must be carried out in compliance with the protocol and the principles of Good 
Clinical Practice:
ICH 
Harmonized 
Tripartite 
Guidelines 
for 
Good 
Clinical
Practice 
1996.
Directive 91/507/EEC, The Rules Governing Medicinal Products in the European Community.
Directive 2001/20/EC, EU Clinical Trials Directive
Directive 2005/28/EC, EU GCP Directive
91/507/EEC, The Rules Governing Medicinal Products in the European Community
MEDDEV 2.12-1 rev 5, Guidelines on a Medical Devices Vigilance System
US 21 Code of Federal Regulations dealing with clinical studies (including parts 50 and 56 
concerning informed consent and IRB regulations).
Declaration of Helsinki and amendments, concerning medical research in humans 
(Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects).
The investigator agrees when signing the protocol to adhere to the instructions and procedures 
described in it and thereby to adhere to the principles of Good Clinical Practice that it 
conforms to.
12.2.1
Institutional Review Board/ Independent Ethics Committee
Before implementing this study, the protocol, the investigator brochure, the curriculum vitae 
of the investigators, the proposed informed consent form and other information to subjects, 
will be submitted to a properly constituted Institutional Review Board/Independent Ethics 
Committee (IRB/IEC) according to national law. The study will only be performed at a study 
site if a full approval of the protocol has been obtained by the IRB/IEC.
12.2.2
Informed consent
The investigator must explain to each patient (and/ or legally authorized representative) the 
nature of the study, its purpose, the procedures involved, the expected duration, the potential 
risks and benefits involved and any discomfort it may entail. Each subject must be informed 
that participation in the study is voluntary and that he/she may withdraw from the study at any 


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 50 of 55
Study No. EP00-401 
time and that withdrawal of consent will not affect his/her subsequent medical treatment or 
relationship with the treating physician.
To cover adolescence of the patients with adequate patient information documents, three 
patient information documents, one for children between 4 and 6 years of age, one for 
children between 7 and 12 years of age, and one for children > 13 years of age are used within 
this clinical trial. Children who can read and write should sign the informed consent on the 
basis of the patient information document according to their relevant age group. At all events 
written informed consent has to be obtained from the patients’ parents or legal guardian. 
These informed consent(s) should be given by means of a standard written statement, written 
in non-technical language. The subject/parents or legal guardian should read and consider the 
statement before signing and dating it, and should be given a copy of the signed document. 
If the subject cannot read or sign the documents, oral presentation may be made and or
signature given by the subject’s legally appointed representative, if witnessed by a person not 
involved in the study, mentioning that the patient could not read or sign the documents. No 
patient can enter the study before his/her informed consent has been obtained.
Female patients of child bearing potential must be informed that taking the study drug may 
involve unknown risks to the fetus if pregnancy were to occur during the study and agree that 
in order to participate in the study they must adhere to the contraception requirement for the 
duration of the study. If there is any question that the subject will not reliably comply, they 
must discontinue the study.
The informed consent form is considered to be part of the protocol, and must be submitted by 
the investigator with it for IRB/IEC approval. 
12.2.3
Declaration of Helsinki
The investigator must conduct the trial in accordance with the principles of the Declaration of 
Helsinki.The Declaration of Helsinki (Document 17.C) is an official policy document of the 
World Medical Association, the global representative body for physicians. It was first adopted 
in 1964 (Helsinki, Finland) and revised in 1975 (Tokyo, Japan), 1983 (Venice, Italy), 1989 
(Hong Kong), 1996 (Somerset-West, South Africa) and 2000 (Edinburgh, Scotland). Note of 
clarification on Paragraph 29 added by the WMA General Assembly, Washington 2002. Note 
of Clarification on Paragraph 30 added by the WMA General Assembly, Tokyo 2004.
13
References
Albertsson-Wikland K and Karlberg J (1997). Postnatal growth of children born small for 
gestational age. Acta Paediatr Suppl; 423:193-5
Barker DJ et al (1990). Fetal and placental size and risk of hypertension in adult life. 
BMJ; 301:259-62
Barker DJ et al (1993). Fetal nutrition and cardiovascular disease in adult life. 
Lancet; 341:938-41
Boguszewski M et al (1997). Hormonal status of short children born small for gestational age. 
Acta Paediatr Suppl; 423:189-92


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 51 of 55
Study No. EP00-401 
Boguszewski MC et al (2000). Serum leptin in short children born small for gestational age: 
dose-dependent effect of growth hormone treatment. Horm Res, 54:120-25
Boyko EJ (2000). Proportion of type 2 diabetes cases resulting from impaired fetal growth. 
Diabetes Care; 23:1260-64
Cance-Rouzaud A et al (1998). Growth hormone, insulin-like growth factor-I and insulin-like 
growth factor binding protein-3 are regulated differently in small-for-gestationa-age and 
appropriate-for-gestational-age neonates. Biol Neonate; 73:347-55
Cole TJ et al (2000). Establishing a standard definition for child overweight and obesity 
worldwide: international survey. BMJ; 320:1240-43
Curhan GC et al (1996). Birth weight and adult hypertension, diabetes mellitus, and obesity in 
US men. Circulation; 94: 3246-50
De Zegher et al (2002). High-dose growth hormone (GH) treatment in non-GH-deficient 
children born small for gestational age induces growth responses related to pretreatment GH 
secretion and associated with a reversible decrease in insulin sensitivity. 
J Clin Endocrinol Metab; 87:148-51
De Zegher F et al (1999). Early, discontinuous, high dose growth hormone treatment to 
normalize height and weight of short children born small for gestational age: results over 6 
years. J Clin Endocrinol Metab; 84:1558-61
De Zegher F et al (2000). Growth hormone treatment of short children born small for 
gestational age: growth responses with continuous and discontinuous regimens over 6 years. 
J Clin Endocrinol Metab; 85:2816-21
Degani S (2001). Fetal biometry: clinical, pathological, and technical considerations. 
Obstet Gynecol Surv; 56:159-67
Economides DL et al (1989). Plasma insulin in appropriate- and small-for-gestational-age 
fetuses. Am J Obstet Gynecol; 160:1091-4
Greulich WW, Pyle SI (1959). Radiographic atlas of skeletal development of hand and wrist. 
2nd Edition; Stanford University Press, California, USA
Hales CN et al (1991). Fetal and infant growth and impaired glucose tolerance at age 64. 
BMJ; 303:1019-1022
Hattersley AT and Tooke JE (1999). The fetal insulin hypothesis: an alternative explanation 
of the association of low birthweight with diabetes and vascular disease. Lancet; 353:1789-92
Hokken-Koelega ACS et al (2004). Small for Gestational Age (SGA): Endocrine and 
metabolic consequences and effects of growth hormone treatment. J Ped Endocrinol Metab; 
17 (Suppl 3):463-9
Katz A et al (2000). Quantitative insulin sensitivity check index: a simple, accurate method 
for assessing insulin sensitivity in humans. J Clin Endocrin Metab; 85: 2402-10


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 52 of 55
Study No. EP00-401 
Lassarre C et al (1991). Serum insulin-like growth factors and insulin-like growth factor 
binding proteins in the human fetus. Relationships with growth in normal subjects and in 
subjects with intrauterine growth retardation. Pediatr Res; 29:219-25
Lee PA et al (2001). International Small for Gestational Age Advisory Board consensus 
development conference statement: management of short children born small for gestational 
age. Pediatrics; 111:1253-61
Leger J et al (1997). Reduced final height and indications for insulin resistance in 20 year olds 
born small for gestational age: regional cohort study. BMJ; 315:341-347
Li C et al (2001). Effects of low birth weight on insulin resistance syndrome in caucasian and 
African-American children. Diabetes Care; 24:2035-42
Lin CC and Santolaya-Forgtas J (1998). Current concepts of fetal growth restriction: part I. 
Causes, classification, and pathophysiology. Obstet Gynecol; 92:1044-55
Lithell HO et al (1996). Relation of size at birth to non-insulin dependent diabetes and insulin 
concentrations in men aged 50-60 years. BMJ; 312:406-10
Lundgren EM et al (2001). Intellectual and psychological performance in males born small for 
gestational age with and without catch-up growth. Pediatr Res; 50:91-6
Marshall WA, Tanner JM (1969). Variations in Pattern of Pubertal Changes in girls. Arch Dis 
Childh; 44:291-303
Marshall WA, Tanner JM (1970). Variations in Pattern of Pubertal Changes in boys. Arch Dis 
Childh; 45:13-23
Matthews DR et al (1985). Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man. 
Diabetologia; 28:412-9
McCance et al (1994). Birth weight and non-insulin dependent diabetes: thrifty genotype, 
thrifty phenotype, or surviving small baby genotype? BMJ; 308:942-5
Ong KK and Dunger DB (2002). Perinatal growth failure: the road to obesity, insulin 
resistance and cardiovascular disease in adults. 
Best Pract Res Clin Endocrinol Metab; 16:191-207
Phillips DI. Insulin resistance as a programmed response to fetal undernutrition. 
Diabetologia 1996; 39:1119-22
Poidvin et al (2017) Risk of Diabetes Treated in Early Adulthood After Growth Hormone 
Treatment of Short Stature in Childhood J Clin Endocrinol Metab, 102(4):1291–8
Prader A, Largo RH, Molinari L, Issler C (1989). Physical growth of Swiss children from 
birth to 20 years of age. First Zurich longitudinal study of growth and development. 
Helv Paediatr Acta Suppl; 52:1-125
Reynolds RM and Phillips DI (1998). Long-term consequences of intrauterine growth 
retardation. Horm Res; 49 (Suppl 2):28-31


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 53 of 55
Study No. EP00-401 
Rich-Edwards JW et al (1997). Birth weight and risk of cardiovascular disease in a cohort of 
women followed up since 1976. BMJ; 315:396-400.
Rich-Edwards JW et al (1999). Birthweight and the risk for type 2 diabetes mellitus in adult 
women. Ann Intern Med; 130:278-84
Rosenfeld R and Cariati S (2002). The role of growth hormone therapy in short children born 
small for gestational age. Medscape CME 
Sas T et al (1999). Growth hormone treatment in children with short stature born small for 
gestational age: 5-year results of a randomized, double-blind dose-response trial. 
J Clin Endocrinol Metab; 84:3064-70
Sas T et al (2000). Body composition, blood pressure, and lipid metabolism before and during 
long-term growth hormone (GH) treatment in children with short stature born small for 
gestational age either with or without GH deficiency. J Clin Endocrinol Metab; 85:3786-92
Sas T et al (2001). Carbohydrate metabolism during long-term growth hormone treatment in 
children with short stature born for small for gestational age. Clin Endocrin; 54:243-51
Stern MP et al (2000). Birth weight and the metabolic syndrome: thrifty phenotype or thrifty 
genotype? Diabetes Metab Res Re; 16:88-93
Tanner JM, Whitehouse RH (1976). Clinical longitudinal standards for height, height velocity, 
and weight velocity and the stages of puberty. Arch Dis Child; 51:170-9
Tanner JM, Whitehouse RH, Takaishi M (1966). Standards from birth to maturity for height, 
weight, height velocity, and weight velocity for British children, 1965, Part I Arch Dis Child; 
41:454-71
Usher R and McLean F (1969). Intrauterine growth of live-born Caucasian infants at sea 
level: standards obtained from measurements in 7 dimensions of infants born between 25 and 
44 weeks of gestation. J Pediatr; 74:901-10
Valdez R et al (1994). Birthweight and adult health outcomes in a biethnic population in the
USA. Diabetologia; 37:624-31
Van der Steen et al. (2017). Metabolic health of young adults who were born small for 
gestational age and treated with growth hormone, after cessation of growth hormone 
treatment: a 5-year longitudinal study. Lancet Diabetes Endocrinol; 5(2):106-16
Ventura SJ et al (2001). Births: final data for 1999. Natl Vital Stat Rep; 49:1-100
WHO 2002: Laboratory Diagnosis and Monitoring of diabetes mellitus 
Yarbrough DE et al (1998). Birth weight, adult weight, and girth as predictors of the 
metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. 
Diabetes Care; 21:1652-8


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 54 of 55
Study No. EP00-401 
Appendices
Tanner Breast Stages
Stage 1
Pre-adolescent; elevation of papilla only.
Stage 2
Breast bud stage; elevation of breast and papilla as a small
mound, enlargement of areola diameter.
Stage 3
Further enlargement of breast and areola, with no separation of 
their contours.
Stage 4
Projection of areola and papilla to form a secondary mound above 
the level of the breast.
Stage 5
Mature stage; projection of papilla only, due to recession of the 
areola to the general contour of the breast.
Source: Marshall WA, Tanner JM: Variations in Pattern of Pubertal Changes in girls. 
Arch Dis Childh 1969; 44: 291-303
Handling of elevated blood glucose levels and OGTT 
Fasting blood 
glucose levels
OGTT
Patient outcome
impaired
impaired
Ongoing
overt
impaired
Ongoing
overt
overt
Discontinuation
As the OGTT is more sensitive than fasting blood glucose assessment, the final decision with 
regards to discontinuation will be eventually based on the result of the OGTT. 
In case of the unlikely situation that fasting blood glucose levels = normal/impaired and 
OGTT=overt, patient outcome = discontinuation.
Overt levels are defined as:

Fasting blood glucose >126 mg/dl or > 7.0 mmol/l 

OGTT > 200 mg/dl or > 11.1 mmol/l after 120 minutes


Sandoz GmbH
Clinical Study Protocol, Version 6.0
Confidential
Page 55 of 55
Study No. EP00-401 
Recommended Dosage of Omnitrope®
5 mg / 1.5 ml cartridge
10 mg / 1.5 ml cartridge
Weight in kg 
Dose dialed 
in mg
Weight in kg 
Dose dialed 
in mg
Weight in kg 
Dose dialed 
in mg
5.0 – 6.4
0.20
45.0 – 46.4
1.60
5.0 - 7.8
0.2
6.5 – 7.8
0.25
46.5 – 47.8
1.65
7.9 – 10.7
0.3
7.9 – 9.2
0.30
47.9 – 49.2
1.70
10.8 – 13.5
0.4
9.3 – 10.7
0.35
49.3 – 50.7
1.75
13.6 – 16.4
0.5
10.8 – 12.1
0.40
50.8 – 52.1
1.80
16.5 – 19.2
0.6
12.2 – 13.5
0.45
52.2 – 53.5
1.85
19.3 – 22.1
0.7
13.6 – 14.9
0.50
53.6 – 54.9
1.90
22.2 – 24.9
0.8
15.0 – 16.4
0.55
55.0 – 56.4
1.95
25.0 – 27.8
0.9
16.5 – 17.8
0.60
56.5 – 57.8
2.00
27.9 – 30.7
1.0
17.9 – 19.2
0.65
57.9 – 59.2
2.05
30.8 – 33.5
1.1
19.3 – 20.7
0.70
59.3 – 60.7
2.10
33.6 – 36.4
1.2
20.8 – 22.1
0.75
60.8 – 62.1
2.15
36.5 – 39.2
1.3
22.2 – 23.5
0.80
62.2 – 63.5
2.20
39.3 – 42.1
1.4
23.6 – 24.9
0.85
63.6 – 64.9
2.25
42.2 – 44.9
1.5
25.0 – 26.4
0.90
65.0 – 66.4
2.30
45.0 – 47.8
1.6
26.5 – 27.8
0.95
66.5 – 67.8
2.35
47.9 – 50.7
1.7
27.9 – 29.2
1.00
67.9 – 69.3
2.40
50.8 – 53.5
1.8
29.3 – 30.7
1.05
69.4 – 70.7
2.45
53.6 – 56.4
1.9
30.8 – 32.1
1.10
70.8 – 72.1
2.50
56.5 – 59.2
2.0
32.2 – 33.5
1.15
72.2 – 73.5
2.55
59.3 - 62.1
2.1
33.6 – 34.9
1.20
73.6 – 75.0
2.60
62.2 – 64.9
2.2
35.0 – 36.4
1.25
75.1 – 76.4
2.65
65.0 – 67.8
2.3
36.5 – 37.8
1.30
76.5 – 77.8
2.70
67.9 – 70.7
2.4
37.9 – 39.2
1.35
77.9 – 79.3
2.75
70.8 – 73.5
2.5
39.3 – 40.7
1.40
79.4 – 80.7
2.80
73.6 – 76.4
2.6
40.8 – 42.1
1.45
80.8 – 82.1
2.85
76.5 – 79.3
2.7
42.2 – 43.5
1.50
82.2 – 83.5
2.90
79.4 – 82.1
2.8
43.6 – 44.9
1.55
83.6 – 85.0
2.95
82.2 – 85.0
2.9

SAP_001.pdf: 
Official Title: 
NCT Number: 
Document Date: 
NCT00537914 
Statistical Analysis Plan Version 5.0: 28 April 2022 
Long-term Phase IV Multicentre Study on the Safety and Efficacy of 
Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)


Sandoz Biopharmaceuticals Clinical Development 
EP2000 (INN: somatropin), Omnitrope 
EP00-401 
Long-term phase IV multicenter study on the safety and 
efficacy of Omnitrope (rhGH) in short children born small 
for gestational age (SGA) 
Statistical Analysis Plan (SAP)  
Document type: 
SAP Documentation 
Document status: 
Final V5.0 
Release date: 
28-APR-2022
Number of pages: 
110 
Property of Sandoz 
 Confidential 
May not be used, divulged, published or otherwise disclosed 
without the consent of Sandoz 
Template Version 4.0, Effective from 23-Apr-2021 


Sandoz GmbH 
Confidential 
Page 2 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
I herewith approve the statistical analysis - Final analysis for EMA 
Report. 
 
Name 
 
Title 
, Sandoz GmbH 
Signature 
 
Date 
 
 
 
I herewith approve the statistical analysis - Final analysis for EMA 
Report. 
 
Name 
 
Title 
, 
 
Signature 
 
Date 
 


Sandoz GmbH 
Confidential 
Page 3 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Document History – Changes compared to previous version of the SAP. 
Date 
Version 
Title 
Purpose of the SAP / Main Changes 
25-Nov-2009 
1.0 
Statistical Analysis Plan for 
Protocol Number: EP00-401 
Initial version 
27-Jul-2011 
1.0 
Statistical Analysis Plan for 
Interim Analysis  
Specific SAP version used for the 1 year 
interim analysis 
Outputs limited to data collected during 
the first year of treatment 
19-Jan-2012 
1.0 
Further statistical Methods for 
Interim Analysis 
Document specifying further 
programming details for 1 year interim 
analysis 
13-Feb-2012 
1.0 
Statistical Analysis Plan for 
Interim Analysis – SAP 
Amendment 
Amendment to specific SAP version 
used for the 1 year interim analysis 
10-Oct-2013 
2.1 
Statistical Analysis Plan for 2 
Years Interim Analysis 
Specific SAP version used for the 2 
years interim analysis 
Outputs limited to data collected during 
the first two years of treatment 
18-Apr-2017 
1.0 
Statistical Analysis Plan – 
Interim Analysis 2017 
 
Specific SAP version prepared for a 
third interim analysis planned for 2017.  
All data available at database cut-off to 
be analysed. This interim analysis was 
not performed. 
11-May-2017 
2.0 
Statistical Analysis Plan – 
Interim Analysis 2017   
(Note: The interim analysis 
2017 was not peformed.) 
Updated version of the specific SAP 
version prepared for a third interim 
analysis planned for 2017 based on 
discussions during the DRM meeting. 
This interim analysis was not 
performed. 
31-May-2021 
4.0 
Statistical Analysis Plan 
SAP version for the final analysis 
including all data available. 
Main changes: 
Removal of per protocol set according 
to  Protocol Amendment 04 dated 24-
Aug-2017 
Updated Type 2 diabetes mellitus 
definition to 2016 revised WHO criteria 
which includes HbA1C. Definitions for 
IGT and IFG added.   
26-Apr-2022 
5.0 
Statistical Analysis Plan 
SAP version for the final analysis 
including all data available.   
Main changes: 
Subgroup analysis of an overweight 
population added. 
Additional tables and figures added. 
 
 
 


Sandoz GmbH 
Confidential 
Page 4 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Table of contents 
Table of contents ...................................................................................................................... 4 
List of abbreviations ................................................................................................................ 6 
1 
Introduction .............................................................................................................................. 7 
2 
Statistical and analytical plans ................................................................................................ 7 
2.1 
Study documents and general considerations ............................................................ 7 
2.2 
Study objectives ........................................................................................................... 7 
2.3 
Endpoints...................................................................................................................... 8 
2.3.1 
Primary endpoint ........................................................................................ 8 
2.3.2 
Secondary endpoints .................................................................................. 8 
2.4 
Statistical methods planned in the protocol ............................................................... 8 
2.5 
Determination of sample size...................................................................................... 8 
2.6 
Definitions of analysis sets ......................................................................................... 9 
2.7 
Subgroup analyses ....................................................................................................... 9 
3 
Changes to planned analyses ................................................................................................... 9 
4 
Statistical analyses ................................................................................................................. 10 
4.1 
General considerations .............................................................................................. 10 
4.2 
Disposition of patients and protocol deviations....................................................... 10 
4.3 
Demographics and baseline characteristics.............................................................. 11 
4.3.1 
Demographics ........................................................................................... 11 
4.3.2 
Medical history ......................................................................................... 11 
4.3.3 
Baseline values of height measurements ................................................ 11 
4.3.4 
Pubertal status ........................................................................................... 12 
4.3.5 
Prior and concomitant medication........................................................... 12 
4.4 
Treatment regimen, compliance and exposure to drug ........................................... 12 
4.5 
Analysis of the primary endpoint ............................................................................. 13 
4.6 
Analysis of secondary endpoints .............................................................................. 13 
4.6.1 
Efficacy evaluation ................................................................................... 13 
4.6.2 
Safety evaluation ...................................................................................... 17 
4.6.3 
Immunogenicity ........................................................................................ 21 
4.7 
Handling of missing data in the analyses ................................................................. 21 
4.8 
Analyses during an ongoing study............................................................................ 22 
5 
Tables, listings and figures .................................................................................................... 23 
5.1 
Demographic Tables including shells ...................................................................... 23 
5.2 
Efficacy and other non-safety Tables including shells............................................ 50 
5.3 
Figures ........................................................................................................................ 81 


Sandoz GmbH 
Confidential 
Page 5 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
5.4 
Safety Tables including shells .................................................................................. 82 
5.5 
Listings ..................................................................................................................... 107 
6 
Literature .............................................................................................................................. 108 
7 
Appendices ........................................................................................................................... 109 
7.1 
Appendix A .............................................................................................................. 109 
7.2 
Appendix B: Height SDS ........................................................................................ 109 
7.3 
Appendix C: BMI SDS ........................................................................................... 109 
7.4 
Appendix D .............................................................................................................. 110 


Sandoz GmbH 
Confidential 
Page 6 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
List of abbreviations 
ADA 
Anti-drug antibodies 
AE 
Adverse event 
 
 
CA 
Chronological age 
CRF 
Case report form 
FAS 
Full analysis set 
FPG 
Fasting plasma glucose 
HA 
Height age 
HbA1C 
Glycated hemoglobin test 
HCP 
Host Cell Protein 
HOMA 
Homeostasis model assessment 
HV 
Height velocity 
HV SDS 
Height velocity standard deviation score 
IFG 
Impaired fasting glucose 
IGT 
Impaired glucose tolerance 
OGTT 
Oral glucose tolerance test 
Q1 
First quartile 
Q3 
Third quartile 
QUICKI 
Quantitative insulin sensitivity check index 
rhGH 
Recombinant human growth hormone 
SAE 
Serious adverse event 
SAF 
Safety set 
SD 
Standard deviation 
SGA 
Small for gestational age 
 
 


Sandoz GmbH 
Confidential 
Page 7 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
1 
Introduction 
This study is performed as part of the Marketing Authorization Holder’s post-authorization Risk 
Management Plan in order to investigate the long-term safety, in particular the diabetogenic 
potential and immunogenicity of Omnitrope treatmentin short children born small for 
gestational age (SGA).  
This study is designed as an open phase IV, prospective, non-comparative, multicenter trial. 
Omnitrope treatment will continue until final height is reached. Treatment should be 
discontinued after the first year of treatment if the height velocity standard deviation score (HV 
SDS) is below +1. Treatment should be discontinued if height velocity is below 2 cm/year 
 
 
 
2 
Statistical and analytical plans  
Data will be analyzed by 
 according to this statistical 
analysis plan. 
2.1 
Study documents and general considerations 
This document describes the procedures and conventions to be used for the final analysis of all 
patients who were included into study EP00-401 and is based on study protocol V6.0, dated 07-
Feb-2020, incorporating amendment no. 05.   
Raw data listings, summary tables, graphs and statistical tests will be generated by means of the 
program SAS 9.4 and SAS/STAT Version 14.3.  
The following descriptive statistical parameters will be shown in summary tables 
• Continuous variables: n (valid cases), n (missing data), mean, standard deviation (SD), 
min, 1st quartile (Q1), median, 3rd quartile (Q3), max 
• Categorical variables: Count and percentage of category. Percentages are routinely based 
on the total category count excluding the missing category if not otherwise mentioned. 
Percentages showing a rate relative to the total number of patients in this group are given 
in special tables (e.g. Adverse Event (AE) tables). Footnotes will specify the percent basis. 
For continuous variables, if not otherwise specified, mean, median and standard deviation 
values will be reported to one decimal place greater than the data were collected. Minimum and 
maximum values will be reported with the same precision, as they were collected.  
Generally, percentages will be displayed in the format xx.d, i.e. one decimal place will be shown; 
if the calculated percentage is 100, no decimal is required (i.e. 100% and not 100.0%). If the 
count is zero no percentage needs to be shown. 
2.2 
Study objectives 
The primary objective of this study is to evaluate the long-term effect of growth hormone 
treatment on the development of diabetes in short children born SGA during the treatment.  
The secondary objectives of this study are:  


Sandoz GmbH 
Confidential 
Page 8 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
• to report the incidence of anti-recombinant human growth hormone (rhGH) antibodies 
during Omnitrope treatment 
• to evaluate the efficacy (with respect to changes in height parameters) of Omnitrope 
treatment in short children born SGA 
• to evaluate IGF-1 and IGFBP-3 levels during treatment 
• to evaluate incidence and severity of adverse events 
2.3 
Endpoints 
2.3.1 
Primary endpoint 
The development of diabetes is the primary endpoint of the study and is evaluated on the basis 
of the carbohydrate metabolism (fasting plasma glucose (FPG), oral glucose tolerance test 
(OGTT)) and HbA1C.  
2.3.2 
Secondary endpoints 
The development of anti-rhGH antibodies is a secondary endpoint.  
The efficacy endpoints of this study are the height and the standardized height (SDS), the height 
velocity (HV) and the HV SDS assessed at screening, every 3 months during the first two years 
of GH treatment and annually thereafter until final height is reached (end of treatment).  
Additionally efficacy endpoints of this study are the development of the hGH-induced serum 
parameters IGF-1 and IGFBP-3 assessed by a central laboratory at screening, after 3, 6, 9, 12 
months and then biannually during treatment.  
Additional criteria for assessing safety will consist of monitoring and recording all (serious) 
adverse events, vital signs and body weight, physical condition, hematology, blood chemistry, 
thyroid function tests, lipids and urinalysis. Fundoscopy will be performed if intracranial 
hypertension is suspected. 
2.4 
Statistical methods planned in the protocol 
Analyses planned are described in section 10 of the protocol.  
Safety and efficacy endpoints will be summarized descriptively. For all efficacy endpoints mean 
difference between the baseline visit and all later visits and respective 95% confidence will be 
provided.  
2.5 
Determination of sample size 
There was no formal sample size calculation for this study which is intended to exploratorily 
investigate the long-term effect of the treatment with respect to the development of diabetes. 
No such incidences are currently available to allow for a rigorous sample size estimation. 
Results obtained in this study will be compared to data published in the literature. 
 
 
Patients dropping out before completing 1 year of treatment will be replaced. 


Sandoz GmbH 
Confidential 
Page 9 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
 
 
2.6 
Definitions of analysis sets 
The safety analysis set (SAF) comprises all patients who have received at least one dose of 
study medication and had at least one post-baseline safety assessment. All safety analyses will 
be based for the SAF. 
The full analysis set (FAS) follows the intent-to-treat principle and consists of all patients who 
received at least one dose of study medication.. All baseline and efficacy analyses will be 
summarized for the FAS.  
2.7 
Subgroup analyses 
Since the study population consists of patients treated with Omnitrope 5 mg/ml powder for the 
first twelve months and with Omnitrope 5 mg/1.5 ml solution for injection thereafter as well as 
of patients treated continuously with Omnitrope 5 mg/1.5 ml mg/ml solution for injection, a 
corresponding subgroup analysis will be performed.  
Moreover, a subgroup analysis will also be done for an overweight population with international 
cut-off points for BMI for overweight by sex and age as defined by the percentile that passes 
through BMI of 25 at age 18.  
Further subgroup investigations concerning efficacy endpoints will be carried out with regard 
to sex, completers and total. 
3 
Changes to planned analyses 
The assessment of laboratory findings related to diabetes mellitus is no longer based on WHO 
definition of 2006, but on the version published in 2016. 
The protocol planned to analyze treatment compliance based on the percentage of medication 
used compared to the amount prescribed for  each visit and the frequency of non-compliant 
patients (daily dose range 80% or >120%). This approach was changed currently the number of 
non-compliant patients will be assessed based on the investigator’s assessment that is collected 
on dose change page in the CRF. 
Analysis for anti-HCP was added. 


Sandoz GmbH 
Confidential 
Page 10 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
4 
Statistical analyses  
4.1 
General considerations 
Baseline visit 
In principal, Visit V01 (start) is regarded as baseline visit. For some patients only a screening 
visit, but no baseline visit was performed. For these patients screening visit will be used as 
baseline visits. 
Alignment of final visits 
A final visit should be performed for all patients terminating study drug. These visits will be 
analyzed together with the regularly performed study visits.  A final visit will be assigned to the 
appropriate study visit as follows: 
In a first step the respective limit between two visit used for assignment, will be assessed as 
follows: limit = (Day on which VX [= Visit X] should have been performed - Day on which 
VX-1 should have been performed)/2.  The respective limit was rounded if necessary.  Days on 
which a visit should have been performed according to protocol will be assessed as follows 
(excluding V0 and V1): Month given in the protocol *(365.25/12) (i.e. V2 = Day 92, V3 = Day 
183, V4 = 274 ...). 
In a second step final visits performed between VX-1 and the limit (included) will be assigned 
to VX-1, final visits performed after the limit and prior to VX will be assigned to VX.  
For example: A final visit performed between V3 and V4, will be assigned to V3, if performed 
at or before Day 229 (= (Day 274 + Day 183)/2 = 228.5 => rounded to 229). If performed after 
Day 229 and at or before V4, the final visit will be assigned to V4.  
If due to the assignment of final visits to regular visits two assessments are available for one 
visit, the assessment nearest to the day on which the visit had to be performed will be used.  
If the final visit was performed on the same day as a regular visit, the regular visit will be used 
for analysis.  
Retest of fasting blood glucose 
Retest values for fasting blood glucose will be listed only. 
4.2 
Disposition of patients and protocol deviations 
Information regarding patient enrolment and patient disposition over time will be summarized 
in a table, listing the participating sites and providing the following variables: site code, number 
of patients enrolled at screening and number of patients at subsequent visits. Further, a table 
providing number of patients screened, and number and percentage in each analysis set will be 
provided.  
Protocol deviations were collected based on the PD specification and were classified during the 
DDRM by the reponsible team members. Based on these a summary table and listing of all 
important protocol deviations will be provided, sorted by site code and patient number. In 


Sandoz GmbH 
Confidential 
Page 11 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
addition to site code and patient number, this listing includes: a description of the deviation, the 
deviation code, and a variable indicating whether the patient discontinued study treatment 
prematurely. If a patient was withdrawn from the study, date and reason for withdrawal are 
given. 
A listing of all patients who discontinued the study will be provided, sorted by site code and 
patient number. In addition to site code and patient number, this listing includes date and 
primary reason for study discontinuation as well as information on last study drug intake. 
Additionally, number and percentage of patients having completed the study as planned, 
discontinuing the study prematurely as well as the primary reason for discontinuation will be 
summarized. 
4.3 
Demographics and baseline characteristics 
4.3.1 
Demographics 
Demographic data of patients are collected at the screening visit (month 0). 
Demographic information will be summarized for age, height, height SDS, height velocity (HV), 
HV SDS, weight, BMI, BMI SDS, sex, and ethnic origin. Separate summaries of age, sex and 
ethnic origin will be produced, stratified by initial treatment (powder/solution). Further ethnic 
origin will be stratified by sex.  
Separate tables by country and by age group will be prepared for FAS. 
Parents’ height 
Parents’ height data will be stratified by sex and initial treatment.  
Patient birth history 
Birth weight, birth length, birth weight SDS, birth length SDS and gestational age will be 
summarized for the whole group of patients and stratified by sex and initial treatment. 
Assessment of birth weight and length SDS is described in the Project Specific Procedure – 
Calculation of Auxological data v3.0 dated 4-July-2011.  
4.3.2 
Medical history 
Medical history will be recorded at the screening visit and will be coded according to Novartis 
MedDRA, Version 24.1 or later. 
Medical history data will be summarized, providing the proportions resolved, intermittent, and 
ongoing illnesses by MedDRA system organ class and preferred term for the FAS. Further, all 
data on medical histories will be listed sorted by site code, patient number, and date of diagnosis.  
4.3.3 
Baseline values of height measurements 
Values for height parameters measured/derived at start of treatment will be summarized for all 
patients. The summary table will display descriptive statistics for the body height, height SDS, 
midparental adjusted height SDS, HV, HV SDS and for the time period (in days) between date 
of visit and historical height measurement used to calculate height velocity at start of treatment.  


Sandoz GmbH 
Confidential 
Page 12 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Midparental adjusted height SDS is defined as H SDS of the patient minus midparental height 
SDS. The midparental H SDS is defined as 0.5*(H SDS of the mother + H SDS of the father).  
4.3.4 
Pubertal status 
Pubertal status is determined at each visit. 
Pubertal status will be summarized for the whole group of patients as well as for the two sexes 
separately. In these tables, numbers and proportions of Tanner stages will be reported by visit. 
The tables will be produced for the FAS. 
4.3.5 
Prior and concomitant medication 
Concomitant medication is documented at each visit from start of treatment onwards. 
Medication will be coded to the preferred term using the Novartis WHO drug dictionary version 
Novartis WHO DDE 17.3-28.08.2018; all possible ATC codes will also be applied. 
Prior medication is defined as all medication stopped prior to first intake of study medication. 
All other medication is considered as concomitant medication. 
If stop date of medication is given partial only, the last day of months or 31 December will be 
assumed. If neither a stop date is given nor ongoing was ticked, the respective medication was 
regarded as concomitant medication. 
Prior and concomitant medication data will be summarized separately by Anatomical 
Therapeutic Chemical (ATC) term (level 2) and preferred term, providing the proportion of 
patients to whom medication was administered. This summary will be prepared for the FAS. 
4.4 
Treatment regimen, compliance and exposure to drug 
The patient’s exposure to study drug will be calculated from the date of first dose to the date of 
last study drug administration for patients that prematurely discontinued or completed the study, 
and presented in years as a decimal.  
If date of last study drug administration is missing completely or only a year is given and the 
patient has discontinued or completed the study, then the date the patient discontinued or 
completed the study shall be used instead. If date of last study drug administration was given 
only partial (i.e. month and year given), the first date of the month will be assumed as last 
administration date. Study drug exposure in days will be converted to study drug in years as 
follows:  
• Exposure (years) = Exposure (days)/365.25.  
The patient’s exposure to study drug will also be summarized by site for FAS.  
The total daily dose administered per kg body weight will be summarized by visit to assess the 
appropriateness of the applied dose for FAS. 
A summary table providing the number and percentage of patients with any study drug dose 
change documented by reason for dose change overall and by number of times the respective 
reason was documented per patient will be provided. As for some patients dose change records 


Sandoz GmbH 
Confidential 
Page 13 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
were documented when the patient returned to the recommended dose, all records with a daily 
dose of 0.035 mg/kg will be excluded from the summary tables.  
4.5 
Analysis of the primary endpoint 
Definitions according to the World Health Organization (WHO): 
According to the 2016 revised WHO criteria (WHO, 2016), the diagnosis of diabetes mellitus, 
impaired glucose tolerance (IGT) and impaired fasting plasma glucose (IFG) on laboratory 
results is defined by the following criteria:  
Diabetes mellitus (DM): 
FPG ≥ 126 mg/dl (≥7.0 mmol/l) 
or 
2-h plasma glucose ≥ 200 mg/dl (≥11.1 mmol/l) during OGTT 
or 
HbA1C ≥ 6.5% 
Impaired Glucose Tolerance (IGT): 
FPG < 126 mg/dl (<7.0 mmol/l)  
and  
2-h plasma glucose between 140 – 200 mg/dl (≥7.8 and <11.1 mmol/l) 
Impaired Fasting Glucose (IFG): 
FPG 110 - 125 mg/dl (6.1 - 6.9 mmol/l)  
and  
2-h plasma glucose < 140 mg/dl (<7.8 mmol/l) 
The identification of diabetes mellitus on laboratory results had to be in accordance to the 
documentation of diabetes mellitus as an AE. 
4.6 
Analysis of secondary endpoints 
4.6.1 
Efficacy evaluation 
Data regarding efficacy endpoints will be summarized by visit. Time trends of means will be 
presented graphically for the secondary endpoints. 
For all endpoints, 95% confidence intervals will be calculated for the mean difference between 
the baseline visit and all later visits, respectively.  
Summary tables, plots, and confidence intervals will be presented by visit for the FAS 
analysis set as well as by sex and the two Omnitrope formulations (i.e. initially treatment). All 
summary table stratified by initially treatment will be limited to the visit during the first year 
of treatment. Plots presenting parameters in SDS will not be presented by sex. No plots by 
initially treatment will be presented. In summary tables presenting data that is also presented 
graphically confidence limit for means will be added. 


Sandoz GmbH 
Confidential 
Page 14 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
All efficacy analyses will be done by completers (who reached the final height) and total. 
Body height and derived parameters 
Patients' body height is determined at each visit. The three other primary endpoints are 
calculated using the recorded height measurements. HV will be calculated in cm/year as the 
difference between two height measurements divided by the time interval (in days) between 
these two measurements and multiplied by 365.25. Patients' body height at start of treatment 
serves as baseline value for calculating HV at month 3, 6, 9 and 12. From the 15-months-visit 
onwards, the baseline value for HV calculation will be patients' body height at the visit dating 
back 12 month in the past, e.g., height after 3 months will serve as baseline value to determine 
HV at 15-months-visit, height after 6 months will serve as baseline to determine HV at 18- 
months-visit, and so on ("moving 12-months HV basis"). 
HV and HV SDS for the baseline visit are calculated using historical height data. All 
corresponding values are recorded in the CRF. The historical reference values to assess the 
height velocity at screening (V0) and baseline (V1) will be assessed as follows: The historical 
value, which was assessed next to day 365 prior to height assessment at baseline, will be 
selected. If there are two values, one assessed x days prior to day 365 and one assessed x days 
after day 365, the one assessed longer ago will be selected. Derived height velocity values will 
be rounded to two digits. If for any historical height assessments, the assessment date was given 
partial only, the 15th of the respective month will be used. If in the final data negative HV 
values are assessed, this will be set to 0 for analysis.  
Height and height velocity will also be expressed in SDS. SDS reflects the deviation of a 
measured value from the mean value of normally growing children of the same sex and 
chronological age, expressed in units of the standard deviation of normally growing children of 
the same sex and chronological age.  
In general, the SDS values for H and HV will be calculated according to the formula 
SDS=(X1-X2)/SD, where X1 is the measured value, X2 the mean value for the relevant 
chronological age and sex, and SD the standard deviation for the relevant sex and age. 
Standardization of patients’ height will be performed according to the protocol using national 
reference ranges of body height (Appendix B). If respective national references for height are 
provided as median and 3rd percentiles SDS values will be calculated according to the following 
formula: SDS = (X1-X3)/ (0.5*(X3 – X4), where X1 means the measured value, X3 the median 
value for the relevant chronological age and sex, and X4 the 3rd percentile for the relevant 
chronological age and sex applying the respective national references. Resulting SDS values 
will be rounded to two digits.  
To derive reference values for age groups in between the age groups reported in literature, the 
original tables were extended by linear interpolation between the reported values for mean and 
standard deviation. Standardization of a patient’s HV between two successive visits will be 
based not on the patient’s chronological age at the time of the second of the two visits, but on 
the mean of the chronological ages at the two visits. Means and standard deviations of normally 
growing children will be taken from tables provided by Prader (1989). To derive reference 
values for age groups in between the age groups reported by Prader (1989), the original tables 


Sandoz GmbH 
Confidential 
Page 15 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
were extended by linear interpolation between the reported values for mean and standard 
deviation (Appendix A). To derive references values for patients older than the provided age 
groups the reference for the maximal age will be used (for H and HV).  
In order to derive individual HV SDS values, two methods of HV standardization will be used. 
The two alternative methods used for standardization:  
• cross sectional = HV SDSCS,  
• peak centered, HV SDSPC,  
differ only regarding the reference tables used to look up values for means and standard 
deviations (reference values) for the standardization.  
HV SDSCS 
Individual values for HV SDSCS are calculated using reference values from Table 1 (for boys) 
or Table 2 (for girls), both given in Appendix D. Each of these tables was derived by tables 
provided by Prader (1989). For a description of the performed combinations and extensions 
please refer to the foot note below the attached tables. The abbreviation "CS" in HV SDSCS 
stands for "cross sectional", meaning that tabled reference values for specific age groups 
directly correspond to means and standard deviations for HV as observed in the referenced 
longitudinal study. Averages and variability are estimated for each age group from raw data, 
not taking into account any information regarding the individual onset or peak of pubertal 
growth spurt. 
HV SDSPC 
Individual values for HV SDSPC are calculated using reference values from the tables given in 
Appendix D. These HV references were obtained for each sex at the end of the referenced 
longitudinal study, aligning individual velocity curves on mean age of peak height velocity. The 
abbreviation "PC" in HV SDSPC stands for "peak centered". 
Mean time-trends of these four efficacy endpoints will be illustrated graphically.  
All four endpoints will be summarized by visit overall and stratified by sex and initially 
treatment.. In addition, 95% confidence intervals will be calculated for the mean difference 
between the baseline visit and all later visits, respectively.  
4.6.1.1 
IGF-1 and IGFBP-3 serum levels 
Blood samples for the determination of IGF-1 and IGFBP-3 serum levels will be drawn at 
baseline, at 3, 6, 9, 12, 18, and 24 months, then every 6 months during treatment, and at the end 
of treatment. Serum levels as well as ratios of IGF-1 and IGFBP-3 will be assessed by a central 
laboratory. 
Data regarding secondary efficacy parameters will be summarized by visit overall and stratified 
by sex and initially treatment. In summary tables by visit overall confidence limit for means 
will be provided. Time trends of means will be presented graphically for all patients only by 
sex.  In addition, 95% confidence intervals will be calculated for the mean difference between 
the baseline visit and all later visits, respectively. Relative changes from baseline of IGF-1 and 
IGFBP-3 will be summarized by visit. 


Sandoz GmbH 
Confidential 
Page 16 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Shift tables for changes in the reference range classification will be provided for IGF-1 and 
IGFBP-3. Shift tables will be prepared for the two formulations separately. In these tables 
baseline data will be presented in rows and data from the visits at 6, 12, 18, and 24 months will 
be cross-tabulated in columns. The categories "low"(< lower limit of normal), "normal", "high" 
(>upper limit of normal) and "missing" will be used in the shift tables. Shifts between categories 
will be displayed using absolute counts. 
IGF-1, IGFBP-3 and ratio will be expressed in SDS. SDS reflects the deviation of a measured 
value from the mean value of healthy children of the same sex and chronological age, expressed 
in units of the standard deviation of unexposed children of the same sex and chronological age.  
Standardization of patients’ IGF-1, IGFBP-3 and ratio will be performed according to Elmlinger 
(2004). SDS values will be assessed according to the following formulas: SDS = (X1-X2)/((X2-
X3)/2) if X1 < X2 and SDS = (X1-X2)/((X4-X2)/2) if X1 ≥ X2, where X1 means the measured 
value, X2 the mean value for the relevant chronological age and sex, X3 the –2 SD value for 
the relevant chronological age and sex, and X4 the +2 SD value  for the relevant chronological 
age and sex according to Elmlinger (2004). 
Mean, -2 SD, and +2 SD values given by Elmlinger (2004) are provided for age intervals. These 
values were used as references for patients with an age equal to the mid of this age interval. For 
patients with an age between two mids of age intervals, mean, -2 SD, and +2 SD values will be 
interpolated.  
SDS values of secondary efficacy parameters will be summarized by visit overall and stratified 
by sex and initially treatment. In summary tables by visit overall confidence limit for means 
will be provided. Time trends of means will be presented graphically for all patients only. In 
addition, 95% confidence intervals will be calculated for the mean difference between the 
baseline visit and all later visits, respectively. 
4.6.1.2 
Additional efficacy endpoints 
In addition to the endpoints described in 0 and 4.6.1.1, 
 height age will be derived 
in the analysis.  
 
 
 
 
 
 
 
 
For the determination of height age (HA), body height recordings from the baseline and then 
yearly during treatment period will be compared to mean heights given in the extended 
reference tables for height (Appendix A). HA will be derived by taking that age from the 
reference table for which the observed height is the same as the average height in normally 
growing children.  


Sandoz GmbH 
Confidential 
Page 17 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
   
 
 
 
  
 
 
  
To assign one height age value to a given height using the respective reference table, the 
following rule was applied: If the height assessment was between two height assessments in the 
reference table, the lower age is used, if the height assessment was lower or equal to half of the 
distance. Otherwise the upper age will be used (i.e. if higher than half of the distance between 
lower and upper height).  
 
, HA and CA will be summarized by visit overall and stratified by sex and initially treatment. 
In addition 95% confidence intervals will be calculated for the mean difference between 
baseline visit and all later visits, respectively. 
The progresses in CA, 
 and HA will be compared by deriving the means of the following 
ratios: 
/∆CA, ∆HA/∆CA and ∆HA/
. To derive individual ratios corresponding to 
changes ∆CA, 
 and ∆HA will be calculated as the difference in CA, 
 and HA between 
the baseline visit and the annual visits under treatment. Calculated ratios will be summarized 
by visit overall and stratified by sex and initial treatment. Performing one-sample t-tests, it will 
be evaluated whether mean ratios differ significantly from the theoretical value of 1.0. 
4.6.2 
Safety evaluation 
All tables, figures and listings in this section will be presented for the SAF analysis set. 
4.6.2.1 
Adverse events 
Adverse events (AEs) are to be recorded during the whole study period. 
AEs are coded according to Novartis MedDRA, Version 24.1. 
The AE data will be listed, sorted by site code, patient number, and preferred term. This list will 
include: adverse event, MedDRA system organ class, MedDRA preferred term, start date, stop 
date, intensity, outcome, relationship to study drug, action taken, and a variable indicating 
whether an AE was considered a serious adverse event (SAE). 
AEs starting prior to start of treatment will not be included in the summary tables, but listed 
only. 
A general summary table of AEs will contain the total number of AEs, the total number of SAEs, 
and separate descriptions of the splits for the variables relationship to study drug, action taken, 


Sandoz GmbH 
Confidential 
Page 18 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
outcome and intensity. Outcome is categorized according to the CRF as “resolved” (i.e. resolved 
completely or resolved with sequelae), “ongoing”, “fatal” or “unknown”.  
The incidence of an AE is defined as the number of patients who experience that event, divided 
by the number of patients in the SAF population. With AE incidence, each event will be counted 
only once for a given patient. More specifically, if a patient reports the same event more than 
once, as determined by preferred term and system organ class, that patient will be counted only 
once for the incidence of the AE. For example, when a patient reported three instances of 
headache, this patient counts only once towards the total incidence of headache. Incidence of 
events within a system organ class is defined similarly. Whenever incidence is cross-tabulated 
with intensity in the summary tables, the incidence of an AE will be calculated for each level 
of intensity, i.e., the number of patients who experience that AE on a certain level of intensity. 
Incidence tables will provide information about rates of AEs per patient-year, calculated as  
{(number of patients who experience that event) / (years of exposure)}. Additional tables will 
enable a direct comparison of formulation specific rates of events per patient year. 
The occurrence of an AE is defined as the total number of times the event occurs in the SAF 
population. With AE occurrence, a patient may contribute more than once to the total 
occurrence count. More specifically, if a patient reports a particular event, as determined by 
preferred term and system organ class (and having removed duplicate reporting of the same 
event, as described above) more than once, each event will count once towards the total event 
occurrence. Using the above example, headache would be counted three times for the patient 
who reported three separate occurrences of headache. 
Occurrence tables will provide information about rates of AEs per patient-year, calculated as 
{(number of events) / (years of exposure)}. Additional tables will enable a direct comparison 
of formulation specific rates of events per patient year. 
The incidence and occurrence of each AE will be reported by MedDRA system organ class and 
preferred term, cross-tabulated with the intensity, action taken, and outcome. Additionally, total 
incidence and occurrence will be provided for each system organ class.  
The whole set of AE summary tables will be produced for all AEs and separately for adverse 
drug reactions (ADR), serious AEs and serious ADRs. Adverse events will be considered as 
adverse drug reactions if a causal relationship to the study drug is suspected by the investigator. 
For the Final CSR and registry purposes a summary of non-serious AEs by SOC, PT and 
intensity is required in addition. 
AEs of special interest are defined as intracranial haemorrhage and intracranial aneurysm and 
possible drug interaction with sex steroids, corticosteroids, anticonvulsants and cyclosporine. 
4.6.2.2 
Carbohydrate metabolism 
Fasting plasma glucose, insulin levels and glycosylated hemoglobin (HbA1C) are measured at 
baseline (start of treatment), at 6 and 12 months, then annually during GH treatment, and at the 
end of treatment. An OGTT is performed at the same time points.  
The OGTT is a provocation test to examine the efficiency of the body to metabolize glucose. 
The OGTT provides information on latent diabetes states.  


Sandoz GmbH 
Confidential 
Page 19 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Insulin resistance will be estimated using both the homeostasis model assessment (HOMA) and 
quantitative insulin sensitivity check index (QUICKI) 
*
405
(mg/dl)
glucose
fasting
U/ml)
(
insulin
fasting
HOMA
×
=
µ
 
*use constant 22.5 instead of 405 if glucose concentration is reported in mmol/L 
(mg/dl)
glucose
fasting
log
U/ml)
(
insulin
fasting
log
1
QUICKI
+
=
µ
 
Carbohydrate metabolism data will be listed per parameter and will include: visit, sample date, 
parameter result, reference range, outside reference range indicator, clinical significance and a 
column containing comments. 
Carbohydrate metabolism data  as well as HOMA and QUICKI scores will be summarized by 
parameters and visit for the SAF for absolute values, and absolute and relative changes from 
baseline. 
Shift tables for changes in the reference range classification as compared to baseline will be 
prepared for fasting plasma glucose, fasting insulin levels and HbA1C. The categories "low", 
"normal", "high" and "Missing" will be used in the shift tables. Shifts between categories will 
be displayed using absolute counts. Percentages will be provided per baseline category (without 
considering missings) for each post-baseline category, and based on all non-missing patients 
for total line/column. 
In addition number and percentage of patients with DM and without DM finding will be 
presented. Patients fulfilling any criteria for DM given in section 4.5 will be regarded as patients 
with DM, patients not fulfilling any criteria on at least one visit will be considered as patients 
without DM finding. 
Implausible insulin or glucose values will be excluded, i.e. Glucose values below 0.1 mmol/L 
and insulin values below 0.1 pmol/L will not be used for the calculation of HOMA and QUICKI.  
4.6.2.3 
Vital signs 
Vital signs are collected at all visits. 
The vital signs data include: date of examination, systolic blood pressure, diastolic blood 
pressure and pulse rate. 
These data will be summarized by parameters and visit. 
4.6.2.4 
Physical examination 
A thorough physical examination is performed at all visits. 
The frequency of normal and abnormal evaluations and parameters not evaluated will be 
summarized for each physical examination system by visit. Shift table for normal / abnormal 
findings will be presented by body system for each visit versus baseline. The specification for 
other body systems will be reviewed by the sponsor. If this review  identified that the entry 
does not belong to an other body system but to a body system already given in the CRF, the 
entry will be considered for the existing body system. 


Sandoz GmbH 
Confidential 
Page 20 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Weight, BMI and BMI SDS will be summarized by visit for the SAF. For details regarding BMI 
SDS calculation see Appendix C. 
4.6.2.5 
Conversion factors for laboratory parameters 
In order to harmonize laboratory results by using the same units, some laboratory results will 
be converted. Corresponding conversion factors will be displayed in a table. 
All glucose values will be converted to values given in mmol/l (if possible). To omit problems 
in assessment of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) caused 
by this conversion all the converted glucose values will be rounded to one digit before assessing 
IGT and IFG. 
If albumin is given in %, the respective values will be converted to g/l using total protein values. 
4.6.2.6 
Hematology 
Hematology data are collected at baseline (start of treatment), at 6 and 12 months, then annually 
during GH treatment, and at the end of treatment. 
Hematology data include: visit, sample date, parameter result, reference range, outside 
reference range indicator, clinical significance and a column containing comments. The 
parameters included in the hematology data are: hemoglobin, hematocrit, white blood cell count 
(total and differential) (WBC), red blood cell count (RBC), platelet count, mean cell volume 
(MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), 
erythrocyte sedimentation rate (ESR). 
Hematology data will be summarized by parameters and visit. 
 
4.6.2.7 
Blood chemistry 
Blood chemistry data are measured at baseline (start of treatment), at 6 and 12 months, then 
annually during GH treatment, and at the end of treatment. 
Blood chemistry data include: visit, sample date, parameter result, reference range, outside 
reference range indicator, clinical significance and a column containing comments. The blood 
chemistry parameters are creatinine, urea, aspartate aminotransferase (SGOT/AST), alanine 
aminotransferase 
(SGPT/ALT), 
gamma-glutamyltransferase 
(gamma-GT), 
alkaline 
phosphatase, total bilirubin, albumin, total protein, HDL, LDL, sodium, potassium, chloride, 
uric acid, total cholesterol, triglycerides, calcium, phosphorus. 
Blood chemistry will be summarized by parameters and visit for the SAF. Thyroid panel 
Thyroid panel data are will be measured at baseline (start of treatment), at 6 and 12 months, 
then annually during GH treatment, and at the end of treatment. 
Thyroid panel data include: visit, sample date, parameter result, reference range, outside 
reference range indicator, clinical significance and a column containing comments. The thyroid 
panel parameters are free thyroxine (fT4) and thyroid stimulating hormone (TSH). 
Thyroid panel data will be summarized by parameters and visit. 


Sandoz GmbH 
Confidential 
Page 21 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Shift tables for changes in the reference range classification as compared to baseline will be 
provided for each parameter. The categories "low", "normal", "high" and "Missing" will be used 
in the shift tables. Shifts between categories will be displayed using absolute counts. 
Percentages will be provided per baseline category (without considering missings) for each 
post-baseline category, and based on all non-missing patients for total line/column. 
4.6.2.8 
Urinalysis 
Urinalysis data are collected at baseline (start of treatment), at 6 and 12 months, then annually 
during GH treatment, and at the end of treatment. 
The urinalysis data include: visit, sample date, parameter result, clinical significance and a 
column containing comments. The parameters included in the urinalysis data are pH, glucose, 
ketones, bilirubin, protein.  
Ph values will be summarized by visit. 
All remaining urinalysis parameters will be presented as shift tables comparing baseline to post-
baseline values. The categories "+", "++", "+++", “++++” and "Missing" will be used in the 
shift tables. Shifts between categories will be displayed using absolute counts. Percentages will 
be provided per baseline category (without considering missings) for each post-baseline 
category, and based on all non-missing patients for total line/column. 
4.6.3 
Immunogenicity 
All patients with a positive ADA result at any time during the study will be listed individually.  
Tests for anti-rhGH antibodies were performed at baseline, at 3, 6, 9,  12 18 and 24 months, 
then annually during Omnitrope treatment and the end of treatment. As per protocol amendment 
3, the anti HCP testing should be stopped after the amendment became effective in the 
respective country. Therefore, all HCP results since V01 will be presented up to the Visits 
occurred until the amendment 3 became effective. Number and percentage of patients with 
positive test for anti-hGH antibodies and anti-HCP antibodies will be provided by visit and 
overall (for anti-HCP antibodies).  
In addition summary tables and figures for H SDS and HV SDS will be presented for patients 
with and without positive anti-rhGH antibody test. 
4.7 
Handling of missing data in the analyses 
IGF-1 and IGFBP-3 serum levels which are found to be below the level of detection will be 
imputed as one-half of the lower limit of detection for the corresponding analysis. 
If for any laboratory parameter (hematology, blood chemistry, thyroid) a < or > sign is 
documented, this sign will be listed only. For calculation of summary tables, the respective 
value without sign will be used. If it is not possible to assess, whether the laboratory value is 
lower, inside, or higher the normal range, although laboratory value and normal range are given 
(e.g. lower range > upper range; < and > signs used), the respective value will be assessed as 
missing in the shift table. 


Sandoz GmbH 
Confidential 
Page 22 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
To enable calculation of time differences, partial dates will be completed: missing day is set to 
the 15th and missing month set to June, if no remaining dates are available. 
For safety or other efficacy parameters, missing values will not be imputed. 
4.8 
Analyses during an ongoing study 
According to the protocol three interim analyses were planned at the following time points:  
• Q4/2011 with data of patients who completed 1 year of treatment  
• Q4/2012 with data of patients who completed 2 years of treatment  
• Q4/2020 with data of patients who finished treatment 
The first two interim analyses were performed as planned including data on 278 treated patients. 
In the first interim analysis all information regarding the first year of treatment was included 
that was available on 19-Oct-2011; in the second interim analysis all information regarding the 
first two years of treatment were summarized based on data cut-off 20-Mar-2013. The third 
interim analysis was anticipated for Q4 2020 (with data of patients who finished treatment) and 
to be submitted as per the current RMP version 11 by 2021. However, Sandoz reached out to 
EMA in Aug-2021 with submitting PAM to provide the study status and ask for final report 
submission in 2022 EMEA/H/C/000607/MEA/010.3).  
This SAP describes the analyses planned for the final analysis that will be performed when all 
patients have discontinued/completed the study.   


Sandoz GmbH 
Confidential 
Page 23 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
5 
Tables, listings and figures 
5.1 
Demographic Tables including shells 
TABLE 14.1-1 ANALYSIS SETS .............................................................................................. 33 
TABLE 14.1-2 PATIENT ENROLMENT .................................................................................. 34 
TABLE 14.1-3 SUMMARY OF REASONS FOR STUDY DISCONTINUATION (FAS) ... 35 
TABLE 14.1-4 SUMMARY OF PATIENTS EXPOSURE TO STUDY DRUG (FAS) ......... 36 
TABLE 14.1-5 SUMMARY OF TOTAL DAILY DOSE ADMINISTERED PER KG 
BODY WEIGHT (FAS) .......................................................................... 37 
TABLE 14.1-6 SUMMARY OF REASONS FOR DOSE CHANGES (FAS) ......................... 38 
TABLE 14.1-7 SUMMARY OF SEX AND ETHNIC ORIGIN (FAS).................................... 39 
TABLE 14.1-8 SUMMARY OF DEMOGRAPHIC CHARACTERISTICS (FAS) ................ 41 
TABLE 14.1-9 SUMMARY OF PUBERTAL STATUS (FAS) ............................................... 44 
TABLE 14.1-10 SUMMARY OF PATIENTS BIRTH HISTORY (FAS) ............................... 45 
TABLE 14.1-11 SUMMARY OF PARENTS HEIGHT (FAS) ................................................ 46 
TABLE 14.1-12 SUMMARY OF BASELINE VALUES OF HEIGHT 
MEASUREMENTS (FAS) ...................................................................... 47 
TABLE 14.1-13 SUMMARY OF MEDICAL HISTORY (FAS) ............................................. 48 
TABLE 14.1-14 SUMMARY OF CONCOMITANT MEDICATIONS BY ATC TERM 
(FAS) ......................................................................................................... 49 
TABLE 14.1-15 SUMMARY OF PRIOR MEDICATIONS BY ATC TERM (FAS)............. 49 
TABLE 14.1-16 SUMMARY OF PROTOCOL DEVIATION (FAS) ..................................... 49 
Table 14.1-17 Actual number of patients enrolled in the study by age category (Full 
Analysis set).............................................................................................. 50 
Table 14.1-18  Actual number of patients enrolled in the study by country (Full Analysis 
set) ............................................................................................................. 50 
TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND VISIT 
(FAS) ......................................................................................................... 50 
TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, VISIT 
AND SEX (FAS) ...................................................................................... 51 
Programming note: Please add confidence interval for means here. ......................................... 51 
TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, VISIT 
AND INITIAL TREATMENT (FAS) .................................................... 52 
TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT 
BY COMPLETERS, TOTAL AND VISIT (FAS) ................................ 53 
TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT 
BY COMPLETERS, TOTAL, VISIT AND SEX (FAS) ...................... 54 


Sandoz GmbH 
Confidential 
Page 24 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT 
BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 55 
TABLE 14.2-1.3.1 SUMMARY OF HEIGHT STANDARD DEVIATION SCORE 
(HSDS) BY COMPLETERS, TOTAL AND VISIT (FAS) .................. 56 
TABLE 14.2-1.3.2 SUMMARY OF HSDS BY VISIT AND SEX (FAS) ............................... 56 
TABLE 14.2-1.3.3 SUMMARY OF HSDS BY COMPLETERS, TOTAL, VISIT AND 
INITIAL TREATMENT (FAS) .............................................................. 56 
TABLE 14.2-1.3.4 SUMMARY OF HSDS BY COMPLETERS, TOTAL, AND VISIT 
FOR PATIENTS WITH AND WITHOUT POSITIVE ANTI-
RHGH ANTIBODIES (FAS) .................................................................. 56 
TABLE 14.2-1.4.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL AND VISIT (FAS) ....................................... 56 
TABLE 14.2-1.4.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) ............................ 57 
TABLE 14.2-1.4.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT 
(FAS) ......................................................................................................... 57 
TABLE 14.2-1.5.1 SUMMARY OF HEIGHT VELOCITY (HV) BY COMPLETERS, 
TOTAL AND VISIT (FAS) .................................................................... 58 
TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT AND 
SEX (FAS) ................................................................................................ 59 
TABLE 14.2-1.5.3 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT AND 
INITIAL TREATMENT (FAS) .............................................................. 60 
TABLE 14.2-1.6.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL AND VISIT (FAS) ....................................... 60 
TABLE 14.2-1.6.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) ............................ 60 
TABLE 14.2-1.6.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL ANDVISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 60 
TABLE 14.2-1.7.1 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 61 
TABLE 14.2-1.7.2 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS) ...................................................................................... 61 
TABLE 14.2-1.7.3 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL,  VISIT 
AND INITIAL TREATMENT (FAS) .................................................... 61 
TABLE 14.2-1.7.4 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL, AND 
VISIT FOR PATIENTS WITH AND WITHOUT POSITIVE 
ANTI-RHGH ANTIBODIES (FAS)....................................................... 61 


Sandoz GmbH 
Confidential 
Page 25 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.8.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(CS) BY COMPLETERS, TOTAL AND VISIT (FAS) ....................... 61 
TABLE 14.2-1.8.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(CS) BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) ............ 62 
TABLE 14.2-1.8.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(CS) BY, COMPLETERS, TOTAL,  VISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 62 
TABLE 14.2-1.9.1 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 63 
TABLE 14.2-1.9.2 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS) ...................................................................................... 63 
TABLE 14.2-1.9.3 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL,  VISIT 
AND INITIAL TREATMENT (FAS) .................................................... 63 
TABLE 14.2-1.9.4 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL, AND 
VISIT FOR PATIENTS WITH AND WITHOUT POSITIVE 
ANTI-RHGH ANTIBODIES (FAS)....................................................... 63 
TABLE 14.2-1.10.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(PC) BY  COMPLETERS, TOTAL AND VISIT (FAS) ...................... 63 
TABLE 14.2-1.10.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(PC) BY COMPLETERS, TOTAL, VISIT AND SEX (FAS) ............. 63 
TABLE 14.2-1.10.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS 
(PC) BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 64 
TABLE 14.2-2.1.1 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL AND VISIT (FAS) ....................................... 64 
TABLE 14.2-2.1.2 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) ............................ 64 
TABLE 14.2-2.1.3 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT 
(FAS) ......................................................................................................... 64 
TABLE 14.2-2.1.4 SUMMARY OF RELATIVE CHANGE FROM BASELINE OF IGF-
1 SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL 
AND VISIT (FAS) ................................................................................... 64 
TABLE 14.2-2.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 65 
TABLE 14.2-2.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  
VISIT AND SEX (FAS) .......................................................................... 65 


Sandoz GmbH 
Confidential 
Page 26 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  
VISIT AND INITIAL TREATMENT (FAS) ........................................ 65 
TABLE 14.2-2.3.1 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL AND  VISIT (FAS) ...................................... 65 
TABLE 14.2-2.3.2 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL, VISIT AND SEX (FAS) ............................. 66 
TABLE 14.2-2.3.3 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT 
(FAS) ......................................................................................................... 66 
TABLE 14.2-2.3.4 SUMMARY OF RELATIVE CHANGE FROM BASELINE OF 
IGFBP-3 SERUM LEVELS (NMOL/L) BY COMPLETERS, 
TOTAL AND VISIT (FAS) .................................................................... 66 
TABLE 14.2-2.4.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 66 
TABLE 14.2-2.4.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  
VISIT AND SEX (FAS) .......................................................................... 66 
TABLE 14.2-2.4.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  
VISIT AND INITIAL TREATMENT (FAS) ........................................ 67 
TABLE 14.2-2.5 SHIFT TABLE FOR IGF-1  BY COMPLETERS AND TOTAL (FAS) .... 68 
TABLE 14.2-2.6 SHIFT TABLE FOR IGFBP-3 BY COMPLETERS AND TOTAL 
(FAS) ......................................................................................................... 68 
TABLE 14.2-2.7 SHIFT TABLE FOR IGF-1 IN PATIENTS WITH POWDER 
TREATMENT BY COMPLETERS AND TOTAL (FAS) ................... 68 
TABLE 14.2.2.8 SHIFT TABLE FOR IGFBP-3 IN PATIENTS WITH POWDER 
TREATMENT BY COMPLETERS AND TOTAL (FAS) ................... 68 
TABLE 14.2-2.9 SHIFT TABLE FOR IGF-1 IN PATIENTS WITH SOLUTION 
TREATMENT BY COMPLETERS AND TOTAL (FAS) ................... 68 
TABLE 14.2.2.10 SHIFT TABLE FOR IGFBP-3 IN PATIENTS WITH SOLUTION 
TREATMENT BY COMPLETERS AND TOTAL (FAS) ................... 68 
TABLE 14.2-2.11.1 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY 
COMPLETERS, TOTAL AND  VISIT (FAS) ...................................... 70 
TABLE 14.2-2.11.2 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY 
COMPLETERS, TOTAL, VISIT AND SEX (FAS) ............................. 70 
TABLE 14.2-2.11.3 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY 
COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT 
(FAS) ......................................................................................................... 70 


Sandoz GmbH 
Confidential 
Page 27 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.12.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO (NG/MCG) BY COMPLETERS, TOTAL 
AND VISIT (FAS) ................................................................................... 70 
TABLE 14.2-2.12.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO (NG/MCG) BY VISIT AND SEX (FAS) ............. 70 
TABLE 14.2-2.12.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO (NG/MCG) BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS) ........................................ 70 
TABLE 14.2-2.13.1 SUMMARY OF IGF-1 SDS BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 71 
TABLE 14.2-2.13.2 SUMMARY OF IGF-1 SDS  BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS) ...................................................................................... 71 
TABLE 14.2-2.13.3 SUMMARY OF IGF-1 SDS BY COMPLETERS, TOTAL, VISIT 
AND INITIAL TREATMENT (FAS) .................................................... 71 
TABLE 14.2-2.14.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SDS BY COMPLETERS, TOTAL AND VISIT (FAS) ........................ 71 
TABLE 14.2-2.14.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SDS BY COMPLETERS, TOTAL, VISIT AND SEX (FAS) .............. 71 
TABLE 14.2-2.14.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 
SDS BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 72 
TABLE 14.2-2.15.1 SUMMARY OF IGFBP-3 SDS BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 72 
TABLE 14.2-2.15.2 SUMMARY OF IGFBP-3 SDS  BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS) .......................................................................... 72 
TABLE 14.2-2.15.3 SUMMARY OF IGFBP-3 SDS BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS) ........................................ 72 
TABLE 14.2-2.16.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SDS BY COMPLETERS, TOTAL AND VISIT (FAS) ........................ 72 
TABLE 14.2-2.16.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SDS BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) ............. 73 
TABLE 14.2-2.16.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 
SDS BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS)............................................................................... 73 
TABLE 14.2-2.17.1 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS BY COMPLETERS, 
TOTAL AND VISIT (FAS) .................................................................... 73 
TABLE 14.2-2.17.2 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS  BY COMPLETERS, 
TOTAL AND VISIT AND SEX (FAS) ................................................. 73 
TABLE 14.2-2.17.3 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS BY COMPLETERS, 
TOTAL, VISIT AND INITIAL TREATMENT (FAS) ......................... 73 


Sandoz GmbH 
Confidential 
Page 28 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.18.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO SDS BY COMPLETERS, TOTAL AND 
VISIT (FAS) ............................................................................................. 74 
TABLE 14.2-2.18.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO SDS BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS) ...................................................................................... 74 
TABLE 14.2-2.18.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-
1/IGFBP-3 RATIO SDS BY COMPLETERS, TOTAL,  VISIT 
AND INITIAL TREATMENT (FAS) .................................................... 74 
TABLE 14.2-3.1 SUMMARY OF THE DEVELOPMENT OF 
 
HEIGHT AGE IN COMPARISON WITH CHRONOLOGICAL 
AGE BY COMPLETERS AND TOTAL (FAS) ................................... 74 
TABLE 14.2-3.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN
 
 HEIGHT AGE BY COMPLETERS AND TOTAL (FAS) ......... 77 
TABLE 14.2-3.3 SUMMARY OF THE MEAN RATIOS FOR THE COMPARISON OF 
CHANGES IN 
 HEIGHT AGE, AND 
CHRONOLOGICAL AGE (FAS) .......................................................... 78 
TABLE 14.2-3.4 SUMMARY OF OVERWEIGHT PATIENTS BY SEX AND VISIT 
(FAS) ......................................................................................................... 80 
FIGURE 14.2-1.11 Mean body height over time by completer, means ± 95% CI (FAS)........ 81 
FIGURE 14.2-1.11.1 Mean body height over time by completer and sex, means ± 95% 
CI (FAS).................................................................................................... 81 
FIGURE  14.2-1.12 Mean H SDS over time by completer, means ± 95% CI (FAS)............... 81 
FIGURE  14.2-1.12.1 Mean H SDS over time for patients with and without positive anti-
rhGH antibodies, means ± 95% CI (FAS) .............................................. 81 
FIGURE  14.2-1.13 Mean height velocity over time by completer, means ± 95% CI 
(FAS) ......................................................................................................... 81 
FIGURE  14.2-1.13.1 Mean height velocity over time by completer and sex, means ± 
95% CI (FAS) ........................................................................................... 81 
FIGURE  14.2-1.14 Mean HV SDS (cross-sectional) over time by completer, means ± 
95% CI (FAS) ........................................................................................... 81 
FIGURE  14.2-1.14.1 Mean HV SDS (cross-sectional) over time for patients with and 
without positive anti-rhGH antibodies, means ± 95% CI (FAS) .......... 81 
FIGURE  14.2-1.15 Mean HV SDS (peak-centered) over time by completer, means ± 
95% CI (FAS) ........................................................................................... 81 
FIGURE  14.2-1.15.1 Mean HV SDS (peak-centered) over time for patients with and 
without positive anti-rhGH antibodies, means ± 95% CI (FAS) .......... 81 
FIGURE  14.2-2.19 Mean IGF-1 serum levels over time, means ± 95% CI (FAS) ................. 81 
FIGURE  14.2-2.19.1 Mean IGF-1 serum levels over time by sex, means ± 95% CI 
(FAS) ......................................................................................................... 81 
FIGURE  14.2-2.20 Mean IGFBP-3 serum levels over time, means ± 95% CI (FAS) ............ 81 


Sandoz GmbH 
Confidential 
Page 29 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
FIGURE  14.2-2.20.1 Mean IGFBP-3 serum levels over time by sex, means ± 95% CI 
(FAS) ......................................................................................................... 81 
FIGURE  14.2-2.21 Mean IGF-1 SDS serum levels over time, means ± 95% CI (FAS) ........ 81 
FIGURE  14.2-2.22 Mean IGFBP-3 SDS serum levels over time, means ± 95% CI (FAS) ... 82 
TABLE 14.3-1.1 GENERAL SUMMARY OF ADVERSE EVENTS (SAF).......................... 83 
TABLE 14.3-1.2 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY, ALL 
ADVERSE EVENTS (SAF).................................................................... 84 
TABLE 14.3-1.2.1 INCIDENCE OF ADVERSE EVENTS FOR OVERWEIGHT* 
PATIENTS AT BASELINE BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND INTENSITY, ALL ADVERSE 
EVENTS (SAF) ........................................................................................ 84 
TABLE 14.3-1.3 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 84 
TABLE 14.3-1.4 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) ... 84 
TABLE 14.3-1.5 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS 
BY SYSTEM ORGAN CLASS, PREFERRED TERM, AND 
INTENSITY (SAF) .................................................................................. 84 
TABLE 14.3-1.6 INCIDENCE OF NON-SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) ... 84 
TABLE 14.3-1.7 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY, ALL 
ADVERSE EVENTS (SAF).................................................................... 86 
TABLE 14.3-1.8 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 86 
TABLE 14.3-1.9 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) ... 86 
TABLE 14.3-1.10 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE 
EVENTS BY SYSTEM ORGAN CLASS, PREFERRED TERM, 
AND INTENSITY (SAF) ........................................................................ 86 
TABLE 14.3-1.11 OCCURRENCE OF NON-SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND 
INTENSITY (SAF) .................................................................................. 86 
TABLE 14.3-1.12 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME, ALL 
ADVERSE EVENTS (SAF).................................................................... 87 


Sandoz GmbH 
Confidential 
Page 30 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.3-1.13 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 87 
TABLE 14.3-1.14 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND OUTCOME (SAF) .... 87 
TABLE 14.3-1.15 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS 
BY SYSTEM ORGAN CLASS, PREFERRED TERM, AND 
OUTCOME (SAF) ................................................................................... 87 
TABLE 14.3-1.16 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME, ALL 
ADVERSE EVENTS (SAF).................................................................... 88 
TABLE 14.3-1.17 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 88 
TABLE 14.3-1.18 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND OUTCOME (SAF) .... 88 
TABLE 14.3-1.19 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE 
EVENTS BY SYSTEM ORGAN CLASS, PREFERRED TERM, 
AND OUTCOME (SAF) ......................................................................... 88 
TABLE 14.3-1.20 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN, ALL 
ADVERSE EVENTS (SAF).................................................................... 89 
TABLE 14.3-1.21 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 89 
TABLE 14.3-1.22 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND ACTION TAKEN 
(SAF) ......................................................................................................... 89 
TABLE 14.3-1.23 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS 
BY SYSTEM ORGAN CLASS, PREFERRED TERM, AND 
ACTION TAKEN (SAF) ......................................................................... 89 
TABLE 14.3-1.24 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN, ALL 
ADVERSE EVENTS (SAF).................................................................... 90 
TABLE 14.3-1.25 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN, DRUG-
RELATED ADVERSE EVENTS (SAF) ............................................... 90 
TABLE 14.3-1.26 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND ACTION TAKEN 
(SAF) ......................................................................................................... 90 


Sandoz GmbH 
Confidential 
Page 31 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.3-1.27 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE 
EVENTS BY SYSTEM ORGAN CLASS, PREFERRED TERM, 
AND ACTION TAKEN (SAF) ............................................................... 90 
TABLE 14.3-2.1 CONVERSION FACTORS FOR LABORATORY PARAMETERS ......... 91 
TABLE 14.3-2.2 SUMMARY OF HEMATOLOGY DATA (SAF) ........................................ 92 
TABLE 14.3-2.3 SUMMARY OF BLOOD CHEMISTRY (SAF) ........................................... 93 
TABLE 14.3-2.4 SUMMARY OF CARBOHYDRATE METABOLISM INCL. OGTT 
DATA (SAF) ............................................................................................ 94 
TABLE 14.3-2.5 SUMMARY OF ABSOLUTE CHANGES FROM BASELINSE OF 
CARBOHYDRATE METABOLISM INCL. OGTT DATA (SAF) .... 94 
TABLE 14.3-2.6 SUMMARY OF RELATIVE CHANGES FROM BASELINSE OF 
CARBOHYDRATE METABOLISM INCL. OGTT DATA (SAF) .... 94 
TABLES 14.3-2.7 SHIFT TABLES FOR CARBOHYDRATE METABOLISM (SAF) ....... 95 
TABLE 14.3-2.7.1 
SHIFT TABLE FOR HbA1C (SAF) ........................................................ 95 
TABLE 14.3-2.7.2 
SHIFT TABLE FOR FASTING GLUCOSE (SAF) .............................. 95 
TABLE 14.3-2.7.3 
SHIFT TABLE FOR FASTING INSULIN (SAF) ................................ 95 
TABLE 14.3-2.8 SUMMARY OF HOMA AND QUICKI SCORES (SAF) ........................... 96 
TABLE 14.3-2.9 SUMMARY OF ABSOLUTE CHANGES FROM BASELINE OF 
HOMA AND QUICKI SCORES (SAF)................................................. 96 
TABLE 14.3-2.10 SUMMARY OF RELATIVE CHANGES FROM BASELINE OF 
HOMA AND QUICKI SCORES (SAF)................................................. 96 
TABLE 14.3-2.11 SUMMARY OF THYROID PANEL DATA (SAF) .................................. 96 
TABLES 14.3-2.12 SHIFT TABLES FOR THYROID PANEL DATA (SAF) ...................... 97 
TABLE 14.3-2.12.1 SHIFT TABLE FOR FREE THYROXINE (T4) (SAF)........................ 97 
TABLE 14.3-2.12.2 SHIFT TABLE FOR THYROID STIMULATING HORMONE 
(TSH) (SAF) ............................................................................................. 97 
TABLE 14.3-2.13 SUMMARY OF URINALYSIS DATA (SAF) ........................................... 98 
TABLES 14.3-2.14 SHIFT TABLES FOR URINALYSIS DATA (SAF) ............................... 98 
TABLE 14.3-2.14.1 SHIFT TABLE FOR PROTEIN (SAF) .................................................. 98 
TABLE 14.3-2.14.2 SHIFT TABLE FOR GLUCOSE (SAF) ................................................ 98 
TABLE 14.3-2.14.3 SHIFT TABLE FOR KETONES (SAF)................................................. 98 
TABLE 14.3-2.16.4 SHIFT TABLE FOR BILIRUBIN (SAF) .............................................. 99 
TABLE 14.3-3.1 SUMMARY OF VITAL SIGNS (SAF) ....................................................... 101 
TABLE 14.3-3.2 SUMMARY OF PHYSICAL EXAMINATION (SAF) ............................. 102 
TABLE 14.3-3.3 
SHIFT TABLE FOR PHYSICAL EXAMINATION BY BODY 
SYSTEM (SAF) ..................................................................................... 102 
TABLE 14.3-3.4 SUMMARY OF BODY WEIGHT (SAF) ................................................... 104 
TABLE 14.3-3.5 SUMMARY OF BMI (SAF) ........................................................................ 104 


Sandoz GmbH 
Confidential 
Page 32 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.3-3.6 SUMMARY OF BMI SDS (SAF) ................................................................ 104 
TABLE 14.3-3.7 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF DIABETES MELLITUS 
(DM) (SAF) ............................................................................................ 104 
TABLE 14.3-3.7.1 SUMMARY OF OVERWEIGHT* PATIENTS AT BASELINE 
WITH LABORATORY PARAMETERS FULLFILING THE 
DEFINITION OF DIABETES MELLITUS (DM) (SAF) .................. 104 
TABLE 14.3-3.8 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF IMPAIRED GLUCOSE 
TOLERANENCE (IGT) (SAF) ............................................................. 105 
TABLE 14.3-3.9 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF IMPAIRED FASTING 
GLUCOSE (IFG) (SAF) ........................................................................ 105 
TABLE 14.3-3.10 SUMMARY OF ANTI-HGH ANTIBODIES (SAF) ................................ 106 
TABLE 14.3-3.11 SUMMARY OF ANTI-HCP ANTIBODIES (SAF) ................................. 107 
 


Sandoz GmbH 
Confidential 
Page 33 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-1 ANALYSIS SETS 
 
 
Study Population 
(N=XXX) 
 
n 
% 
Patients eligible for treatment 
XXX 
 
Full Analysis Set 
XXX 
(XXX%) 
Safety Analysis Set 
XXX 
(XX.X%) 
Percentages are based on all patients in Full Analysis Set. 


Sandoz GmbH 
Confidential 
Page 34 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-2 PATIENT ENROLMENT  
 
 
Number of patients* 
Site code SCR 
V01 
M0 
V02 
M3 
V03 
M6 
V04 
M9 
V05 
M12 
V06 
M15 
V07 
M18 
V08 
M21 
V09 
M24 
V10 
M30 
V11 
M36 
… 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
… 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
Total 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 
* for whom the respective visit was documented or the final visit was assigned to the respective visit 
Note: One patient had only V01 performed, received study medication and was lost to follow-up 
thereafter. This patient was excluded from the SAF since no information with respect to safety is 
available. 
 


Sandoz GmbH 
Confidential 
Page 35 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-3 SUMMARY OF REASONS FOR STUDY DISCONTINUATION (FAS) 
 
 
Number of patients (%) 
(N=XXX) 
Study terminated 
 XXX  (XX.X%) 
Study discontinuations due to 
  
  Withdrawal of informed consent 
 XXX  (XX.X%) 
  Treatment failure 
 XXX  (XX.X%) 
  Lost to follow-up 
 XXX  (XX.X%) 
  Other 
 XXX  (XX.X%) 
  Adverse event 
 XXX  (XX.X%) 
  … 
  
  Total 
  XXX  (XX.X%) 
 
Note for programmer: 
Sort reasons by frequency. 


Sandoz GmbH 
Confidential 
Page 36 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-4 SUMMARY OF PATIENTS EXPOSURE TO STUDY DRUG (FAS)  
 
Exposure to study drug [years] 
 
N 
Missing 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
Total 
XXX XXX 
   XX.X    XX.X   XX 
XX.X 
   XX.X XX.X 
 XX.X 
Site code 
     
     
         
         
         
         
         
  XXX 
XXX XXX 
   XX.X    XX.X   XX 
XX.X 
   XX.X XX.X 
 XX.X 
  XXX 
XXX XXX 
   XX.X    XX.X   XX 
XX.X 
   XX.X XX.X 
 XX.X 
  … 
XXX XXX 
   XX.X    XX.X   XX 
XX.X 
   XX.X XX.X 
 XX.X 


Sandoz GmbH 
Confidential 
Page 37 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-5 SUMMARY OF TOTAL DAILY DOSE ADMINISTERED PER KG BODY 
WEIGHT (FAS)  
 
Total daily dose administered [mg/kg] 
 
N 
Missing 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
Visit 
     
     
        
        
        
 
         
 
        
  XXX 
XXX 
XXX 
   XX.X 
   XX.X 
  XX 
XX.X 
   XX.X 
XX.X 
 XX.X 
  XXX 
XXX 
XXX 
   XX.X 
   XX.X 
  XX 
XX.X 
   XX.X 
XX.X 
 XX.X 
  … 
XXX 
XXX 
   XX.X 
   XX.X 
  XX 
XX.X 
   XX.X 
XX.X 
 XX.X 


Sandoz GmbH 
Confidential 
Page 38 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-6 SUMMARY OF REASONS FOR DOSE CHANGES (FAS) 
 
Number of patients (%) 
(N=XXX) 
Overall 
 
 
 
Any dose change documented 
 
XXX  (XX.X%) 
 
Reason for dose change 
 
 
 
 Patient is unable to tolerate the protocol-specified  
 
 dosing scheme 
 
XXX  (XX.X%) 
 
   Reason documented 1 time 
 
XXX  (XX.X%) 
             Reason documented 2 times 
 
XXX  (XX.X%) 
 
   … 
 
XXX  (XX.X%) 
    Dose interruption 
 
XXX  (XX.X%) 
 
   Reason documented 1 time 
 
XXX  (XX.X%) 
             Reason documented 2 times 
 
XXX  (XX.X%) 
 
   … 
 
XXX  (XX.X%) 
   IGF-1/IGFBP-3 ratio exceeds +2SD 
 
XXX  (XX.X%) 
 
   Reason documented 1 time 
 
XXX  (XX.X%) 
             Reason documented 2 times 
 
XXX  (XX.X%) 
 
   … 
 
XXX  (XX.X%) 
 
 Non-compliance 
 
XXX  (XX.X%) 
 
   Reason documented 1 time 
 
XXX  (XX.X%) 
             Reason documented 2 times 
 
XXX  (XX.X%) 
 
   … 
 
XXX  (XX.X%) 
   Other 
 
XXX  (XX.X%) 
 
   Reason documented 1 time 
 
XXX  (XX.X%) 
             Reason documented 2 times 
 
XXX  (XX.X%) 
 
   … 
 
XXX  (XX.X%) 
 
  … 
 
XXX  (XX.X%) 
 
Note for programmer:  
Classification of other variable will be provided by the sponsor. 
 


Sandoz GmbH 
Confidential 
Page 39 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-7 SUMMARY OF SEX AND ETHNIC ORIGIN (FAS)  
 
Characteristic 
 
Number of patients (%) 
Sex 
 
 
      Male 
 
 XXX  (XX.X%) 
      Female 
 
 XXX  (XX.X%) 
      Total 
 
 XXX  (XX.X%) 
Initial treatment 
 
 
      Solution 
 
 XXX  (XX.X%) 
      Powder 
 
 XXX  (XX.X%) 
      Total 
 
 XXX  (XX.X%) 
Sex by initial treatment 
 
 
      Solution 
 
 
            Male 
 
 XXX  (XX.X%) 
            Female 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
      Powder 
 
 
            Male 
 
 XXX  (XX.X%) 
            Female 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
Ethnic origin 
 
 
      Caucasian 
 
 XXX  (XX.X%) 
      Oriental 
 
 XXX  (XX.X%) 
      Other 
 
 XXX  (XX.X%) 
      Black 
 
 XXX  (XX.X%) 
      Total 
 
 XXX  (XX.X%) 
Ethnic origin by initial treatment 
 
 
      Solution 
 
 
            Caucasian 
 
 XXX  (XX.X%) 
            Oriental 
 
 XXX  (XX.X%) 
            Other 
 
 XXX  (XX.X%) 
            Black 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
      Powder 
 
 
            Caucasian 
 
 XXX  (XX.X%) 
            Black 
 
 XXX  (XX.X%) 
            Oriental 
 
 XXX  (XX.X%) 
            Other 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
Ethnic origin by sex 
 
 
      Male 
 
 
            Caucasian 
 
XXX  (XX.X%) 
            Oriental 
 
 XXX  (XX.X%) 
            Black 
 
 XXX  (XX.X%) 


Sandoz GmbH 
Confidential 
Page 40 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Characteristic 
 
Number of patients (%) 
            Other 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
      Female 
 
 
            Caucasian 
 
 XXX  (XX.X%) 
            Other 
 
 XXX  (XX.X%) 
            Black 
 
 XXX  (XX.X%) 
            Oriental 
 
 XXX  (XX.X%) 
            Total 
 
 XXX  (XX.X%) 
 


Sandoz GmbH 
Confidential 
Page 41 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-8 SUMMARY OF DEMOGRAPHIC CHARACTERISTICS (FAS) 
 
Characteristic 
 
Total 
Female 
Male 
Age at screening (years)* 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Age at screening (years)* for 
patients with initial powder 
treatment 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Age at screening (years)* for 
patients with initial solution 
treatment 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Height SDS at screening 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Height at screening (cm) 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 


Sandoz GmbH 
Confidential 
Page 42 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Characteristic 
 
Total 
Female 
Male 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Height velocity SDS at 
screening 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Height velocity at screening 
(cm/yr) 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
Weight at screening (kg) 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
 
 
 
 
BMI at screening 
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 


Sandoz GmbH 
Confidential 
Page 43 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Characteristic 
 
Total 
Female 
Male 
 
Max 
X.X 
X.X 
X.X 
 
 
 
 
 
BMI SDS at screening  
N 
XXX 
XXX 
XXX 
 
Mean 
X.XX 
X.XX 
X.XX 
 
Std 
X.XX 
X.XX 
X.XX 
 
Min 
X.X 
X.X 
X.X 
 
Q1 
X.XX 
X.XX 
X.XX 
 
Median 
X.XX 
X.XX 
X.XX 
 
Q3 
X.XX 
X.XX 
X.XX 
 
Max 
X.X 
X.X 
X.X 
 
 
 
 
 
* calculated in whole years from visit date when demography data was collected 


Sandoz GmbH 
Confidential 
Page 44 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-9 SUMMARY OF PUBERTAL STATUS (FAS)  
 
 
Number of patients (%) 
Sex 
Visit 
Total Missing 
N 
 
Tanner I 
Tanner II 
Tanner III 
Tanner IV 
Tanner V 
Male   
SCR   XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
V01    XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
… 
 
 
 
 
 
 
 
 
 
 
Female 
SCR   XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
V01    XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
… 
 
 
 
 
 
 
 
 
 
 
Total  
SCR   XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
V01    XXX 
XXX 
XXX  
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
 
… 
 
 
 
 
 
 
 
 
 
 
 


Sandoz GmbH 
Confidential 
Page 45 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-10 SUMMARY OF PATIENTS BIRTH HISTORY (FAS) 
 
 
N 
Missing 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
Birth Weight 
(g) 
Males 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
 
Birth Length 
(cm) 
Males 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
 
Gestational 
Age 
(weeks) 
Males 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
 
Birth Weight 
SDS 
Males 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
 
Birth Length 
SDS 
Males 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 


Sandoz GmbH 
Confidential 
Page 46 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-11 SUMMARY OF PARENTS HEIGHT (FAS)  
 
 
 
N 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
Father’s height 
(cm) 
Males 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
Mother’s height 
(cm) 
Males 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X XX.X 
XXX.X XXX.X 
XXX.X 
XXX.X 
XXX.X 
 


Sandoz GmbH 
Confidential 
Page 47 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-12 SUMMARY OF BASELINE VALUES OF HEIGHT MEASUREMENTS (FAS) 
 
 
N 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
Height (cm) 
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
Height SDS 
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
Height Velocity 
(cm/yr) 
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
Height Velocity 
SDS 
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
 
 
 
 
 
 
 
 
 
Time since 
historical  
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
measurement 
(days) 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
Midparental 
adjusted  
Males 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
Height SDS 
Females 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Powder 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Solution 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
 
Total 
XX 
XXX.X 
XX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 
XXX.X 


Sandoz GmbH 
Confidential 
Page 48 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-13 SUMMARY OF MEDICAL HISTORY (FAS) 
 
Note for programmer: 
Sort by overall frequency. 
Novartis MedDRA version 
System Organ Class 
  Preferred Term 
Number of patients 
(%) with resolved 
illness 
(N=XXX) 
Number of patients 
(%) with intermittent 
illness 
(N=XXX) 
Number of patients 
(%) with ongoing 
illness 
(N=XXX) 
Total 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 
Infections and infestations 
 
 
 
  Total 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 
  Pneumonia 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 
  Varicella 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 
  Bronchitis 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 
  …. 
XX (XX.X%) 
XX (XX.X%) 
XX (XX.X%) 


Sandoz GmbH 
Confidential 
Page 49 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.1-14 SUMMARY OF CONCOMITANT MEDICATIONS BY ATC TERM (FAS) 
TABLE 14.1-15 SUMMARY OF PRIOR MEDICATIONS BY ATC TERM (FAS) 
 
Concomitant Medication 
  ATC Code Level 2 
    Preferred Term 
Number of patients (%) to whom 
medication was administered 
(N=XXX) 
TOTAL 
XX (XX.X%) 
ANTIBACTERIALS FOR SYSTEMIC USE 
XX (XX.X%) 
      Cefuroxime Axetil 
XX (XX.X%) 
      Clarithromycin 
XX (XX.X%) 
      Amoxicillin W/Clavulanate Potassium 
XX (XX.X%) 
      Amoxicillin 
XX (XX.X%) 
      Azithromycin 
XX (XX.X%) 
      Bactrim 
XX (XX.X%) 
      Amoxi-Clavulanico 
XX (XX.X%) 
      …. 
XX (XX.X%) 
Note for programmer: 
 Sort by overall frequency. 
 
TABLE 14.1-16 SUMMARY OF PROTOCOL DEVIATION (FAS) 
Category 
  Protocol deviation 
 
All Patients 
(N=XXX) 
n(%) 
Any protocol deviation 
XX (XX.X%) 
   Protocol deviation regarding 
 
     Inclusion/exclusion criteria 
XX (XX.X%) 
 
 
INCL 1 not met: …. 
XX (XX.X%) 
             … 
 
 
Withdrawal criteria met, but patient not discontinued 
XX (XX.X%) 
 
Failure to perform key procedures 
XX (XX.X%) 
 
 
Missing visit 
XX (XX.X%) 
 
 
Deviations from protocol specified window 
XX (XX.X%) 
 
 
Key asssessments not performed: other lab parameters 
XX (XX.X%) 
 
 
… 
 
 
Trial treatment deviation 
XX (XX.X%) 
 
Prohibited concomitant medication 
XX (XX.X%) 
     GCP-related deviation 
XX (XX.X%) 
 
 
Re-consent ICF missing 
XX (XX.X%) 
 
 
Re-consent ICF not appropriately obtained 
XX (XX.X%) 
             … 
 
Note for programmer: Provide only available categories. s available. Sort by descending frequency. 
Use Sandoz main category and PD description (based on PD ID) according to PD specification for categories.  
 


Sandoz GmbH 
Confidential 
Page 50 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Table 14.1-17 Actual number of patients enrolled in the study by age category (Full 
Analysis set) 
 
Age (years) 
Number of patients (%) 
(N=XXX) 
0-<4y 
 XX  (XX.X%) 
4y- <12y 
 XX  (XX.X%) 
12y-<18y 
 XX  (XX.X%) 
 >=18y 
 XX  (XX.X%) 
 
  
 
Table 14.1-18  Actual number of patients enrolled in the study by country (Full 
Analysis set) 
Country 
Number of patients (%) 
(N=XXX) 
Germany 
 XX  (XX.X%) 
Italy 
 XX  (XX.X%) 
..... 
 XX  (XX.X%) 
 
  
 
5.2 
Efficacy and other non-safety Tables including shells 
 
TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS) 
 
Visit 
N 
N miss 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
V01 
XX 
XX 
XXX.XX 
XX.XX 
XXX 
XXX.XX 
XXX.XX 
XXX.XX 
XXX 
V03 
XX 
XX 
XXX.XX 
XX.XX 
XXX 
XXX.XX 
XXX.XX 
XXX.XX 
XXX 
V05 
XX 
XX 
XXX.XX 
XX.XX 
XXX 
XXX.XX 
XXX.XX 
XXX.XX 
XXX 
… 
 
 
 
 
 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here.  


Sandoz GmbH 
Confidential 
Page 51 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX 
(FAS) 
 
Visit 
by 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
V01 
Males 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Females 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
 
 
 
 
 
 
 
 
 
 
V02 
Males 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Females 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
 
 
 
 
 
 
 
 
 
 
.. 
Males 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Females 
XX 
XX 
XXX.X XX.X XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total)  
before column Visit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Programming note: Please add confidence interval for means here.  


Sandoz GmbH 
Confidential 
Page 52 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS) 
 
Visit 
by 
N 
N miss 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
V01 
Powder 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Solution 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
 
 
 
 
 
 
 
 
 
 
V02 
Powder 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Solution 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
 
 
 
 
 
 
 
 
 
 
.. 
Powder 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
 
Solution 
XX 
XX 
XXX.X XX.X 
XXX 
XXX.X 
XXX.X 
XXX.X 
XXX 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 53 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
 
Difference between 
visits 
N 
Mean difference (cm) 
95% confidence interval for mean 
difference 
V02 - V01 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
V03 - V01 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
.. - V01 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 54 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT BY 
COMPLETERS, TOTAL, VISIT AND SEX (FAS) 
 
Difference between 
visits 
by 
N 
Mean difference (cm) 
95% confidence interval for mean 
difference 
V02 - V01 
Males 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
Females 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
 
 
 
 
V03 - V01 
Males 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
Females 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
 
 
 
 
.. - V01 
Males 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
Females 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 55 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HEIGHT BY 
COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
 
Difference between 
visits 
by 
N 
Mean difference (cm) 
95% confidence interval for mean 
difference 
V02 - V01 
Powder 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
Solution 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
 
 
 
 
V03 - V01 
Powder 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
Solution 
XX 
XX.XX 
[ XX.XX; XX.XX ]            
 
 
 
 
 
.. - V01 
Powder 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
Solution 
XX 
XX.XX 
[ XX.XX; XX.XX ] 
 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit.   
 


Sandoz GmbH 
Confidential 
Page 56 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.3.1 SUMMARY OF HEIGHT STANDARD DEVIATION SCORE (HSDS) BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-1.3.2 SUMMARY OF HSDS BY VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.3.3 SUMMARY OF HSDS BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-1.3.4 SUMMARY OF HSDS BY COMPLETERS, TOTAL, AND VISIT FOR 
PATIENTS WITH AND WITHOUT POSITIVE ANTI-RHGH ANTIBODIES 
(FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Present patient with and without positive anti-rhGH antibodies instead of 
sex. Please add one column ‘Status’ (value: Completers, Total) before column Visit. 
 
 
TABLE 14.2-1.4.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 57 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.4.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.4.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HSDS BY 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT (FAS) 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 58 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.5.1 SUMMARY OF HEIGHT VELOCITY (HV) BY COMPLETERS, TOTAL 
AND VISIT (FAS) 
 
Visit 
Basis 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
01 
historical data 
XX 
XX 
XX.XX X.X 
XX.X 
XX.X 
XX.X 
XX.X XX.X 
02 
visit 01 
XX 
XX 
XX.XX X.XX XX.X 
XX.X 
XX.X 
XX.X XX.X 
.. 
visit 01 
XX 
XX 
XX.XX X.XX XX.X 
XX.X 
XX.X 
XX.X XX.X 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 


Sandoz GmbH 
Confidential 
Page 59 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT AND SEX (FAS) 
 
Visit 
Basis 
by 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
V01 
historical 
data 
Males 
XX 
XX 
XX.XX X.X 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Females XX 
XX 
XX.XX X.XX 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
V02 
V01 
Males 
XX 
XX 
XX.XX X.XX 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Females XX 
XX 
XX.XX X.XX 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
.. 
V01 
Males 
XX 
XX 
XX.XX X.XX 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Females XX 
XX 
XX.XX X.XX 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 


Sandoz GmbH 
Confidential 
Page 60 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.5.3 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS) 
 
Visit 
Basis 
by 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
V01 
historical 
data 
Powder 
XX 
XX 
XX.XX X.X 
XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Solution 
XX 
XX 
XX.XX X.XX XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
V02 
V01 
Powder 
XX 
XX 
XX.XX X.XX XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Solution 
XX 
XX 
XX.XX X.XX XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
.. 
V01 
Powder 
XX 
XX 
XX.XX X.XX XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
Solution 
XX 
XX 
XX.XX X.XX XX.X 
XX.X XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-1.6.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.6.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.6.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV BY 
COMPLETERS, TOTAL ANDVISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 


Sandoz GmbH 
Confidential 
Page 61 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
TABLE 14.2-1.7.1 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL AND VISIT 
(FAS) 
See shell for TABLE 14.2-1.5.1 SUMMARY OF HEIGHT VELOCITY (HV) BY 
COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-1.7.2 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL,  VISIT AND 
SEX (FAS) 
See shell for TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.7.3 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL,  VISIT AND 
INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.5.3 SUMMARY OF HV BY COMPLETERS, TOTAL,  VISIT 
AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.7.4 SUMMARY OF HV SDS (CS) BY COMPLETERS, TOTAL, AND VISIT 
FOR PATIENTS WITH AND WITHOUT POSITIVE ANTI-RHGH 
ANTIBODIES (FAS) 
 See shell for TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT 
AND SEX (FAS) 
Programming note: Present patient with and without positive anti-rhGH antibodies instead of 
sex. Please add one column ‘Status’ (value: Completers, Total) before column Visit. 
 
TABLE 14.2-1.8.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (CS) BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 


Sandoz GmbH 
Confidential 
Page 62 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
TABLE 14.2-1.8.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (CS) BY 
COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.8.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (CS) BY, 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
 


Sandoz GmbH 
Confidential 
Page 63 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-1.9.1 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL AND VISIT 
(FAS) 
See shell for TABLE 14.2-1.5.1 SUMMARY OF HEIGHT VELOCITY (HV) BY 
COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
TABLE 14.2-1.9.2 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL,  VISIT AND 
SEX (FAS) 
See shell for TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL,  VISIT 
AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.9.3 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL,  VISIT AND 
INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.5.3 SUMMARY OF HV BY COMPLETERS, TOTAL,  VISIT 
AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-1.9.4 SUMMARY OF HV SDS (PC) BY COMPLETERS, TOTAL, AND VISIT 
FOR PATIENTS WITH AND WITHOUT POSITIVE ANTI-RHGH 
ANTIBODIES (FAS) 
 See shell for TABLE 14.2-1.5.2 SUMMARY OF HV BY COMPLETERS, TOTAL, VISIT 
AND SEX (FAS) 
Programming note: Present patient with and without positive anti-rhGH antibodies instead of 
sex. Please add one column ‘Status’ (value: Completers, Total) before column Visit. 
 
TABLE 14.2-1.10.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (PC) 
BY  COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.10.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (PC) 
BY COMPLETERS, TOTAL, VISIT AND SEX (FAS) 


Sandoz GmbH 
Confidential 
Page 64 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-1.10.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN HV SDS (PC) 
BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.1.1 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY COMPLETERS, 
TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-2.1.2 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY COMPLETERS, 
TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-2.1.3 SUMMARY OF IGF-1 SERUM LEVELS (NMOL/L) BY COMPLETERS, 
TOTAL,  VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-2.1.4 SUMMARY OF RELATIVE CHANGE FROM BASELINE OF IGF-1 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 


Sandoz GmbH 
Confidential 
Page 65 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
 
TABLE 14.2-2.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  VISIT AND INITIAL 
TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.3.1 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL AND  VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 


Sandoz GmbH 
Confidential 
Page 66 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.3.2 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL, VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-2.3.3 SUMMARY OF IGFBP-3 SERUM LEVELS (NMOL/L) BY 
COMPLETERS, TOTAL,  VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-2.3.4 SUMMARY OF RELATIVE CHANGE FROM BASELINE OF IGFBP-3 
SERUM LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.4.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.4.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 67 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.4.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SERUM 
LEVELS (NMOL/L) BY COMPLETERS, TOTAL,  VISIT AND INITIAL 
TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 68 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.5 SHIFT TABLE FOR IGF-1  BY COMPLETERS AND TOTAL (FAS) 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 
TABLE 14.2-2.6 SHIFT TABLE FOR IGFBP-3 BY COMPLETERS AND TOTAL (FAS)  
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 
TABLE 14.2-2.7 SHIFT TABLE FOR IGF-1 IN PATIENTS WITH POWDER TREATMENT 
BY COMPLETERS AND TOTAL (FAS)  
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 
TABLE 14.2.2.8 SHIFT TABLE FOR IGFBP-3 IN PATIENTS WITH POWDER TREATMENT 
BY COMPLETERS AND TOTAL (FAS)  
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 
TABLE 14.2-2.9 SHIFT TABLE FOR IGF-1 IN PATIENTS WITH SOLUTION TREATMENT 
BY COMPLETERS AND TOTAL (FAS)  
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 
TABLE 14.2.2.10 SHIFT TABLE FOR IGFBP-3 IN PATIENTS WITH SOLUTION 
TREATMENT BY COMPLETERS AND TOTAL (FAS)  
 
Comparison 
(Compared vs Baseline)  Baseline 
Compared Visit 
Total 
Low 
Normal 
High 
Missing 
V02 vs V01 
Low 
XX 
XX 
XX 
XX 
XX 
Normal 
XX 
XX 
XX 
XX 
XX 
High 
XX 
XX 
XX 
XX 
XX 
Missing 
XX 
XX 
XX 
XX 
XX 
Total 
XX 
XX 
XX 
XX 
XX 


Sandoz GmbH 
Confidential 
Page 69 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Comparison 
(Compared vs Baseline)  Baseline 
Compared Visit 
Total 
Low 
Normal 
High 
Missing 
V03 vs V02 
Low 
XX 
XX 
XX 
XX 
XX 
Normal 
XX 
XX 
XX 
XX 
XX 
High 
XX 
XX 
XX 
XX 
XX 
Missing 
XX 
XX 
XX 
XX 
XX 
Total 
XX 
XX 
XX 
XX 
XX 
V.. vs V.. 
Low 
XX 
XX 
XX 
XX 
XX 
Normal 
XX 
XX 
XX 
XX 
XX 
High 
XX 
XX 
XX 
XX 
XX 
Missing 
XX 
XX 
XX 
XX 
XX 
Total 
XX 
XX 
XX 
XX 
XX 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Comparison. 
 


Sandoz GmbH 
Confidential 
Page 70 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-2.11.1 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY COMPLETERS, 
TOTAL AND  VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit 
TABLE 14.2-2.11.2 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY COMPLETERS, 
TOTAL, VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit 
TABLE 14.2-2.11.3 SUMMARY OF IGF-1/IGFBP-3 RATIO (NG/MCG) BY COMPLETERS, 
TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-2.12.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO (NG/MCG) BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-2.12.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO (NG/MCG) BY VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
TABLE 14.2-2.12.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO (NG/MCG) BY COMPLETERS, TOTAL, VISIT AND INITIAL 
TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 


Sandoz GmbH 
Confidential 
Page 71 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
TABLE 14.2-2.13.1 SUMMARY OF IGF-1 SDS BY COMPLETERS, TOTAL AND VISIT 
(FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-2.13.2 SUMMARY OF IGF-1 SDS  BY COMPLETERS, TOTAL,  VISIT AND 
SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.13.3 SUMMARY OF IGF-1 SDS BY COMPLETERS, TOTAL, VISIT AND 
INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.14.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SDS BY 
COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.14.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SDS BY 
COMPLETERS, TOTAL, VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 


Sandoz GmbH 
Confidential 
Page 72 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
TABLE 14.2-2.14.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1 SDS BY 
COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.15.1 SUMMARY OF IGFBP-3 SDS BY COMPLETERS, TOTAL AND VISIT 
(FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. Please add confidence interval for means here. 
 
TABLE 14.2-2.15.2 SUMMARY OF IGFBP-3 SDS  BY COMPLETERS, TOTAL, VISIT AND 
SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.15.3 SUMMARY OF IGFBP-3 SDS BY COMPLETERS, TOTAL, VISIT AND 
INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.16.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SDS 
BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 


Sandoz GmbH 
Confidential 
Page 73 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
TABLE 14.2-2.16.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SDS 
BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
 
TABLE 14.2-2.16.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGFBP-3 SDS 
BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.17.1 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS BY COMPLETERS, 
TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.1.1 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL AND 
VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.17.2 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS  BY COMPLETERS, 
TOTAL AND VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.1.2 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.17.3 SUMMARY OF IGF-1/IGFBP-3 RATIO SDS BY COMPLETERS, 
TOTAL, VISIT AND INITIAL TREATMENT (FAS) 
See shell for TABLE 14.2-1.1.3 SUMMARY OF HEIGHT BY COMPLETERS, TOTAL, 
VISIT AND INITIAL TREATMENT (FAS). 


Sandoz GmbH 
Confidential 
Page 74 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.18.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO SDS BY COMPLETERS, TOTAL AND VISIT (FAS) 
See shell for TABLE 14.2-1.2.1 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL AND VISIT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.18.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO SDS BY COMPLETERS, TOTAL,  VISIT AND SEX (FAS) 
See shell for TABLE 14.2-1.2.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND SEX (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-2.18.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN IGF-1/IGFBP-3 
RATIO SDS BY COMPLETERS, TOTAL,  VISIT AND INITIAL 
TREATMENT (FAS) 
See shell for TABLE 14.2-1.2.3 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
HEIGHT BY COMPLETERS, TOTAL, VISIT AND INITIAL TREATMENT (FAS). 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 
TABLE 14.2-3.1 SUMMARY OF THE DEVELOPMENT OF 
 HEIGHT AGE 
IN COMPARISON WITH CHRONOLOGICAL AGE BY COMPLETERS 
AND TOTAL (FAS)  
 
Visit 
by 
N 
N 
miss 
Mean SD 
Min 
Q1 
Median Q3 
Max 
Chronological 
age* (years) 
 V01 
Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
V05 
Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 


Sandoz GmbH 
Confidential 
Page 75 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
… 
Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
 
 
 
 
 
 
 
 
 
 
Height age§ 
(years) 
 
V01^ 
Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
V05& Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 


Sandoz GmbH 
Confidential 
Page 76 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
… 
Males 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Females 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Powder 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Solution 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
 
 
Total 
XX XX 
XX.XX 
X.XX XX.X XX.X 
XX.X 
XX.X XX.X 
* Chronological age determined using date of x-ray  
 
^ Height age determined using height data from the measurement performed closest to pretreatment 
x-ray date 
. 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Visit. 
 


Sandoz GmbH 
Confidential 
Page 77 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-3.2 ANALYSIS OF MEAN CHANGE FROM BASELINE IN 
 AND 
HEIGHT AGE BY COMPLETERS AND TOTAL (FAS)  
Parameter  
Difference 
between visits 
by 
N 
Mean 
difference 
95% Confidence interval 
for mean difference 
Height age (years) 
V05 - V01 
Males 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Females 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Powder 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Solution 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Total 
XX 
X.XX 
[ X.XX; X.XX ] 
 
… 
Males 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Females 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Powder 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Solution 
XX 
X.XX 
[ X.XX; X.XX ] 
 
 
Total 
XX 
X.XX 
[ X.XX; X.XX ] 
. 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before column 
Parameter. 


Sandoz GmbH 
Confidential 
Page 78 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-3.3 SUMMARY OF THE MEAN RATIOS FOR THE COMPARISON OF CHANGES IN 
 HEIGHT AGE, AND 
CHRONOLOGICAL AGE (FAS)  
 
 
Individual ratio of 
changes derived 
between visits 
By 
N 
Missing 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
p-value # 
/ ∆CA 
V05 - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Solution 
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Total    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
 
 
V.. - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Solution 
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Total    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
 
∆HA / ∆CA 
V05 - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Solution 
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Total    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
 
 
V.. - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Solution 
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 


Sandoz GmbH 
Confidential 
Page 79 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
Individual ratio of 
changes derived 
between visits 
By 
N 
Missing 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
p-value # 
 
 
Total    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
 
∆HA / 
 
V.. - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Solution 
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Total    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
 
 
V09 - V01 
Males    
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Females  
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
Powder   
XXX 
XXX 
X.XX 
X.XX 
X.X 
X.X 
X.XX 
X.X 
X.X 
X.XXXX 
 
 
  XXX 
XXX 
X.XX 
X.XX 
X.X 
X.XX 
X.X 
X.X 
X.X 
X.X 
XXX 
 
 
  XXX 
XXX 
X.XX 
X.XX 
X.X 
X.XX 
X.X 
X.X 
X.X 
X.X 
XXX 
 
 
 
; HA - Height Age; CA - Chronological Age 
# two-sided p-value for t-test with null hypothesis that ratio equals 1 
Programming note: Please add one column ‘Status’ (value: Completers, Total) before first column. 
 
 
 
 
 
 
 
 


Sandoz GmbH 
Confidential 
Page 80 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
TABLE 14.2-3.4 SUMMARY OF OVERWEIGHT PATIENTS BY SEX AND VISIT (FAS) 
 
 
Number of patients (%) 
Sex 
Visit 
Total 
Missing 
N 
 
Normal 
Overweight* 
 
  
Male   
Baseline   
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
V02       
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
… 
 
 
 
 
 
 
   
 
Female 
Baseline   
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
V02       
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
… 
 
 
 
 
 
 
   
 
Total  
Baseline   
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
V02       
XXX 
XXX 
XXX 
 
XXX (XX.X%) 
XXX (XX.X%) 
   
 
… 
 
 
 
 
 
 
   
 
 
 
* Defined by international cut off points for BMI for overweight by sex and age at visit. The cut-off point is defined by the percentile that 
passes through BMI at 25 kg/m² at age 18.  
 
 
 


Sandoz GmbH 
Confidential 
Page 81 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
5.3 
Figures 
FIGURE 14.2-1.11 Mean body height over time by completer, means ± 95% CI (FAS)  
FIGURE 14.2-1.11.1 Mean body height over time by completer and sex, means ± 95% CI (FAS) 
FIGURE  14.2-1.12 Mean H SDS over time by completer, means ± 95% CI (FAS)  
FIGURE  14.2-1.12.1 Mean H SDS over time for patients with and without positive anti-rhGH antibodies, means ± 95% CI (FAS)  
FIGURE  14.2-1.13 Mean height velocity over time by completer, means ± 95% CI (FAS)  
FIGURE  14.2-1.13.1 Mean height velocity over time by completer and sex, means ± 95% CI (FAS)  
FIGURE  14.2-1.14 Mean HV SDS (cross-sectional) over time by completer, means ± 95% CI (FAS)  
FIGURE  14.2-1.14.1 Mean HV SDS (cross-sectional) over time for patients with and without positive anti-rhGH antibodies, means 
± 95% CI (FAS)  
FIGURE  14.2-1.15 Mean HV SDS (peak-centered) over time by completer, means ± 95% CI (FAS)  
FIGURE  14.2-1.15.1 Mean HV SDS (peak-centered) over time for patients with and without positive anti-rhGH antibodies, means ± 
95% CI (FAS)  
FIGURE  14.2-2.19 Mean IGF-1 serum levels over time, means ± 95% CI (FAS)  
FIGURE  14.2-2.19.1 Mean IGF-1 serum levels over time by sex, means ± 95% CI (FAS)  
FIGURE  14.2-2.20 Mean IGFBP-3 serum levels over time, means ± 95% CI (FAS)  
FIGURE  14.2-2.20.1 Mean IGFBP-3 serum levels over time by sex, means ± 95% CI (FAS)  
FIGURE  14.2-2.21 Mean IGF-1 SDS serum levels over time, means ± 95% CI (FAS)  


Sandoz GmbH 
Confidential 
Page 82 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
FIGURE  14.2-2.22 Mean IGFBP-3 SDS serum levels over time, means ± 95% CI (FAS) 
 
5.4 
Safety Tables including shells 


Sandoz GmbH 
Confidential 
Page 83 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.1 GENERAL SUMMARY OF ADVERSE EVENTS (SAF) 
 
 
Number of patients (%) 
(N=277) 
Number of adverse 
events (%) 
Any adverse events 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
Relationship to study drug 
       
         
      
         
  Not suspected 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Suspected 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Missing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
Intensity 
       
         
      
         
  Mild 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Moderate 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Severe 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Missing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
Serious adverse event 
       
         
      
         
  No 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Yes 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Missing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
Outcome 
       
         
      
         
  Resolved 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Ongoing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Missing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
Action taken 
       
         
      
         
  Nothing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Study drug dosage adjusted/temporarily 
interrupted 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Study drug permanently discontinued due to this 
AE 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Concomitant medication given 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Non-drug therapy given 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Hospitalization/prolonged hospitalization 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
  Missing 
   XXX 
 (XX.X%) 
  XXX 
 (XX.X%) 
No AEs (including SAEs) that started prior to start of treatment are included. 
 


Sandoz GmbH 
Confidential 
Page 84 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.2 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND INTENSITY, ALL ADVERSE EVENTS (SAF) 
TABLE 14.3-1.2.1 INCIDENCE OF ADVERSE EVENTS FOR OVERWEIGHT* PATIENTS 
AT BASELINE BY SYSTEM ORGAN CLASS, PREFERRED TERM, AND 
INTENSITY, ALL ADVERSE EVENTS (SAF) 
 Defined by international cut off points for BMI for overweight by sex and age at baseline. 
The cut-off point is defined by the percentile that passes through BMI at 25 kg/m² at age 18.. 
Programming note: Same table shell as Table 14.3-1.2 will be used. 
 
TABLE 14.3-1.3 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND INTENSITY, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.4 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
TABLE 14.3-1.5 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
TABLE 14.3-1.6 INCIDENCE OF NON-SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
 
 
Intensity 
 
Novartis MedDRA version 
System Organ Class 
  Preferred Term 
Mild 
Moderate 
Severe 
Missing 
Total 
number 
of patients 
Patients 
per 
patient 
years# 
Blood and lymphatic system 
disorders 
 
 
 
 
 
       
  Any AE 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Anaemia 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Eosinophilia 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Leukopenia 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Lymphadenitis 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Lymphadenopathy 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Neutropenia 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Splenomegaly 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 


Sandoz GmbH 
Confidential 
Page 85 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
 
Intensity 
 
Novartis MedDRA version 
System Organ Class 
  Preferred Term 
Mild 
Moderate 
Severe 
Missing 
Total 
number 
of patients 
Patients 
per 
patient 
years# 
  Thrombocytopenia 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Thrombocytosis 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
Cardiac disorders 
 
 
 
 
 
       
  Any AE 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  … 
XX (XX.X%) XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each 
patient was treated).   


Sandoz GmbH 
Confidential 
Page 86 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.7 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND INTENSITY, ALL ADVERSE EVENTS (SAF) 
TABLE 14.3-1.8 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND INTENSITY, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.9 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
TABLE 14.3-1.10 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
TABLE 14.3-1.11 OCCURRENCE OF NON-SERIOUS ADVERSE EVENTS BY SYSTEM 
ORGAN CLASS, PREFERRED TERM, AND INTENSITY (SAF) 
 
 
 
Intensity 
 
Events 
per 
Patient 
Year 
SOC 
Preferred term 
Mild 
Moderate Severe 
Missing 
Total 
SOC1 
ANY 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term 1 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term 2 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term X 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
SOC2 
ANY 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term 1 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term 2 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
Preferred Term X 
XX  
XX  
XX 
XX  
XX  
X.XXX 
 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each 
patient was treated).   
 


Sandoz GmbH 
Confidential 
Page 87 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.12 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND OUTCOME, ALL ADVERSE EVENTS (SAF) 
TABLE 14.3-1.13 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND OUTCOME, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.14 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME (SAF) 
TABLE 14.3-1.15 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND OUTCOME (SAF) 
 
 
Outcome 
 
Novartis MedDRA version 
System Organ Class 
  Preferred Term 
Resolved 
Ongoing 
Fatal 
Missing 
Total number 
of patients 
Patients 
per 
patient 
years# 
Blood and lymphatic 
system disorders 
 
 
 
 
 
       
  Any AE 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Anaemia 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Eosinophilia 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Leukopenia 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Lymphadenitis 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Lymphadenopathy 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Neutropenia 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Splenomegaly 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Thrombocytopenia 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  Thrombocytosis 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
Cardiac disorders 
 
 
 
 
 
       
  Any AE 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
  … 
XX (XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX (XX.X%)  X.XXX 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each patient was treated).   


Sandoz GmbH 
Confidential 
Page 88 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.16 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND OUTCOME, ALL ADVERSE EVENTS (SAF) 
TABLE 14.3-1.17 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND OUTCOME, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.18 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND OUTCOME (SAF) 
TABLE 14.3-1.19 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND OUTCOME (SAF) 
 
 
Outcome 
 
Novartis MedDRA 19.1 
System organ class 
  Preferred Term 
Resolved Ongoing Fatal 
Missing 
Total 
Events per 
patient 
year# 
Blood and lymphatic system disorders 
 
 
 
 
   X.XXX 
  ANY 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Anaemia 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Eosinophilia 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Leukopenia 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Lymphadenitis 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Lymphadenopathy 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Neutropenia 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Splenomegaly 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Thrombocytopenia 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  Thrombocytosis 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
Cardiac disorders 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
  ANY 
  XXX 
  XXX 
 XXX 
  XXX 
  XXX 
   X.XXX 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each patient was treated).   
 
 


Sandoz GmbH 
Confidential 
Page 89 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.20 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND ACTION TAKEN, ALL ADVERSE EVENTS 
(SAF) 
TABLE 14.3-1.21 INCIDENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND ACTION TAKEN, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.22 INCIDENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN (SAF) 
TABLE 14.3-1.23 INCIDENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND ACTION TAKEN 
(SAF) 
 
 
Action taken 
 
Novartis MedDRA 19.1 
System Organ Class 
  Preferred Term 
Nothing 
Study 
drug 
dosage 
adjusted 
/tempo- 
rarily 
inter- 
rupted 
Study 
drug 
perma- 
nently 
disc- 
ontinued 
due to 
this AE 
Conco- 
mitant 
medi- 
cation 
given 
Non-drug 
therapy 
given 
Hospital- 
ization/ 
prolonge
d 
hospital- 
ization 
Missing 
Patients 
per 
patient 
years# 
Blood and lymphatic 
system disorders 
 
 
 
 
 
 
 
       
  Any AE 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
 X.XXX 
  Anaemia 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
  Eosinophilia 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
  Leukopenia 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
  Lymphadenitis 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
  Lymphadenopathy 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
  Neutropenia 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
XX 
(XX.X%) 
X.XXX 
… 
 
 
 
 
 
 
 
 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each patient was treated).   
 
 


Sandoz GmbH 
Confidential 
Page 90 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-1.24 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND ACTION TAKEN, ALL ADVERSE EVENTS 
(SAF) 
TABLE 14.3-1.25 OCCURRENCE OF ADVERSE EVENTS BY SYSTEM ORGAN CLASS, 
PREFERRED TERM, AND ACTION TAKEN, DRUG-RELATED ADVERSE 
EVENTS (SAF) 
TABLE 14.3-1.26 OCCURRENCE OF SERIOUS ADVERSE EVENTS BY SYSTEM ORGAN 
CLASS, PREFERRED TERM, AND ACTION TAKEN (SAF) 
TABLE 14.3-1.27 OCCURRENCE OF DRUG-RELATED SERIOUS ADVERSE EVENTS BY 
SYSTEM ORGAN CLASS, PREFERRED TERM, AND ACTION TAKEN 
(SAF) 
 
 
Action taken 
 
Novartis MedDRA 
19.1 
System organ class 
  Preferred Term 
Nothin
g 
Study 
drug 
dosage 
adjusted 
/tempo- 
rarily 
inter- 
rupted 
Study 
drug 
perma- 
nently 
disc- 
ontinued 
due to 
this AE 
Conco- 
mitant 
medi- 
cation 
given 
Non-drug 
therapy 
given 
Hospital- 
ization/ 
prolonge
d 
hospital- 
ization 
Missing 
Total 
Events 
per 
patient 
year# 
Blood and lymphatic 
system disorders 
 
 
 
 
 
 
 
 
         
  ANY 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Anaemia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Eosinophilia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Leukopenia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Lymphadenitis 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Lymphadenopathy 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Neutropenia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Splenomegaly 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Thrombocytopenia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Thrombocytosis 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
Cardiac disorders 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  ANY 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
  Bradycardia 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
… 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
XXX 
 X.XXX 
No AEs (including SAEs) that started prior to start of treatment are included. 
# Patient years = XXX.XXX 
Patient years are calculated as years of exposure (i.e. total sum of the number of years that each 
patient was treated).   
 


Sandoz GmbH 
Confidential 
Page 91 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.1 CONVERSION FACTORS FOR LABORATORY PARAMETERS 
 
 
Parameter 
Unit measured 
Conversion 
factor 
Unit derived 
Hematology 
Hematocrit 
% / 100 
 
Value 
 
Hemoglobin 
g/dl 
10 
g/l 
 
MCHC 
g/dl 
10 
g/l 
 
 
 
 
 
Blood chemistry 
Total protein 
g/dl 
10 
g/l 
 
Creatinine 
mg/dl 
XX.X 
umol/l 
 
Total bilirubin 
mg/dl 
XX.X 
umol/l 
 
Urea 
mg/dl 
X.XXX 
mmol/l 
 
 
 
 
 
… 
… 
… 
… 
… 
 


Sandoz GmbH 
Confidential 
Page 92 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.2 SUMMARY OF HEMATOLOGY DATA (SAF) 
 
Parameter (unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Media
n 
Q3 
Max 
Hemoglobin (g/l) 
V01 
XX 
XX 
XXX.X
X 
XX.XX 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.
XX 
XX
X 
 
V03 
XX 
XX 
XXX.X
X 
XX.XX 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.
XX 
XX
X 
 
V05 
XX 
XX 
XXX.X
X 
XX.XX 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.
XX 
XX
X 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hematocrit (l/l) 
V01 
XX 
XX 
X.XX 
X.XXX 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
V03 
XX 
XX 
X.XX 
X.XXX 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
V05 
XX 
XX 
X.XX 
X.XXX 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 


Sandoz GmbH 
Confidential 
Page 93 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.3 SUMMARY OF BLOOD CHEMISTRY (SAF) 
 
Parameter (unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Media
n 
Q3 
Max 
Parameter1 
(unit1) 
V01 
XX 
XX 
XXX.X
X 
XX.X
X 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.X
X 
XX
X 
 
V03 
XX 
XX 
XXX.X
X 
XX.X
X 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.X
X 
XX
X 
 
V05 
XX 
XX 
XXX.X
X 
XX.X
X 
XX
X 
XXX.
XX 
XXX.X
X 
XXX.X
X 
XX
X 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter2 
(unit2) 
V01 
XX 
XX 
X.XX 
X.XX
X 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
V03 
XX 
XX 
X.XX 
X.XX
X 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
V05 
XX 
XX 
X.XX 
X.XX
X 
X.X
X 
X.XX 
X.XX 
X.XX 
X.X
X 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 


Sandoz GmbH 
Confidential 
Page 94 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.4 SUMMARY OF CARBOHYDRATE METABOLISM INCL. OGTT DATA 
(SAF) 
TABLE 14.3-2.5 SUMMARY OF ABSOLUTE CHANGES FROM BASELINSE OF 
CARBOHYDRATE METABOLISM INCL. OGTT DATA (SAF) 
TABLE 14.3-2.6 SUMMARY OF RELATIVE CHANGES FROM BASELINSE OF 
CARBOHYDRATE METABOLISM INCL. OGTT DATA (SAF) 
 
Parameter 
(unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Media
n 
Q3 
Max 
Parameter
1 (unit1) 
V01 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
V03 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
V05 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter
2 (unit2) 
V01 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V03 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V05 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 


Sandoz GmbH 
Confidential 
Page 95 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLES 14.3-2.7 SHIFT TABLES FOR CARBOHYDRATE METABOLISM (SAF) 
TABLE 14.3-2.7.1 
SHIFT TABLE FOR HbA1C (SAF) 
TABLE 14.3-2.7.2 
SHIFT TABLE FOR FASTING GLUCOSE (SAF) 
TABLE 14.3-2.7.3 
SHIFT TABLE FOR FASTING INSULIN (SAF) 
 
Comparison 
(Baseline vs 
Compared) 
Base Visit 
Low 
Normal 
High 
Missing 
Total 
V01 vs V03 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
Missing        
  XX          
XX          
XX          
 XX  
  XX          
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     XXX (100.0%) 
 
V01 vs V05 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
Missing        
  XX          
XX          
XX          
 XX  
  XX            
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     XXX (100.0%) 
 
V… vs V.. 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX      XX ( XX.X%) 
 
Missing        
  XX          
XX          
XX          
 XX  
XX            
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     XXX (100.0%) 
 
 


Sandoz GmbH 
Confidential 
Page 96 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.8 SUMMARY OF HOMA AND QUICKI SCORES (SAF) 
TABLE 14.3-2.9 SUMMARY OF ABSOLUTE CHANGES FROM BASELINE OF HOMA 
AND QUICKI SCORES (SAF) 
TABLE 14.3-2.10 SUMMARY OF RELATIVE CHANGES FROM BASELINE OF HOMA 
AND QUICKI SCORES (SAF) 
TABLE 14.3-2.11 SUMMARY OF THYROID PANEL DATA (SAF) 
 
Parameter 
(unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
Parameter1 
(unit1) 
V01 
XX 
XX 
XXX.XX XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
V03 
XX 
XX 
XXX.XX XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
V05 
XX 
XX 
XXX.XX XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter2 
(unit2) 
V01 
XX 
XX 
X.XX 
X.XXX X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V03 
XX 
XX 
X.XX 
X.XXX X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V05 
XX 
XX 
X.XX 
X.XXX X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 


Sandoz GmbH 
Confidential 
Page 97 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLES 14.3-2.12 SHIFT TABLES FOR THYROID PANEL DATA (SAF) 
TABLE 14.3-2.12.1 
SHIFT TABLE FOR FREE THYROXINE (T4) (SAF) 
TABLE 14.3-2.12.2 SHIFT TABLE FOR THYROID STIMULATING HORMONE (TSH) 
(SAF) 
 
Comparison 
(Baseline vs Compared) Base Visit 
Low 
Normal 
High 
Missing Total 
V01 vs V03 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX         XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX       
XX ( XX.X%) 
 
Missing          XX          
XX          
XX          
 XX  
  XX          
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     
XXX (100.0%) 
 
V01 vs V05 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX         XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX       
XX ( XX.X%) 
 
Missing          XX          
XX          
XX          
 XX  
  XX            
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     
XXX (100.0%) 
 
V01 vs V.. 
Low               XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX    
XX ( XX.X%) 
 
Normal         XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX         XX ( XX.X%) 
 
High             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX       
XX ( XX.X%) 
 
Missing          XX          
XX          
XX          
 XX  
XX            
 
Total             XX ( XX.X%) 
XX ( XX.X%) 
XX ( XX.X%) 
 XX     
XXX (100.0%) 
 
 


Sandoz GmbH 
Confidential 
Page 98 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.13 SUMMARY OF URINALYSIS DATA (SAF) 
 
Parameter 
(unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Media
n 
Q3 
Max 
Parameter
1 (unit1) 
V01 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
V03 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
V05 
XX 
XX 
XXX.
XX 
XX.X
X 
XXX 
XXX.
XX 
XXX.
XX 
XXX.
XX 
XXX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter
2 (unit2) 
V01 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V03 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
V05 
XX 
XX 
X.XX 
X.XX
X 
X.XX 
X.XX 
X.XX 
X.XX 
X.XX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
TABLES 14.3-2.14 SHIFT TABLES FOR URINALYSIS DATA (SAF) 
TABLE 14.3-2.14.1 
SHIFT TABLE FOR PROTEIN (SAF) 
TABLE 14.3-2.14.2 
SHIFT TABLE FOR GLUCOSE (SAF) 
TABLE 14.3-2.14.3 
SHIFT TABLE FOR KETONES (SAF) 
 
 


Sandoz GmbH 
Confidential 
Page 99 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-2.16.4 
SHIFT TABLE FOR BILIRUBIN (SAF) 
Comparison 
(Baseline vs 
Compared) 
Base Visit 
Negative 
+ 
++ 
+ 
++ 
Missing 
Total 
V01 vs V03 
Negative             XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
+                         XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
++                       XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
+++                     XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
++++                   XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
Missing               XX 
XX 
XX 
XX 
XX 
XX 
XX 
 
Total                   XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XX 
XXX 
(XX.X%) 
 
V.. vs V… 
Negative             XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
+                         XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
++                       XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
+++                     XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
++++                   XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
  XX 
XXX 
(XX.X%) 
 
Missing               XX 
XX 
XX 
XX 
XX 
XX 
XX 


Sandoz GmbH 
Confidential 
Page 100 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
Comparison 
(Baseline vs 
Compared) 
Base Visit 
Negative 
+ 
++ 
+ 
++ 
Missing 
Total 
 
Total                   XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XXX 
(XX.X%) 
XX 
XXX 
(XX.X%) 
 


Sandoz GmbH 
Confidential 
Page 101 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-3.1 SUMMARY OF VITAL SIGNS (SAF) 
 
Parameter 
(unit) 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median 
Q3 
Max 
Parameter1 
(unit1) 
V01 
XX 
XX 
XXX.XX 
XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
V03 
XX 
XX 
XXX.XX 
XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
V05 
XX 
XX 
XXX.XX 
XX.XX XXX 
XXX.XX XXX.XX 
XXX.XX XXX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter2 
(unit2) 
V01 
XX 
XX 
X.XX 
X.XXX X.XX X.XX 
X.XX 
X.XX 
X.XX 
 
V03 
XX 
XX 
X.XX 
X.XXX X.XX X.XX 
X.XX 
X.XX 
X.XX 
 
V05 
XX 
XX 
X.XX 
X.XXX X.XX X.XX 
X.XX 
X.XX 
X.XX 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 


Sandoz GmbH 
Confidential 
Page 102 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-3.2 SUMMARY OF PHYSICAL EXAMINATION (SAF) 
 
 
Significant findings 
Number of patients (%) 
Body System 
Visit 
Total 
Missing N 
Yes 
No 
General appearance 
  SCR 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V01 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V02 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V03 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V04 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V05 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V06 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V07 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V08 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  … 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
Head 
  SCR 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V01 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V02 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V03 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V04 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V05 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V06 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V07 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
  V08 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
 … 
XXX 
XXX 
XXX 
XX (XX.X%) 
XX (XX.X%) 
 
TABLE 14.3-3.3 SHIFT TABLE FOR PHYSICAL EXAMINATION BY BODY SYSTEM 
(SAF) 
Body System 
Comparison 
(Baseline vs 
Compared) 
Base Visit Normal 
Abnormal 
Missing Total 
General appearance V01 vs V02 
Normal        XX ( XX.X%) XX ( XX.X%)  XX    
XX ( XX.X%) 
 
Abnormal   XX ( XX.X%) XX ( XX.X%)  XX        XX ( XX.X%) 
 
Missing         XX          
XX          
 XX  
  XX          
 
Total           XX ( XX.X%) XX ( XX.X%)  XX     
XXX 
(100.0%) 
V01 vs V03 
Normal        XX ( XX.X%) XX ( XX.X%)  XX    
XX ( XX.X%) 
 
Abnormal   XX ( XX.X%) XX ( XX.X%)  XX        XX ( XX.X%) 
 
Missing         XX          
XX          
 XX  
  XX            
 
Total           XX ( XX.X%) XX ( XX.X%)  XX     
XXX 
(100.0%) 
... 
... 
... 
... 
... 
... 


Sandoz GmbH 
Confidential 
Page 103 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
Body System 
Comparison 
(Baseline vs 
Compared) 
Base Visit Normal 
Abnormal 
Missing Total 
 
 
 
 
 
 
Head 
V01 vs V02 
Normal        XX ( XX.X%) XX ( XX.X%)  XX    
XX ( XX.X%) 
 
Abnormal   XX ( XX.X%) XX ( XX.X%)  XX        XX ( XX.X%) 
 
Missing         XX          
XX          
 XX  
XX            
 
Total           XX ( XX.X%) XX ( XX.X%)  XX     
XXX 
(100.0%) 
V01 vs V03 
Normal        XX ( XX.X%) XX ( XX.X%)  XX    
XX ( XX.X%) 
 
Abnormal   XX ( XX.X%) XX ( XX.X%)  XX        XX ( XX.X%) 
 
Missing         XX          
XX          
 XX  
XX            
 
Total           XX ( XX.X%) XX ( XX.X%)  XX     
XXX 
(100.0%) 
 
 
 
 
 
 
... 
... 
... 
... 
... 
... 
 


Sandoz GmbH 
Confidential 
Page 104 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-3.4 SUMMARY OF BODY WEIGHT (SAF) 
TABLE 14.3-3.5 SUMMARY OF BMI (SAF) 
TABLE 14.3-3.6 SUMMARY OF BMI SDS (SAF) 
 
 
Visit 
N 
N 
miss 
Mean 
SD 
Min 
Q1 
Median Q3 
Max 
BMI SDS 
01 
XX 
XX 
XX.X 
X.X 
XX.X 
XX.X XX.X 
XX.X 
XX.X 
 
02 
XX 
XX 
XX.X 
X.X 
XX.X 
XX.X XX.X 
XX.X 
XX.X 
 
03 
XX 
XX 
XX.X 
X.X 
XX.X 
XX.X XX.X 
XX.X 
XX.X 
 
… 
XX 
XX 
XX.X 
X.X 
XX.X 
XX.X XX.X 
XX.X 
XX.X 
 
TABLE 14.3-3.7 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF DIABETES MELLITUS (DM) (SAF) 
 
 
Total 
Number of patients with DM 
(%) 
Number of patients without 
DM finding (%) 
Female 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Male 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Total 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
DM is defined as fulfilment of one of the following criteria: 
1. FPG ≥126 mg/dl (≥7.0 mmol/l) during safety lab assessment or as -10min value of OGTT 
2. 2-h plasma glucose ≥ 200 mg/dl (≥11.1 mmol/l) during OGTT 
3. HbA1C ≥ 6.5% 
Patients not fulfilling at least one criteria on at least one visit are considered as patients without DM finding 
 
TABLE 14.3-3.7.1 SUMMARY OF OVERWEIGHT* PATIENTS AT BASELINE WITH 
LABORATORY PARAMETERS FULLFILING THE DEFINITION OF 
DIABETES MELLITUS (DM) (SAF) 
 
Sex 
Total 
Number of patients with DM 
(%) 
Number of patients without 
DM finding (%) 
Female 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Male 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Total 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
 
*  Defined by international cut off points for BMI for overweight by sex and age at baseline. The cut-off point is defined by the 
percentile that passes through BMI at 25 kg/m² at age 18. 
DM is defined as fulfilment of one of the following criteria: 
1. FPG ≥126 mg/dl (≥7.0 mmol/l) during OGTT or safety lab assessment 
2. 2-h plasma glucose ≥ 200 mg/dl (≥11.1 mmol/l) during OGTT 
3. HbA1C ≥ 6.5% 
Patients not fulfilling at least one criteria on at least one visit are considered as patients without DM finding 


Sandoz GmbH 
Confidential 
Page 105 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
 
TABLE 14.3-3.8 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF IMPAIRED GLUCOSE 
TOLERANENCE (IGT) (SAF) 
 
 
Total 
Number of patients with IGT 
(%) 
Number of patients without 
IGT finding (%) 
Female 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Male 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Total 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
IGT is defined as fulfilment of all of the following criteria: 
1. FPG < 126 mg/dl (<7.0 mmol/l) during OGTT or safety lab assessment 
2. 2-h plasma glucose between 140 – 200 mg/dl (≥7.8 and <11.1 mmol/l) during OGTT 
Patients not fulfilling all criteria on at least one visit are considered as patients without IGT finding 
 
 
TABLE 14.3-3.9 SUMMARY OF PATIENTS WITH LABORATORY PARAMETERS 
FULLFILING THE DEFINITION OF IMPAIRED FASTING GLUCOSE (IFG) 
(SAF) 
 
 
Total 
Number of patients with IFG 
(%) 
Number of patients without 
IFG finding (%) 
Female 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Male 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
Total 
 XXX 
XX (XX.X%) 
XX (XX.X%) 
IFG  is defined as fulfilment of all of the following criteria: 
1. FPG 110 - 125 mg/dl (6.1 - 6.9 mmol/l) during OGTT or safety lab assessment 
2. 2-h plasma glucose < 140 mg/dl (<7.8 mmol/l) during OGTT 
Patients not fulfilling all criteria on at least one visit are considered as patients without IFG finding. 
 


Sandoz GmbH 
Confidential 
Page 106 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-3.10 SUMMARY OF ANTI-HGH ANTIBODIES (SAF) 
 
Visit 
Total 
Missing 
N 
Number of patients with positive test result (%) 
V01        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V02        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V03        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V04        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V05        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V07        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V…        
     XXX 
XXX 
XXX 
XX (XX.X%) 
 
 


Sandoz GmbH 
Confidential 
Page 107 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
TABLE 14.3-3.11 SUMMARY OF ANTI-HCP ANTIBODIES (SAF) 
 
Visit 
Total 
Missing 
N 
Number of patients with positive test result (%) 
V01        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V02        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V03        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V04        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V05        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V07        
     XXX 
XXX 
XXX 
XX (XX.X%) 
V…        
     XXX 
XXX 
XXX 
XX (XX.X%) 
Total* 
     XXX 
XXX 
XXX 
XX (XX.X%) 
* including all final assessments 
 
5.5 
Listings 
16.2.1 
Discontinued patients (FAS) 
16.2.2 
Protocol deviations (FAS) 
16.2.3  
Medical history (FAS) 
 
16.2.4  
Compliance and/or drug concentration data 
16.2.4.1 Dose changes (FAS) 
16.2.5  
Adverse events listings 
16.2.5.1 All adverse events (FAS) 
16.2.5.2 All fatal adverse events (FAS) 
16.2.5.3 All adverse events belonging to MedDRA High Level Term Diabetes mellitus (incl. 
subtypes) (FAS) 
16.2.5.4 All adverse events belonging to MedDRA High Level Term Hyperglycemia 
Condition NEC (FAS) 
16.2.5.5 All adverse events belonging to MedDRA System Organ Class Neoplams benign, 
malignant and unspecified (incl. cysts ans polyps) (FAS) 
16.2.5.6   All adverse events of special interest (FAS) 
16.2.6 
Laboratory measurements 
16.2.6.1 HbA1c (FAS) 
16.2.6.2 Glucose (FAS) 
16.2.6.3 Insulin (FAS) 
16.2.6.4 Oral Glucose Tolerance Test (OGTT) (FAS) 


Sandoz GmbH 
Confidential 
Page 108 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
16.2.6.5 HOMA and QUICKI Score (FAS) 
16.2.6.6 Positive hGH-Antibodies results (FAS) 
16.2.6.7 Positive HCP-Antibodies results (FAS) 
6 
Literature 
Cole TJ et al (2000). Establishing a standard definition for child overweight and obesity 
worldwide: international survey. BMJ; 320:1240-43 
Cole and Green (1992) Smoothing reference centile curves: the LMS method and penalized 
likelihood. Statistics in Medicine, 11, 1305-1319. 
Prader A, Largo RH, Molinari L, Issler C (1989) Physical growth of Swiss children from birth 
to 20 years of age. First Zurich longitudinal study of growth and development. Helv Paediatr 
Acta Suppl; 52: 1-125. 
Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of hand and wrist. 
2nd edition, Stanford University Press, California, USA. 
Tanner JM, Whitehouse RH, Cameron N, et al (1983) Assessment of Skeletal Maturity and 
Prediction of Adult Height (TW2 Method). Academic Press, London.  
Tanner JM, Landt KW, Cameron N, et al (1983) Prediction of adult height from height and 
bone age in childhood. Archives of Disease in Childhood, 58, 767-76. 
Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Archives 
of Disease in Childhood, 44, p. 291-303. 
Elmlinger MW, Kühnel W, Weber MM, Ranke MB (2004) Reference ranges for two 
automated chemiluminescent assays for serum insulin-like growth factor I (IGF-1) and IGF 
binding protein 3 (IGFBP-3), Clinical Chemistry and Laboratory Medicine, 42(6), 654-64. 


Sandoz GmbH 
Confidential 
Page 109 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
7 
Appendices 
7.1 
Appendix A 
Height Reference Tables for Boys and Girls, Prader Standards (1989) 
7.2 
Appendix B: Height SDS 
The following national references for the calculation of Height SDS will be used: 
Country 
Calculation Literature reference 
Belgium 
Median, 3rd 
Percentile 
Data manually extracted from Flemish Growth Charts 2 – 20 years.  
H/1-20040916-EP/2-20 – Vrije Universiteit Brussel,  
Antropogenetica & Katholieke Universiteit Leuven,  
Jeugdgezondheidszorg – vub, kul © 2005  
www.vub.ac.be/groeicurven (Mean of three measurements) 
Czech 
republic 
Mean, SD 
Celostatni antropologicky vyzkum detí a mladeze 2001, Ceska 
republika J Vignerova, P.Blaha, Praha 2006 
Georgia 
Mean, SD 
Prader A, Largo RH, Molinari L, et al (1989) Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
Germany 
Mean, SD 
Reinken L., van Oost, G.: Longitudinale Körperentwicklung 
gesunder Kinder von 0 bis 18 Jahren; Klin Pädiatr 204, 129-133 
(1992) 
Hungary 
Mean, SD 
Joubert Joubert K., Darvay S., Gyenis G., Éltetö Ö., Mag K., van't 
Hof M., Ágfalvi R.: Az Országos Longitudinális Gyermeknövekedés-
vizsgálat eredményei születéstöl 18 éves korig. I. Központi 
Statisztikai Hivatal - Népességtudományi Kutatóintézet (Hungarian 
Central Statistical Office - Demographic Research Institute, 2006) 
Poland 
Median, 3rd 
Percentile 
Iwona Palczewska, Zofia Niedzwiecka: 
Medycyna - Wieku Rozwojowego 
Dawniej Problemy Medycyny Wieku Rozwojowego 
Suplement I do nr 2 kwiecien-czerwiec tom V 2001 Warszawa ISSN 
1428-345X 
Developmental Period Medicine 
Instytut Matki i Dziecka 
Romania 
Mean, SD 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
7.3 
Appendix C: BMI SDS  
As the probability distribution of the BMI is skewed, a satisfying description of the BMI needs 
additional characterization of the skewness. This is usually done by the LMS method (Cole and 
Green 1992). If the same reference for height and weight also included BMI reference values 
they were used. If the reference for height and weight does not include BMI reference values 
they were appropriately derived from height and weight. For patients older than the maximal 
age for that a reference is given, the reference for the oldest patients will be used. 
The following references for the calculation of BMI SDS will be used in each country: 


Sandoz GmbH 
Confidential 
Page 110 of 110 
SAP V5.0 
 
Study No. EP00-401 
 
 
 
Country 
Literature reference 
Belgium 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
Czech republic 
Bláha P, Vignerová et al (2003)] Celostátní antropologický výzkum 
dĕtí a mládeže 2001. Ces-slov Pediat; 58 (12):766-70 
Germany 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
Georgia 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
Hungary 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
Poland 
Palczewska I, Niedzwiecka Z (2001)] Wskazniki rozwoju 
somatycznego dzieci i mlodziezy Warszawskiej. Med Wieku Rosz; 2, 
suppl. 1. 
Romania 
Prader A, Largo RH, Molinari L, et al (1989)] Physical growth of 
Swiss children from birth to 20 years of age. Helv Paediat Acta; 43 
Suppl 52:1-125 
7.4 
Appendix D 
Peak Height Velocity Centered Height Velocity Reference Tables for Boys and Girls 
Cross-Sectional Height Velocity Reference Tables for Boys and Girls, Prader Standards 
(1989).